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FOLATE PATHWAY INHIBITOR RESISTANCE MECHANISMS 
IN BURKHOLDERIA PSEUDOMALLEI 
 
Antimicrobials are invaluable tools used to facilitate the treatment of infectious diseases. 
Their use has saved millions of lives since their introduction in the early 1900’s. Unfortunately, 
due to the increased incidence and dispersal of antimicrobial resistance determinants, many of 
these drugs are no longer efficacious. This greatly limits the options available for treatment of 
serious bacterial infections, including melioidosis, which is caused by Burkholderia 
pseudomallei, a Gram-negative saprophyte. This organism is intrinsically resistant to many 
antimicrobials. Additionally, there have been reports of B. pseudomallei isolates resistant to 
several of the antimicrobials currently used for treatment, including the trimethoprim and 
sulfamethoxazole combination, co-trimoxazole. The overarching goal of this project was to 
identify and characterize mechanisms of trimethoprim and sulfamethoxazole resistance in 
clinical and environmental isolates, as well as in laboratory induced mutants. Prior to these 
studies, very little work has been done to identify and characterize the mechanisms by which B. 
pseudomallei strains are or could become resistant to folate-pathway inhibitors, specifically 
trimethoprim and sulfamethoxazole. 
During the initial phases of these studies, we determined the antimicrobial susceptibilities 
of a large collection of clinical and environmental isolates from Thailand and Australia (n = 65). 
A high frequency of naturally-occurring resistance to trimethoprim alone (40%) was observed. 
However these strains were susceptible to sulfamethoxazole and to the co-trimoxazole 
combination. Trimethoprim resistance in a subset of these strains was due to increased 
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expression of an efflux pump belonging to the resistance nodulation and cellular division (RND) 
superfamily, BpeEF-OprC, in the presence of trimethoprim. This efflux pump had been 
previously shown to efflux trimethoprim, chloramphenicol and tetracyclines when expressed in 
surrogate bacterial strains. The molecular mechanism of increased BpeEF-OprC expression in 
these isolates remains unknown. Similarly, decreased susceptibility in laboratory mutants 
selected on trimethoprim were due to mutations leading to amino acid substitutions in BpeT, 
which caused overexpression of BpeEF-OprC, or FolA, the trimethoprim drug target. This is the 
first description of mutations to FolA conferring trimethoprim resistance in B. pseudomallei, 
though similar mutations have been observed in B. cenocepacia and Escherichia coli. A similar 
study to select for sulfamethoxazole resistance, instead suggested that B. pseudomallei may be 
able to tolerate high concentrations of the drug.  
Studies to characterize laboratory induced mutants selected on co-trimoxazole led to the 
identification of two novel resistance determinants. Mutations to BpeS, a newly named LysR-
type regulator with high similarity to the cognate BpeEF-OprC efflux pump regulator, BpeT, 
cause increased BpeEF-OprC expression in these strains. Additionally mutations to Ptr1, an 
annotated pteridine reductase, partially contributed to the decreased co-trimoxazole 
susceptibility. However, it is unclear what function Ptr1 has in the folate synthesis pathway, as 
deletion of this gene also caused slight decreases in antimicrobial susceptibility. Finally, in a 
collection of co-trimoxazole resistant clinical isolates from Thailand, high-level expression of the 
BpeEF-OprC was found in the resistant isolates. A mutation to BpeS was also observed in two of 
the clinical isolates that had BpeT-independent BpeEF-OprC overexpression. Co-trimoxazole 
resistant isolates were each resistant to both trimethoprim and sulfamethoxazole individually. 
However, deletion of the bpeEF-oprC efflux pump structural genes in all isolates resistant to co-
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trimoxazole or isolates resistant to trimethoprim alone (except those with a mutant FolA) 
resulted in antimicrobial susceptibility to trimethoprim, co-trimoxazole and sulfamethoxazole. 
These data suggest that sulfamethoxazole is also a substrate of the BpeEF-OprC efflux pump and 
this RND pump is the major resistance determinant contributing to clinically relevant folate 
pathway inhibitor resistance in B. pseudomallei.  
To summarize, we have identified and described several resistance determinants in B. 
pseudomallei causing decreased susceptibilities to trimethoprim, sulfamethoxazole and/or co-
trimoxazole; these include drug target and metabolic pathway modifications and overexpression 
of the BpeEF-OprC efflux pump. Further characterization of these mechanisms and the 
development of specific detection assays could allow for rapid determination of antimicrobial 
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CHAPTER 1:  Introduction to Burkholderia pseudomallei 
 
1.1  The Organism of Interest  
1.1.1 Discovery and characterization. 
Melioidosis, also called Whitmore’s disease, was first described in 1911 in Rangoon 
(presently the city of Yangon in Burma) (1, 2). Whitmore and Krishnaswami described their 
findings from observations of patients and autopsies performed on several diseased victims. The 
authors isolated a bacterium on potato slants and peptone agar. They characterized a Gram-
negative, motile, rod-shaped organism, and confirmed it as the pathogen of interest by fulfilling 
Koch’s postulates. They named this bacterium Bacillus pseudomallei (1), based on the Greek 
adjective pseudês meaning false, as it was similar to a previously described Bacillus mallei 
bacterium. This was the first discovery of the organism that was re-named several times 
throughout its history (3), but was finally named Burkholderia pseudomallei in 1992 (4). 
The bacteria are relatively small in size, measuring approximately 0.8 μm by 1.5 μm (5) 
with rounded ends (6). B. pseudomallei is a Gram-negative and non-spore forming bacterium, 
but can display bipolar staining resulting in a safety-pin appearance microscopically (1, 5, 7). In 
contrast to other Burkholderia spp., including B. thailandensis, B. pseudomallei cannot 
assimilate the monosaccharide arabinose (8). Macroscopically, it grows well on general media in 
ambient air. B. pseudomallei typically forms opaque, white creamy colonies that display a very 
textured, rugose, appearance after extended incubation on standard nutritional media, but they 
also can display diverse morphologies that can switch based on environmental conditions, such 
as nutrition depletion, reduced iron availability, increased temperature, and sub-inhibitory 
concentrations of antimicrobials (9). Interestingly, this organism is also associated with a distinct 
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odor that has been described as sweet and earthy or milky (5). B. pseudomallei is a catalase and 
oxidase positive organism that is capable of utilizing citrate as a sole carbon-source and growth 
on MacConkey agar (4). It is a hardy organism that is very resistant to degradation, can survive 
in the environment for extended periods of time, and is able to tolerate variation in both pH and 
temperature despite being a non-spore former (10). This may be due to the ability of the bacteria 
to enter a viable but non-culturable form (11, 12). It is, however, quite sensitive to ultra-violet 
light and dehydration (10). B. pseudomallei requires the water content in soil to be above 10% 
and is more sensitive to ultraviolet radiation than other soil-borne bacteria (10).  
 
1.1.2 The Burkholderia genus. 
The Burkholderia genus was proposed by Yabuuchi et al. in 1992 based on similarities of 
a number of species in 16S rRNA, DNA homology, lipid and fatty acid composition, and 
phenotype (4). This genus originally included seven species: B. cepacia (the reference 
organism), B. caryophylli, B. gladioli, B. mallei, B. pickettii, B. pseudomallei, and B. 
solanacearum (4). As of October 2013 in the List of Prokaryotic Names with Standing 
Nomenclature (LPSN) the Burkholderia genus consists of 75 distinct species of bacteria and an 
additional 8 bacteria listed as Candidatus Burkholderia spp. (13, 14). The Candidatus taxon is 
used to describe prokaryotes that have not been well characterized (15, 16) or those that are 
characterized but unculturable with current methods (17). The Burkholderia genus is continuing 
to grow with the discovery of novel organisms.  
Burkholderia spp. originate from diverse ecological niches including: soils, surface 
waters, and a variety of hosts, including humans, animals and plants (18). Several Burkholderia 
spp. have been identified as significant plant pathogens, including B. caryophylli, B. plantarii, B. 
glumae and B. andropogonis (18). B. pseudomallei possesses several gene clusters and type III 
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secretion systems similar to those identified in plant pathogens, which suggests an interaction 
with plants and the rhizosphere in endemic regions (19, 20).  
The vast majority of Burkholderia spp. are of little public health concern in humans with 
several major exceptions in addition to B. pseudomallei (18). B. mallei is an obligate mammalian 
pathogen (21), as it has undergone genome reduction and can no longer adapt to an autonomous 
life style (22-24). The reservoir for this organism is primarily horses (21), but also includes 
closely related donkeys and mules (25). B. mallei is the highly pathogenic etiologic agent of the 
disease glanders (21), which results in high mortality rates despite rapid and appropriate 
treatment (26). Several other Burkholderia spp. have been found to cause serious infections in 
immune compromised individuals, particularly those struggling with cystic fibrosis; these 
include: the B. cepacia complex (B. cepacia, B. multivorans, B. cenocepacia, B. stabilis, B. 
vietnamiensis, B. dolosa, B. ambifaria, B. anthia, B. pyrrocinia and B. ubonensis), B. fungorum, 
B. gladioli, B. oklahomensis and B. thailandensis (18, 27-29).  
The Burkholderia genus includes two frequently used surrogate organisms with reduced 
virulence for studies of B. pseudomallei, Burkholderia thailandensis (30, 31) and Burkholderia 
cepacia (32). However, studies in surrogates without confirmatory testing in B. pseudomallei 
and/or B. mallei are becoming uncommon due to inherent differences between these species both 
genetically and phenotypically. Two attenuated strains of B. pseudomallei have recently become 
available, and are preferred for testing over surrogate species (33, 34). 
 
1.1.3 Geographic distribution. 
Historically the distribution of B. pseudomallei was thought to be confined between 20°N 
and 20°S in the moist tropical regions of Southeast Asia and  regions of tropical Australia (6, 35-
37). We now know that while B. pseudomallei is widely considered endemic to Southeast Asia 
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and northern Australia, it is also considered emerging in other tropical and sub-tropical regions 
of the world (Figure 1.1) (38, 39). Cases of melioidosis have occurred in the Indian 
subcontinent, regions of the Middle East, Africa, South America and Central America (6). 
However, the true distribution is likely larger than documented, as melioidosis is an often under-
diagnosed condition especially in areas of the world with poorly developed health infrastructure 
and where B. pseudomallei is not a well known pathogen (38).  
 
 
Figure 1.11 Global geographic distribution of reported melioidosis cases. A recent study 
illustrates the distribution of reported Burkholderia pseudomallei infections. Source (39).  
 
Also of note are outbreaks caused by the importation of B. pseudomallei to non-endemic 
areas. Some notable outbreaks include Paris, France in 1975 (40), London, England in 1992 (41, 
42), and South America (38, 43, 44). While it is suggested that B. pseudomallei will remain 
confined to the environments of warmer regions, such as Columbia (44), in Europe it is assumed 
that B. pseudomallei did not, and would not, survive in the environment in more temperate 
regions. This is because temperatures drop below 0°C and these temperatures cannot be tolerated 





Burkholderia spp. are unique compared to other prokaryotes in that they have multiple 
circular chromosomes, whereas most bacteria typically have one (45). For instance the B. 
pseudomallei strain K96243 genome consists of two chromosomes that are 4.07 and 3.17 
megabase pairs in size and encode for 3,460 and 2,395 predicted genes, respectively (45, 46). Of 
these, a predicted 2,590 genes are shared with other members of the Burkholderia genus, and as 
a result, are suggested to represent the essential core genome (47-49). Interestingly, many of the 
genes on the larger chromosome, Chromosome 1, are associated with cellular growth and 
metabolism, while those on the smaller chromosome, Chromosome 2, are linked with survival 
and adaptation to changing environments (45).  
High genetic variability has even been observed in B. pseudomallei isolated from the 
same patient throughout the course of infection and treatment, suggesting rapid adaptation of this 
organism to its environment (50). This has also been observed following longer periods leading 
to relapsing infections (51), and may be the result of frequent recombination events. B. 
pseudomallei appears to be a genetically promiscuous organism. It is known to integrate large 
regions of DNA, genomic islands, into its chromosomes (48). These genetic features are likely 
obtained from other bacterial species possibly during interactions in the environment. In contrast 
to this, certain strains of B. pseudomallei have been found lacking large regions of their 
chromosomes (52). Both the integration of foreign DNA and loss of genetic regions is likely due 
to the bacteria’s natural homologous recombination mechanisms (53). Based on advanced 
statistical analysis, B. pseudomallei is expected to have a high rate of recombination and a low 
rate of mutation (54). This is additionally supported by the large number of B. pseudomallei 
strains and Burkholderia spp., suggested by Hanage et al. to be an indication of increased 
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recombination rates (54). B. pseudomallei has a very high guanine and cytosine (gc) composition 
compared with other bacterial species. The 69% gc content (35) greatly increases the difficulty 
of genetic manipulation, primer design, and DNA sequencing. 
 
1.1.5 Virulence factors. 
Burkholderia pseudomallei is well adapted for its life as a facultative intracellular 
pathogen. B. pseudomallei has been shown to modulate its own uptake or engulfment by host 
cells including macrophages, at which point the bacterium escapes the endosome and replicates 
within the host cytoplasm (55). From this point it uses actin-based motility to spread between 
adjacent cells and create multi-nucleated giant cells (56). This route of molecular pathogenesis is 
similar to that of Salmonella and Listeria (57). At least 28 specific genes have been identified 
that play a role in B. pseudomallei adhesion, invasion and escape from endosomes, intracellular 
survival, cell to cell spread, actin-based motility and the formation of multinucleated giant cells 
(57, 58). Among these are the Bsa type III secretion system (59), which is necessary for escape 
from endosomes, and BimA, which is essential for actin-based motility and thus required for 
cell-to-cell spread (60). 
In addition to its ability to invade host cells, B. pseudomallei has demonstrated its ability 
to effectively evade host defenses, as it is resistant to complement and lysosomal defensins (61). 
It also has the ability to synthesize proteases, lipase, catalase, peroxidase, superoxide dismutase, 
lecithinase, haemolysins, siderophores, a capsule, numerous type III and type VI secretion 
systems, and flagella as virulence factors (62-64).  
Many Gram-negative bacteria including Burkholderia spp. are capable of producing N-
acyl-homoserine lactone (AHL), a signaling molecule that allows bacteria to monitor their 
population density, known as quorum sensing (65). Once the cell recognizes a quorum, 
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transcriptional activation and up-regulation of virulence factors occurs. These virulence factors 
are commonly associated with pathogenesis, and may include: siderophores, proteases, 
chitinases, lipases, swimming motility, biofilm production, etc. (66). Burkholderia spp. have 
been shown to produce biofilms (67), which may contribute to decreased efficacy of 
antimicrobial therapy and play a role in latency. 
 
1.1.6 Select Agent status. 
B. pseudomallei is categorized as Tier 1 (formerly Category B) Select Agent by the 
Centers for Disease Control and Prevention (CDC) (68) and the Animal and Plant Health 
Inspection Service (APHIS) based on criteria set forth by the Public Health Security and 
Bioterrorism Preparedness and Response Act (69) and the Agricultural Bioterrorism Protection 
Act of 2002 (68). Primarily these criteria identified agents with increased potential for public 
health impact based on morbidity and mortality, ease of dispersion and transmission, public 
perception and requirements for surveillance, diagnostics and treatment (68). As a result, 
research with B. pseudomallei is required to be performed in a Biosafety Level 3 (BSL-3) 
registered space with strict biosecurity and biosafety requirements. Additionally, the Select 
Agent status places restrictions on some types of experiments that can be performed; primarily 
restricting those that would increase virulence or impair the effectiveness of currently 
recommended treatments. Current B. pseudomallei research is focused on developing a better 
understanding the epidemiology, prevalence and transmission and to improve prevention, 
diagnosis and treatment of melioidosis (70). While this has greatly increased interest and 
availability of funding for some types of research on this organism, it has also limited the 
available tools and techniques that are approved for research on B. pseudomallei (71).  
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Recently several attenuated strains of B. pseudomallei have been constructed that are now 
considered excluded from the Select Agent program (33, 34). The Bp82 attenuated strain 
(1026bΔpurM) has been shown to be completely avirulent in immune deficient mice including 
those with severe combined immune deficiency (SCID) (33). These strains can now be used for 
studies that would not be possible with virulent B. pseudomallei. 
 
1.2   Melioidosis 
Melioidosis is a serious, often fatal, infectious disease that occurs in the tropics and 
subtropics, primarily in the hyper-endemic regions of Southeast Asia and Northern Australia. It 
is largely a seasonal disease, and typically infects immune compromised individuals especially 
those with frequent contact with soils and water. The average rate of incidence in highly endemic 
regions is between 3.6 and 5.5 cases per 100,000 people (72). Melioidosis is not commonly 
known in the Western world, however there are cases of travelers returning with infections, 
concerns of the broadening distribution of B. pseudomallei environmentally in a warming 
climate and the risk of intentional release of this agent as a possible bioweapon. 
 
1.2.1 Routes of infection. 
Burkholderia pseudomallei has a relatively low infectious dose; when administered 
intraperitoneally the 50% lethal dose (LD50) for B. pseudomallei in Syrian hamsters is less than 
ten bacteria (73), however the infectious dose varies dependent on the route of infection and 
bacterial strain (74). It is also important to note that there is no data available about the LD50 for 
humans and animal models may not be an accurate estimation of this dose (19).  
There are several known routes of infection for melioidosis; these include 1) cutaneous, 
typically exposure to the organism through broken skin and open wounds, 2) inhalation, such as 
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the aspiration of contaminated water and soils during extreme weather events and heavy rainfall, 
3) ingestion of contaminated water or food, and 4) iatrogenic inoculation (74-78). 
Since B. pseudomallei is found primarily in moist soils and surface water in endemic 
areas (79, 80), it is not surprising that an epidemiological link is established between cases of 
melioidosis and exposure to mud and/or surface waters (3). Cutaneous exposure is suggested to 
be the most common route of infection (6); typically resulting from the exposure of cuts and 
abrasions with contaminated soils and surface water often resulting from occupational hazards 
(37, 81).  
Experimental research has shown that laboratory animals can be infected by aerosol 
challenges (74). Infection by inhalation leads to rapid onset of disease, and this route of infection 
is thought to be responsible for the infection of helicopter crews during the Vietnam War, as 
contaminated soils and water were aerosolized by air currents from the helicopter blades (36). 
The incidence of melioidosis in returning soldiers and helicopter crew members from the 
Vietnam War resulted in the nicknaming of melioidosis as the “Vietnamese time bomb” (104, 
122, 123). The incubation time for cases associated with extreme weather is relatively short, 
which again suggests inhalation as the route of infection (82). Increased cases of inhalation-
related melioidosis cases have been reported following heavy rain and wind from monsoons (83).  
There is quite a bit of evidence that B. pseudomallei causes infections following near drownings 
(37, 84, 85) and the ingestion of contaminated drinking water or from other bodies of water in 
both humans and animals (76, 86). The lack of chlorination in water sources has been 
implemented in case clusters of melioidosis (87). Several studies have been able to culture B. 
pseudomallei from the gastrointestinal tract and in feces (88-90). One can thus speculate that 
food grown or rinsed with contaminated water may be a common source of infection. However, 
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contrary to this, Cheng et al. found no correlation between chlorination of drinking water and 
incidence in the endemic Northern Territory of Australia (91).  
While there is increasing focus on B. pseudomallei research and diagnostics there have 
only been a few cases of iatrogenic inoculations. A study following 60 laboratorians over 15 
years showed only a few individuals had changes in serology, which suggested a low rate of 
subclinical infection. However, this incidence rate was similar to that of the local population, and 
thus suggests the seroconversion was likely due to environmental factors other than working in a 
laboratory, as described in the editorial note (92). Infection with B. pseudomallei is unlikely in a 
laboratory setting under normal work conditions with safe practices (92, 93). 
While the most likely routes of infection with B. pseudomallei are known, the mode of 
infection in individual patients is often unknown. Melioidosis in tourists to endemic regions 
often occurs without any apparent contact with soils (94). In fact, only in 25% of cases is there 
sufficient evidence to suggest a likely route of infection in melioidosis patients (81).  
 
1.2.2 Transmission. 
Melioidosis is typically acquired from interactions with the environment; there is very 
little evidence of person-to-person, animal-to-person, and vector transmission of this disease 
(77). Person-to-person transmission of melioidosis occurs very infrequently (95), a case of 
venereal transmission was the first report in 1975 (96). Additionally, there have been two 
reported cases of mother to child transmission in Australia (97). In one of these cases, B. 
pseudomallei cultures obtained from breast milk were identical to those found in the infant’s 
blood and cerebrospinal fluid by pulsed-field gel electrophoresis (97). Zoonotic transmission of 
melioidosis to humans has been very rarely documented; several cases were discussed by Choy 
et al. in 2000 (98). These infections primarily resulted from occupational exposure to infected 
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animals and presented as wound infections (98). Vector-transmission of melioidosis, by 
Xenopsylla cheopis, the oriental rat flea, and Aedes aegypti mosquitoes from infected to naïve 
guinea pigs, was demonstrated by Blanc and Baltazard in 1949 (99). There is limited evidence to 
support these findings, as very few studies investigating vector transmission have been done 
since (100). However, even if vector transmission does occur, one can argue that its contribution 
to new infections of melioidosis would be limited, as septic melioidosis is of short duration, 
therefore there would only be a very narrow window for a vector to feed on an infected 
individual, become infected and transmit disease. 
 
1.2.3 Risk factors. 
Individuals with chronic health conditions including diabetes mellitus, renal disease, 
thalassemia, and alcoholism have been shown to have significantly higher risk of melioidosis 
infection (37, 101-103). Additionally increased risk of melioidosis is also linked to gender, 
extreme weather events, and occupational and recreational contact with soils and waters in 
endemic regions (6).  
In 2000, a prospective 10 year epidemiologic study of melioidosis in Darwin, Northern 
Australia included of 252 melioidosis patients ranging in age from 16 months to 91 years (104). 
In this study male cases outnumbered female, accounting for 75% of the cases. This gender bias 
was further supported by other studies including a 14-year prospective study in the Northern 
Territory of Australia (105) and in a 10-year study at the University of Malaya Medical Centre in 
Malaysia (106). Additionally, Currie et al. observed that the vast majority of these patients had 
similar medical complications, predisposing risk factors for melioidosis (80%). These included 
diabetes mellitus, history of hazardous alcohol use, and chronic disease (lung or renal) (104). 
Cystic fibrosis has also been shown to be a significant risk for the development of pulmonary 
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melioidosis (3, 107-109). However, HIV infection has not been shown to increase risk of 
melioidosis (110, 111). Interestingly many of these health-related risk factors can been attributed 
to impaired antimicrobial function of neutrophils (6) and altered function of macrophages (112). 
Additionally there is an observed decrease in T-cell mediated immune function in patients with 
diabetes mellitus (113, 114).  
As a result of B. pseudomallei being a soil and water-borne pathogen, extreme weather 
events such as tsunamis, typhoons, and unusually heavy monsoon rainfalls during the rainy 
season have been associated with outbreaks of melioidosis (104, 105, 115-117). On July 18-19, 
2005 the Typhoon Haitang hit Taiwan, resulting in very heavy rainfall. From July 21 through 
August 24, 2005 there were 54 reported cases of melioidosis in Taiwan, which far exceeded the 
9.4 average annual cases that were seen from 2001 to 2004 (82). These cases had molecular 
diversity, which suggested that the outbreak was not due to a common contaminated source. In 
the Northern Territory of Australia, 13 cyclones occurring in the summer of 1998-1999 were 
linked with several case clusters of molecularly diverse melioidosis (6). Extreme weather related 
melioidosis clusters only contribute to a small portion of the public health burden, however 
Currie et al. found that 85% of individual melioidosis cases in northern Australia also occur 
during the tropical monsoon season (104). Global climate change has the potential to increase the 
frequency and severity of extreme weather events. These extreme weather events may also play a 
role in melioidosis distribution, moving B. pseudomallei by water and wind currents within a 
region. A warming and wetter climate could increase the geographic distribution of B. 
pseudomallei worldwide (118). 
Finally, melioidosis appears to be an occupational hazard to those who work outdoors 
including farmers in endemic regions. There is an observed 6-fold higher incidence rate of 
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melioidosis in farmers compared to other populations (101). Rice farmers are often the model 
population for these studies in Southeast Asia (117). However, those with other occupations 
where frequent contact with the soil, such as construction workers and those who are frequently 
outdoors for recreational reasons, are at increased risk as well (119). These populations, 
especially those with other underlying health conditions, would greatly benefit from vaccination 
(101). 
 
1.2.4  Clinical manifestations. 
The incubation time of B. pseudomallei infection is highly variable and largely dependent 
on the route of infection, bacterial strain, and size of inoculum (6). Incubation times can be very 
short when high concentrations of bacteria are encountered, such as in the case of near 
drownings (84, 120). In about 25% of cases where an exposure was able to be determined, there 
was a 1 to 21 day incubation time to the onset of clinical symptoms (81). However, historically 
latent periods have been documented as long as 62 years in a former prisoner of war from World 
War II (121).  
Melioidosis is a disease with incredible variability of clinical presentation; in fact, it has 
been referred to as the “the remarkable imitator” (124) and “the great mimicker” (125, 126). 
Melioidosis most commonly presents as a respiratory infection or pneumonia (3), however acute 
presentation of disease also includes: cutaneous or wound infection, urinary tract infection, 
septicemia, empyema, septic arthritis, visceral abscess or suppurative parotitis in children (3, 7, 
127). Typical disease presentation is categorized into five states: localized, transient bacteremia, 
non-disseminated septicemia, disseminated septicemia and unconfirmed infection (128).  
Serological assays suggest that most B. pseudomallei infections are in fact asymptomatic 
(129-131). However, melioidosis is one of the most commonly fatal infectious diseases in 
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northeast Thailand (132) and the most fatal pneumonia in the Top End region of northern 
Australia (133). B. pseudomallei has the capacity to disseminate hematogenously causing 
overwhelming infection with foci in the liver, spleen and brain (3, 134). In the severe form of 
disease, melioidosis can manifest as a septicemia and can lead to septic shock. Without prompt 
diagnosis and treatment, this condition is fatal in about 90% of cases (3, 117). Between 35% and 
50% of severe septicemic melioidosis cases are fatal within the first 48 hours of patient 
admission (6, 135). Typically such severe cases of melioidosis occur in individuals with one or 
more risk factors (37, 102, 136). As mentioned previously, B. pseudomallei is resistant to many 
broad spectrum antimicrobials commonly used for sepsis (3) this greatly necessitates prompt 
diagnosis to allow treatment with effective antimicrobials in severe cases.  
 
1.2.5 Chronic infection. 
Sadly, despite what appears to be effective treatment, recurrent infections with B. 
pseudomallei are very common among survivors (137). Approximately 6% of patients relapse 
within the first year, and 13% report relapses within 10 years post-initial infection (116, 138). 
Not surprisingly, higher rates of relapse were observed in individuals who were immune-
suppressed (139, 140), those who did not follow treatment recommendations (139, 141), were 
prescribed shorter eradication phase treatments (142), or had more severe disease (137). More 
recently, lower rates of relapses have been reported, this is likely due to improved eradication 
phase treatments (140, 142), to be further discussed in Chapter 2.  
It is not well understood how B. pseudomallei establishes latent infections in the host, but 
it may involve the production of biofilms, and is most likely characterized by reduction or arrest 
of cellular growth and replication. B. pseudomallei avoids the immune response and persists in a 
host by residing within professional phagocytic cells (143). Latent organisms can reside in the 
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host until a time of stress and immune-suppression, at which point the infection becomes 
reactivated and can result in severe disease with mortality rates comparable to acute infection 
(137, 144). While a study by Chaowagul et al. in 1993 did not observe increased antimicrobial 
resistance in organisms recovered from relapses (137), decreased antimicrobial susceptibilities 
were observed in several other studies (145, 146), suggesting B. pseudomallei can adapt based on 
selective pressure in vivo. A better understanding of how B. pseudomallei is capable of persisting 
in the host and evading both host immune defenses and treatment would likely lead to the 
development of efficacious vaccines, improved treatments for chronic and latent infections and 
better diagnostic methods.  
 
1.2.6 Diagnostics. 
Traditional microbiological methods of selective culture and biochemical analysis remain 
the gold standard for the diagnosis of melioidosis (135, 147). While this method is highly 
specific, it has low sensitivity and is time intensive, as it requires several days to determine the 
result (135, 147). There has been much research into the development of rapid detection assays 
with high specificity and sensitivity. Serologic assays including enzyme-linked immunosorbent 
assays (ELISA) and indirect hemagglutination assays (IHA) are valuable diagnostic assays, but 
unfortunately yield frequent false positives when used in endemic regions, as there are elevated 
antibody levels even in healthy populations. Nearly 100% of children over the age of 4 years in 
Thailand are seropositive (3, 117, 131, 148, 149).  
There are many molecular detection techniques, including polymerase chain reaction 
(PCR) assays, developed and validated to detect B. pseudomallei, which have greatly improved 
specificity compared to immunological techniques, and improved sensitivity compared to culture 
(11, 150-154). However, the concentration of B. pseudomallei in clinical samples, especially 
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blood, is highly variable and typically too low for reliable detection (155, 156). Molecular 
detection would likely be improved with the use of other clinical specimens such as sputum, 
urine or pus (156). The development and, most importantly, the validation and implementation of 
modern molecular techniques for diagnosis will hopefully allow for earlier detection of 
melioidosis, resulting in prompt treatment with appropriate antibiotics, which is essential to 
reduce mortality (3).  
 
1.2.7 Treatment. 
B. pseudomallei is naturally resistant to many antimicrobials often used for the treatment 
of sepsis, including β-lactams, penicillins, aminoglycosides, macrolides, and polymyxin B (73). 
Timely diagnosis of melioidosis is imperative to ensure treatment with efficacious antimicrobials 
(3, 6), and has shown to greatly reduce mortality (117, 157). 
At the 2010 U.S. Department of Health and Human Services Burkholderia workshop, 
subject matter experts from around the world gathered to develop recommendations for the 
treatment of B. pseudomallei and B. mallei infections (158). These guidelines were developed 
based on past experimentally determined drug regimen efficacies and current knowledge of 
antimicrobial susceptibilities of these agents, this will discussed further in Chapter 2. The 
current recommendations for melioidosis include two phases of treatment, the intensive and 
eradication phase (93, 94, 158, 159). The initial intensive phase consists of intravenous 
ceftazidime or a carbapenem (meropenem or imipenem) for a minimum of 10-14 days (158). 
During this phase of treatment it is expected that the clinical state of the patient will markedly 
improve, though this process may be very slow (158). The intensive phase is then followed by an 
extended eradication phase of oral co-trimoxazole or co-amoxiclav (a combination of amoxicillin 
and the β-lactamase inhibitor clavulanic acid) for 12-20 weeks (158, 159). Co-amoxiclav should 
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be used for the treatment in the case of pregnancy (158, 160). This stage of treatment was 
intended to reduce the risk of relapsing infection (141, 161).  
 
1.2.8 Prevention and control. 
The development of a vaccine has been long awaited and is greatly needed. However, 
despite intensive research and the investigation of multiple candidates, there is still no vaccine 
available to prevent melioidosis in humans (162). A number of vaccine candidates have been 
tested, but so far no vaccine has been able to fully protect against melioidosis in both its acute 
and chronic form. This work is underway and must include research to understand strain 
variation in endemic areas and identify conserved antigens for vaccine development, or the use 
of a live-attenuated or whole cell vaccine (162).  
Since B. pseudomallei is a saprophytic organism that is primary transmitted from contact 
with contaminated soil and surface water in endemic areas, one of the primary initiatives should 
be education of the public. There could be reduced morbidity and mortality caused by 
melioidosis in endemic regions if the public was educated to understand the importance of 
immediately cleaning wounds, covering wounds, and wearing proper foot and hand protection 
that would reduce injuries and potential exposure when working outside (118, 126). Rice paddy 
workers, rubber plantation farmers, and other outdoor workers, especially those with pre-existing 
chronic health conditions, are the greatest population at risk. Education of these workers and 
their employers would likely reduce the incidence rate of melioidosis among this population. 
Those individuals with pre-existing health-related risk factors for melioidosis should also be 
educated, especially considering the more severe outcome of melioidosis that these patients can 
suffer (106). It also would be important to warn travelers to endemic regions, especially those 
with risk factors, of this disease. At a community level, heightened awareness of the potential for 
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melioidosis to be transmitted through contaminated water sources and through body fluids, 
though rarely reported, could reduce the number of cases (118). Large animal die-offs should be 
investigated; since B. pseudomallei can infect both human and animal populations they may be 
sentinel events indicating a risk of human exposure (118).  
A recent study indicated that environmental management of the pathogen maybe 
possible. Inglis and Buller in 2001 found that in an area where B. pseudomallei was highly 
prevalent in soil and surface water, the reintroduction of native vegetation and remediation of 
chemical fertilizers helped to eradicate B. pseudomallei in the soil (12). There are currently 
studies ongoing to further investigate this potential in rice paddies and rubber plantations (118). 
Additionally, the reduced use of fertilizers and restoration of endogenous vegetation should be 
further investigated as a potential method for environmental remediation of B. pseudomallei 
(163). 
Melioidosis is a notifiable disease in some regions of Australia, which has led to the 
development of a standard case definition (164). It is likely that melioidosis is emerging in other 
tropical and sub-tropical regions of the world where this infection is unrecognized (118). 
Improved diagnostic capacity in rural areas and other regions of the world would improve 
surveillance of the distribution and prevalence of B. pseudomallei. Better surveillance of 
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CHAPTER 2: Antimicrobials and Antibiotics 
 
Antibiotics are naturally occurring antimicrobials that are produced by living organisms 
(bacteria, protozoa, fungi and plants) to eliminate their competition for space and resources (1). 
These compounds are toxic to living organisms at high concentrations (3). Typically organisms 
that produce antibiotics also possess mechanisms to protect themselves, this will be discussed 
further in Section 2.2.4. However, recent studies have suggested that the concentrations of 
antibiotics in the environment would likely be too low to negatively affect nearby competitors 
(3). Instead it is suggested that these compounds may serve as signaling molecules for 
communication between organisms, as these compounds modulate the expression of a wide array 
of genes (3).  
Antimicrobial is a broad term used to describe synthetically made or modified antibiotics, 
but also includes naturally-occurring antibiotics as well. Often both terms are used 
interchangeably or antibiotic will be used to describe clinically relevant antimicrobials. Careful 
design of antimicrobial compounds by medicinal chemists for clinical use allows for 
optimization of the drugs. Prokaryotic cells are unique from eukaryotic cells in many ways, 
which would require too much time and space to discuss here. But many of these differences can 
be exploited for the design of antimicrobials that will specifically inhibit bacteria with limited 
toxicity to the person or animal being treated. Proteomic, genomic and advanced chemical 
modeling techniques are used to ensure that new compounds target highly conserved regions, 
often the active site, of essential compounds that are unique to prokaryotes. The high affinity to 
the drug target with minimal cross-reactivity is important, as any negative effect on eukaryotic 
cells could cause toxicity in a patient.  
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As marvels of modern medicine, antimicrobials have drastically altered our ability to 
combat bacterial infections that challenge our immune systems. Since their introduction and 
widespread use, there have been dramatic reductions in the morbidity and mortality caused by 
many infectious diseases.  
 
2.1 Antimicrobial Classes 
Typically antimicrobials can be grouped into classes based on several factors: route of 
administration, antimicrobial effect, chemical structure and the drug target. The route of 
administration is important in the clinical setting, as most antimicrobials are optimized for oral 
administration, which facilitates outpatient care; however, for more serious infections 
intravenous antimicrobials are preferred as there is generally greater bioavailability of the drug. 
Some antimicrobials are bactericidal, meaning that they cause lysis or cellular death, while 
others that are bacteriostatic only cause arrest of cellular growth and replication when testing in 
vitro (4). This is a traditional method of antimicrobial classification that is determined by 
performing a kill-curve and monitoring the number of viable bacteria over time in the presence 
of the antimicrobial. In the presence of a bacteriostatic compound there will be minimal change 
in the number of viable cells over time, while a bactericidal drug will leave only a very small 
percentage or no viable cells. However, this does not allow for discrimination between cell death 
and persistence of the organism in a viable but non-culturable state, which could indicate 
antimicrobial tolerance.  
A common way to group antimicrobials is based on the essential cellular process that 
they inhibit, or their mode of action. These separate classes target cell wall synthesis, protein 
synthesis, genetic material (DNA and/or RNA) synthesis, and folate synthesis (5). These will be 
discussed and structural groups will be used as examples for each antimicrobial mechanism.  
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2.1.1 Cell wall biosynthesis inhibitors. 
The integrity of the bacterial cell wall is essential for survival and proliferation. 
Additionally, the bacterial cell wall is unique from those of other organisms, making it an ideal 
drug target. Cell wall biosynthesis is targeted by the β-lactam family of antimicrobials, including 
penicillins (structurally similar or modified compounds derived from the first described 
antibiotic, a product of Penicillium notatum; e.g. amoxicillin and carbenicillin) (6) 
cephalosporins (e.g ceftazidime) (5), carbapenems (e.g. meropenem and imipenem) and the 
monobactams (5). The β-lactam drugs target transpeptidases and carboxypeptidases known as 
penicillin-binding proteins (7). These proteins were so named as they bind penicillin, however 
the name does not aid in describing the function of these compounds. There are a number of 
penicillin binding proteins that are essential for polymerization, crosslinking, and elongation of 
the cell, which are all necessary processes for peptidoglycan crosslinking and thus cellular 
division and survival.  
In addition to the β-lactams, glycopeptides and lipoglycopeptides, such as vancomycin, 
also prevent cell wall synthesis by inhibiting the synthesis of peptidoglycan, transglycosylation 
and transpeptidation (5) These antimicrobials are very effective against Gram-positive bacteria, 
but have limited efficacy against Gram-negatives, as not all of these compounds can cross the 
outer membrane of Gram-negatives (5).  
 
2.1.2 DNA and RNA biosynthesis inhibitors. 
In addition to the cell wall synthesis, DNA synthesis is also essential for replication of the 
bacterium and maintenance of the genetic information. RNA synthesis is necessary for 
transcription of mRNA and other RNAs that are necessary for protein production and 
transcriptional regulation. This machinery is targeted by several structural classes. Quinolones 
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(e.g. nalidixic acid) and the derived fluoroquinolones (e.g. ciprofloxacin and norfloxacin) target 
DNA gyrase (8) and topoisomerase IV (9). These compounds prevent the supercoiling of DNA 
and inhibit the ligase activity of gyrase and topoisomerase IV but not the endonuclease activity. 
This ultimately results in double-stranded DNA breaks (10). Double-stranded DNA breaks 
initiate the SOS response in bacteria, which causes large genetic recombination events and 
mutagenic polymerase activity. Rifampicins inhibit the activity of DNA-directed RNA 
polymerase, thereby inhibiting transcription (5). Integrity of DNA and RNA synthesis is 
important, as is the translation of that genetic material into functional proteins and enzymes.  
 
2.1.3 Protein biosynthesis inhibitors. 
Protein synthesis is essential in bacteria for many cellular processes including 
maintenance of homeostasis, genetic material and the cell wall, as well as growth and replication. 
The bacterial ribosome is unique consisting of 30S and 50S subunits, whereas eukaryotic cells 
have ribosomes composed of 40S and 60S ribosomal subunits. This distinction provides unique 
targets for antimicrobials. The protein synthesis machinery is targeted by several classes of 
drugs. Aminoglycosides (e.g. gentamicin and kanamycin) specifically act on the 16S rRNA of 
the 30S subunit preventing ribosomal translocation and thus translation. Additionally 
aminoglycosides have been shown to impair the proofreading capacity of the ribosome causing 
errors and early termination (11, 12). Tetracyclines (e.g. tetracycline and doxycycline) also target 
the 30S ribosomal subunit, but prevent aminoacyl-tRNA from associating with the ribosome (5). 
Macrolides (e.g. erythromycin and cethromycin) on the other hand, bind the 50S subunit and in 
doing so prevent peptidyl transferase activity and ribosomal translocation (13, 14). Similarly, 
chloramphenicol prevents peptidyl transferase activity by binding the 23S rRNA of the 50S 
subunit (13).  
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2.1.4 Folate biosynthesis inhibitors. 
Folate is essential in all living organisms (15), as it plays a critical role in the synthesis of 
purine nucleotides for DNA and RNA synthesis. Tetrahydrofolate (H4folate) is a one-carbon 
donor in a number of biosynthetic pathways, including the synthesis of methionine, purines and 
thymine (15). Animals have the ability to scavenge folate from the environment and thus in 
animals folic acid (a B vitamin) is an essential nutrient, though there are also pterin and para-
aminobenzoic acid (pABA) salvage pathways (2). In contrast, most pathogenic bacteria cannot 
utilize exogenous folates in vitro (16) or in vivo (17); instead prokaryotes must synthesize 
H4folate starting with GTP processing by GTP cyclohydrolase I (GCHY-I) (2) (Figure 2.1). This 
pathway is complex and highly conserved in prokaryotes. Both the salvage and biosynthetic 
folate pathway have the same final steps, which includes processing of dihydrofolate (H2folate) 
into H4folate, though the dihydrofolate reductase (DHFR) enzyme responsible is structurally 
dissimilar in bacteria compared with that found in animals. Within the folate synthesis pathway 
there are a several steps that have been targeted by synthetic antimicrobials including the DHFR 
and the enzyme responsible for a previous step, dihydropteroate synthetase (DHPS) (2).  
Sulfonamides were actually the first antimicrobial drugs used. Prontosil was developed 
by Bayer and was used clinically in the early 1930’s. Since that time there have been many 
sulfonamides (e.g. sulfamethoxoazole) developed and used for the inhibition of the DHPS 
(Figure 2.1). The DHPS enzyme catalyzes the synthesis of 7,8-dihdropteroate from 6-
hydroxymethyl-7,8-dihydropterin pyrophosphate (DHPPP) using pABA to condense DHPPP 




activity. Benzylpyrimides (e.g. trimethoprim) inhibit the activity of dihydrofolate reductase 
(DHFR)further down the synthesis pathway (Figure 2.1). They were discovered by Hitchings et 
al. in the late 1940’s (18, 19). The DHFR enzyme is necessary for the synthesis of H4folate from 
H2folate. Benzylpyrimidies are similar in structure to a portion of the H2folate and will 
competitively bind the DHFR enzyme inhibiting its activity. Trimethoprim, and other 
diaminopyrimidines are specific inhibitors of bacterial DHFRs, with nearly 10
4
 times higher 
binding affinity due to structural differences between bacterial and mammalian DHFRs (20-22). 
In 2000, Quinlavin et al. reinvestigated the mechanisms of action of trimethoprim (20). They 
Figure 2.12 Folate biosynthesis and salvage pathways. This illustration shows the bacterial 
folate synthetic pathway (pink) and the para-aminobenzoic acid (pABA) synthesis pathway 
(blue). Some organisms possess folate salvage pathways (green) while other salvage necessary 
precursors including pterin (yellow) and pABA (purple). Source (2). 
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observed that in trimethoprim treated cells H4folate levels diminished initially, then H2folate 
levels declined as the H2folate was catabolized or oxidized into more stable precursors, including 
para-aminobenzoyl-glutamate (pABGlu) and folic acid (20). This suggests that trimethoprim 
inhibits both DHFR and the conversion of folic acid to H2folate (20). Trimethoprim, 2,4-
diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine is an synthetic antimicrobial and is the preferred 
inhibitor of its class because it is broad spectrum, highly specific for the bacterial enzyme, and 
exhibits good pharmacokinetic and pharmacodynamic properties for use as a therapeutic (23). 
Trimethoprim was first used in the early 1960’s in the United Kingdom and since then has 
become a commonly used antimicrobial agent (24), though it is now often prescribed in 
combination with sulfonamides, such as sulfamethoxazole. 
Sulfonamides and benzylpyrimides are commonly used in combination (e.g. 
trimethoprim and sulfamethoxazole), as studies have shown significant increases in the efficacy 
of treatment. This combination approach is recommended for clinical use when there is concern 
about the emergence of antimicrobial resistance, such as when lengthy treatment regimens are 
required, including that of tuberculosis (25) or melioidosis (26). Combination therapy is also 
encouraged when there is an observed synergist effect, meaning the antimicrobial effect of the 
combination is greater than the sum of the effect of each individual drug (25). Additionally 
combination therapy is often prescribed when the etiological agent of a critically ill patient is still 
unknown and to improve the antimicrobial spectrum (25). 
 
2.2   Antimicrobial Resistance 
Recently the threat of “super bacteria” has become a concern in the media primarily due 
to the emergence of several high profile, community-acquired, drug resistant organisms, 
including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant 
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Staphylococcus aureus (VRSA), vancomycin-resistant Enterococcus spp. (VRE), multidrug-
resistant Mycobacterium tuberculosis (MDR TB), extensively drug resistant Mycobacterium 
tuberculosis (XDR TB), and most recently carbapenem-resistant Enterobacteriacea (CRE). 
Overall there has been a very sharp increase in the frequency of multi-drug resistance in Gram-
negative organisms (27). In 2001 the World Health Organization (WHO) published a set of 
recommendations on the efficacious use of antimicrobials to slow the emergence of resistance 
(28). Their recommendations include improved 1) surveillance of antimicrobial resistant strains 
(to monitor the distribution of resistance and allow for treatment with appropriate 
antimicrobials), 2) infection control and sanitation in the clinical setting (to reduce nosocomial 
infections), 3) antibiotic use in animals (to reduce the environmental prevalence of antibiotics 
and prevent the emergence of antibiotic resistance in this setting) and 4) public awareness (to 
improve patient compliance with drug regimens and education to enhance understanding on 
when antimicrobial prescription is appropriate). While steps have been made forward in all of 
these areas, there is much work remaining to be done.  
The widespread distribution of antimicrobial resistant bacteria has made many of the first 
discovered antibiotics obsolete (29). This has resulted in increased use and reliance on synthetic 
antimicrobials, for which there are likely no naturally-occurring enzymes that would inactivate 
these drugs. However, antimicrobial resistance in quick to emerge even with synthetically 





Figure 2.23 Timeline of antimicrobial drug emergence. This illustration shows the time 
between the introduction of novel antimicrobials into clinical use and the emergence of resistant 
strains. Source (30). 
 
The underlying causes of antimicrobial resistance to novel therapeutics are debated in the 
literature. Many have argued that increased exposure of a microorganism to an antimicrobial due 
to recurrent infections, very long treatments, patient non-compliance, inappropriate drug choices 
or environmental contamination will cause frequent mutations leading to the emergence of 
resistance (31, 32). Other studies have shown that spontaneous genetic mutations lead to 
resistance just as readily as with exposure to the antimicrobial (33). Cirz et al. recently 
demonstrated that in strains of E. coli with a mutant LexA protein incapable of proteolysis, there 
was a 250-fold decrease in the emergence of ciprofloxacin resistance (29). Their study suggests 
that activation of the SOS response in E. coli, which among other things, leads to the expression 
of a highly mutagenic DNA polymerase, increased the rate at which ciprofloxacin resistance 
arose, though this finding may largely be a result of the fluoroquinolone propensity to cause 
double-stranded DNA breaks, which trigger an SOS response.  
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2.2.1  Antimicrobial susceptibility testing. 
Antimicrobials are commonly tested for their anti-bacterial activity in vitro, this is known 
as antimicrobial susceptibility testing or minimal inhibitory concentration (MIC) testing. The 
MIC of a drug can be determined by dilution, microdilution, disk diffusion or most recently by 
Etest
®
 technique. In the United States, the Clinical and Laboratory Standards Institute (CLSI) 
publishes guidelines for how MIC testing should be performed for many pathogens (34). The 
MIC is used to predict the likelihood of successful treatment with the recommended dosage of 
the antimicrobial tested against the organism of interest. Based on the MIC value for a given 
genus and species, the tested isolate is categorized as “susceptible”, “intermediate” or “resistant”. 
In vivo, these groupings are related to the range of drug concentration that can be achieved 
without significant toxicity, called the therapeutic window. This is largely dependent on the 
pharmacokinetic and pharmacodynamic properties of the drug. If the MIC is shown to fall within 
the therapeutic window, the organism is “susceptible” and it is expected that treatment with the 
tested antimicrobial will be effective (25).  
However, it is complicated to relate the MIC in vitro to the true activity of the drug in 
vivo. In the laboratory setting, bacteria are given all the nutritional components they need and are 
tested during active growth and replication (35). Many antimicrobial drugs, such as gentamicin 
and rifampin are only inhibitory during active growth of the organism. During latency it can then 
be assumed that organisms such as B. pseudomallei would be tolerant to all of the above-
mentioned antibiotics as well as others, though this would not be evident by in vitro MIC testing. 
Other mechanisms such as biofilm production and stress-induced responses may impair the 
efficacy of antimicrobial therapy, but these factors may be considered drug tolerance rather than 
resistance (36).  
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2.2.2  Mechanisms of drug resistance. 
Bacteria have versatile mechanisms that protect them from the toxic effects of 
antimicrobials. Antimicrobial resistance can be intrinsic, meaning that reduced drug 
susceptibility is a function of the inherent physiological properties of the bacterium (37), or 
acquired in populations that were previously susceptible, usually by horizontal gene transfer or 
by random mutation(s). Acquired resistance mechanisms are especially concerning as they can 
rapidly disseminate across bacterial populations, potentially making the specific drug ineffective 
against many pathogens.  
 
Figure 2.34 Illustration depicting known mechanisms of antimicrobial resistance. This 
illustration shows the major mechanisms of antimicrobial resistance in bacteria, including 
reduced drug accumulation (efflux and exclusion), alteration of the drug target or targeted 
pathway, overexpression of the target, and inactivation or sequestration of the drug. Source (36). 
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Antimicrobial resistance is generally a function of one or several of the following, which 
will be discussed in more detail below: modification of the drug target, inactivation of the drug, 
active efflux, changes to the targeted pathway(s), overproduction of the target, sequestration of 
the drug, reduced drug permeability or a combination of mechanisms (Figure 2.3) (36, 38).  
 
2.2.3  Drug target modification. 
Modification of the antimicrobial drug target can prevent interactions of the antimicrobial 
with the target. However, it is important that these modifications maintain function of the drug 
target, as many antimicrobial targets are enzymes involved in essential cell processes. Mutations 
that cause major changes in an enzyme structure might allow the bacteria to be resistant to the 
drug; however the cell will likely be negatively affected, i.e. the mutation will result in a fitness 
cost. Typically drug target modifications are acquired as a result of accumulated chromosomal 
mutations (39, 40) and cause slight distortions in structure. These mutations may occur 
spontaneously or by selective pressure. An example is the modification of the trimethoprim drug 
target, DHFR. This enzyme is required for folate synthesis, an essential process in bacteria 
(Section 2.1.4).  
There are currently over 20 different trimethoprim resistant DHFRs known to be 
transferable between organisms (42, 43). Some of these DHFRs have originated from organisms 
other than bacteria, such as the Plasmodium falciparum parasite (44), while others originate from 
various bacterial species, including Bacteriodes spp., Clostridium spp. Neisseria spp. and 
Mycobacterium catarrhalis (24). These trimethoprim resistant DHFRs are commonly used in 




Other than mutations to the structure of the drug target itself, small molecules can 
competitively bind to the target and modify it to prevent or disrupt the association of the target 
with the antimicrobial or absence of the drug target. This mechanism confers resistance to 
tetracycline, where Tet(O) binds the post-translocational ribosome and causes conformational 
changes to the ribosome allowing for the dissociation of tetracycline, ultimately resuming protein 
synthesis (45). Deletion of the target is a rare but very effective resistance mechanism. 
Chromosomal deletions of large regions containing the penicillin-binding protein 3 (PBP 3) have 
been observed in several clinical B. pseudomallei isolates resistant to ceftazidime (41). The 
absence of this gene, while conferring resistance, affected cellular division and resulted in long 
filamentous growth and reduced growth rates (41). This mechanism of ceftazidime resistance 
will be discussed further in Section 2.3.2. 
 
2.2.4 Enzymatic drug inactivation or modification. 
Naturally occurring antibiotics are produced by many genera of bacteria. Interestingly, 
the organisms that produce antimicrobials would also be negatively affected by the compounds. 
However, the production of such antimicrobials is often coupled with expression of mechanisms 
for protection. These defenses tend to cause inactivation or destruction the molecular structure of 
the drug. A well-known example is the hydrolysis of the β-lactam ring by β-lactamase enzymes. 
There are a number of different β-lactamases that target various drugs including penicillins and 
cephalosporins, and are generally classified by the drugs they inhibit (e.g. penicillinases, 
cephalosporinases and oxacillinases) (46). The first identified penicillinase was described in 
1940 in Escherichia coli prior to the use of penicillin clinically (47). Most β-lactamases have 
broad activity but do not cause inactivation of the carbapenems (e.g. meropenem and imipenem). 
However, a number of carbapenemases have recently been identified in Gram-negative bacteria 
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(48) and these resistance determinants are spreading rapidly in the clinical setting (49-51). 
Efforts are ongoing to prevent further dissemination of these resistance genes and preserve the 
efficacy of carbapenems, which are often used for the treatment of severe or multi-drug resistant 
infections (49). In B. pseudomallei the chromosomally-encoded PenA β-lactamase is linked with 
resistance to co-amoxiclav (106). The PenA β-lactamase will be discussed further in Section 2.3. 
In addition to enzymes that degrade the antimicrobial, in some cases enzymes alter the 
drug by the addition of chemical groups. For example acetyltransferase (52) and 
phosphotransferase (53) will add acetyl or phosphate groups, respectively, to chloramphenicol 
causing a loss of its antimicrobial properties. Similarly, plasmid-encoded adenylyltransferases 
can modify aminoglycosides, such as streptomycin and spectinomycin (54).  
 
2.2.5  Drug target pathway modification. 
Modification of the essential pathway targeted by an antimicrobial is complicated and 
typically involves horizontal gene transfer of a replacement enzyme for the susceptible drug 
target. There is much un-cited mention of metabolic bypass resulting in trimethoprim and 
sulfamethoxazole resistance in the literature. However, recently the presence of a folM gene in E. 
coli was shown to complement strains lacking dihydrofolate reductase (55). It is feasible that 
such a gene with limited structural homology, but similar function, could replace an 
antimicrobial inhibited enzyme (FolM will be further discussed in Chapters 5 & 6). Additionally 
one could speculate that replacement of the entire pathway would result in a resistant phenotype. 
For example, an isolate that acquires the eukaryotic genes necessary for scavenging folic acid 
from the environment and subsequent processing of the compound into the essential H4folate 




2.2.6  Drug target overproduction. 
Antimicrobials are designed to have high affinity for their respective targets, which 
provides effective inhibition. However, mutations that cause increased expression of the drug 
target can result in resistance to the antimicrobial. This resistance is a function of an imbalance 
caused by a high concentration of drug target overwhelming the inhibitory capacity of the 
available antimicrobial. Theoretically this problem could be alleviated by further increasing the 
concentration of the antimicrobial; however this is not typically feasible as it could cause toxicity 
to the patient. Similarly, the overproduction of drug target substrates would improve competitive 
binding of the substrate over the structurally similar antimicrobial. An example of this was 
described in the 1940’s, where the overproduction of pABA was found to result in sulfonamide 
resistance in clinical Staphylococcus aureus isolates (56, 57). Sulfonamides, as described in 
Section 2.1.4, are structural analogs of pABA and competitively bind to DHPS causing 
inhibition of the enzyme function. However, the reported 100-fold overproduction of pABA 
improved the frequency at which DHPS bound pABA instead of the sulfonamide. The 
overproduction of drug target and substrates may not be possible for resistance to all 
antimicrobials, as often overproduction can slow growth and replication in addition to having 
toxic effects on the cells.  
 
2.2.7  Drug sequestration. 
Among rare antimicrobial resistance mechanisms, proteins that selectively bind 
antimicrobials preventing their association with the intended drug target have been noted. An 
example of this was described in E. coli strains that were resistant to coumermycin A1 (58). The 
authors found that overexpression of the wild-type gyrB gene resulted in lower available drug 
concentrations. This was not observed in strains expressing a truncated version of the gyrB gene. 
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Interestingly, GyrB is the drug target for coumermycin A1, and its overexpression is thought to 
allow binding between the 2 compounds, resulting in sequestration of the drug and thus allowing 
other functioning DNA gyrase components to remain unaffected (58). Though this particular 
example could potentially be considered target overproduction as well, target overproduction 
would not necessarily allow for sequestration of the drug. Sequestration would require high 
affinity binding and sufficient levels to cause a significant decrease of the unbound available 
antimicrobial. 
 
2.2.8  Reduced drug permeability. 
Reduced cell permeability is primarily a function of the outer membrane found in Gram-
negative organisms (59, 60). Some bacteria have significantly reduced outer membrane 
permeability compared to others (e.g. B. cepacia membrane permeability is 89% lower than that 
of E. coli (61)). The cell permeability is largely dependent on the structure and chemical 
modifications to the lipid A component of the lipopolysaccharide, found in the outer membrane 
of Gram-negative bacteria (62) and protein channels, porins, in the outer membrane (63). Porins, 
such as OmpD, are necessary for the transport of solutes across the outer membrane (59, 64). 
Porins allow for size exclusion of many large compounds, including some antimicrobials (65). 
Reduced expression of the outer membrane porins can further inhibit the influx of antimicrobials 
(66). The reduced rate of influx decreases the accumulation of the drug in the bacterial cell, and 
thus its antimicrobial properties. Siritapetawee et al. demonstrated this in 2004 as they 
determined the permeability rates of a number of antimicrobials in Burkholderia spp. (65). Small 
molecule diffusion can be reduced by 5 to 100 fold (67, 68), thereby reducing the uptake of 
hydrophobic agents including β-lactams and rifamycin (69).  
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Biofilms are also known to reduce the inhibitory effect of antimicrobials against bacteria, 
either directly by interactions with the drug or indirectly by alterations to the cell membrane 
permeability or general increased fitness of the bacteria. The genes stimulated by quorum 
sensing include those necessary for the production of biofilms. Biofilms are multicellular 
communities that are attached to surfaces (such as bone, tissue, catheters, etc.) and consist of 
bacteria embedded in a biopolymeric extracellular matrix (70). Bacteria within biofilms are 
overall more resistant to antimicrobials, likely due to the inability of the drug to readily diffuse 
through the extracellular matrix. In some cases MIC changes of 1,000 fold were observed (71). 
Biofilm production within the host organism impairs the efficacy of clinical treatment and may 
provide an explanation for chronic infections.  
 
2.2.9  Drug efflux. 
Efflux pumps are membrane associated protein complexes that actively mediate the 
extrusion of potentially harmful substrates, such as heavy metals, toxins and antimicrobials, from 
the bacterial cytoplasm or periplasmic space to the exterior of the cell (37). This efflux is an 
energy-dependent process that is driven by either the proton motive force (72) or ATP hydrolysis 
(73). There are five major classes of bacterial efflux pumps: ATP-binding cassette (ABC) family 
(74), the major facilitator superfamily (MFS) (75), multidrug and toxic compound extrusion 
(MATE) family (76), the resistance-nodulation-division (RND) family (77) and the small 
multidrug resistance (SMR) family (Figure 2.4) (78). 
While other efflux pumps are functional as a single component, RND efflux pumps are 
unique in that they are tripartite. The RND transporter protein is located in the cytoplasmic 
membrane and recognizes specific substrates for extrusion (80). The outer membrane protein 
(OMP) consists of β-barrels that anchor the protein to the outer membrane (79). Finally the 
48 
 
membrane fusion protein (MFP) interacts with both the RND transporter and the OMP either to 
hold the complex together or bridge the gap between these two components (81-83). Typically 
the transporter, OMP and MFP are expressed from the same operon, which is tightly regulated 
by local and/or global regulators (79). Overexpression of efflux pumps can be triggered by 
effectors including the drug itself or by mutations to regulators or promoters (84-87). 
Interestingly, in some organisms there is a negative correlation between expression of RND 
efflux pumps and outer membrane porins, such as with increased AcrAB-TolC production and  
 
 
Figure 2.45 Illustration depicting the various superfamilies of efflux pumps. Source (79).  
Abbreviations: MFS, major facilitator superfamily; SMR, small multidrug resistance 
superfamily; MATE, multidrug and toxic compound extrusion superfamily; RND, resistance-
nodulation-cell division superfamily; ABC, ATP-binding cassette superfamily.  
 
decreased OmpF levels in Escherichia coli (79). This combination of increased efflux and 
decreased influx has a strong synergist effect on the antimicrobial susceptibility of the bacterium. 
The combination of reduced cell permeability and efflux has been implicated for the extensive 
intrinsic resistance of B. pseudomallei to many diverse classes of antimicrobials (36, 88). This 
synergy is demonstrated by the differential antimicrobial susceptibility results observed from 
49 
 
expression of the BpeEF-OprC efflux pump in various gram-negative organisms. When 
expressed in B. pseudomallei this efflux pump caused significantly higher reductions in 
chloramphenicol and trimethoprim susceptibilities compared to that observed in Pseudomonas 
aeruginosa (36, 89). 
The natural physiological role of efflux pumps in bacterial populations is not well 
understood (90). Several functions other than antimicrobial efflux were discussed by Piddock 
and Poole in their recent reviews of the subject. These included response to cellular stress, 
response to environmental stress, and the dispersal of virulence factors (91, 92). Interestingly, 
soil dwelling bacteria on average have many more efflux pumps than those from other niches 
(93). It may be a function of efflux pumps to protect the cell from molecules produced by 
competing bacteria and plants (94).  
 
2.3 Clinically Relevant Antimicrobial Resistance in B. pseudomallei 
2.3.1  Intrinsic resistance. 
Burkholderia pseudomallei, as described in Chapter 1, is a Gram-negative pathogen 
responsible for the severe disease melioidosis. The antimicrobial therapy for melioidosis is 
difficult due to the intrinsic resistance of B. pseudomallei to various antimicrobial classes 
including aminoglycosides, macrolides, cephalosporins, penicillins, and tetracyclines, which will 
be discussed briefly.  





 generation cephalosporins is the enzymatic inactivation of the 
antimicrobials by a β-lactamase PenA (33, 95-97).  
Aminoglycosides, including gentamicin, kanamycin, spectinomycin, streptomycin and 
tobramycin, are very effectively expelled from B. pseudomallei by the AmrAB-OprA RND 
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efflux pump and to a lesser extent by the BpeAB-OprB RND efflux pump (98, 99). Recent 
studies have identified and characterized strains naturally lacking the AmrAB-OprA efflux pump 
which are susceptible to these antimicrobials (98, 100). Similarly macrolides, including 
clarithromycin and erythromycin, are good substrates for the AmrAB-OprA efflux pump and are 
also effluxed at low levels by BpeAB-OprB (36). The BpeAB-OprB efflux pump expels 
quinolones including rifampicin (101).  
Intrinsic resistance to tetracyclines occurs as a result of efflux. Doxycycline has been 
shown to be a substrate of the AmrAB-OprA, BpeAB-OprB and BpeEF-OprC efflux pumps (36, 
89, 101). Finally, B. pseudomallei is naturally insensitive to polymyxin B, likely due to the 
lipopolysaccharide component of the outer membrane (36, 102). Because B. pseudomallei is 
naturally resistant to so many classes of antimicrobials there are currently very few choices, and 
the development of an efficacious treatment regimen is complicated. The current 
recommendations for treatment of melioidosis are largely the result of which antimicrobials B. 
pseudomallei is not intrinsically resistant to and provide the greatest success. 
 
2.3.2  Acquired resistance. 
Acquired resistance in B. pseudomallei is relatively rare, though resistant isolates have 
been identified clinically following the acute and chronic phases of treatment. The initial 
treatment for melioidosis consists of intravenous ceftazidime (a 3
rd
 generation cephalosporin) for 
a minimum of 10-14 days (26). The use of ceftazidime as an initial therapeutic for melioidosis 
has improved mortality rates drastically from 80% to 43% (103). Currently, resistance to 
ceftazidime is rare in B. pseudomallei, however several clinical cases have been reported in 
response to treatment with ceftazidime (41, 97, 104). In a recent study characterizing several 
ceftazidime resistant clinical isolates, deletion of BPSS1219, encoding PBP 3 the ceftazidime 
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drug target was observed (41). Large chromosomal deletions were noted in the clinical strains, 
which included three penicillin-binding proteins. However, the testing of targeted deletions of 
each gene indicated that BPSS1219 deletion was responsible for the observed high-level 
resistance. This gene also appears to be important for cellular division, as isolates lacking this 
gene require glycerol in the media and are very slow growing, and interestingly, isolates lacking 
BPSS1219 were found to have increased susceptibility to imipenem (41), a secondary drug 
choice for the intensive phase treatment.  
In other clinical isolates, resistance to ceftazidime was found to be a result of either 
mutation to the PenA β-lactamase (i.e. C69Y or P167S) (97, 105) or due to overexpression of 
PenA (105). In addition to causing ceftazidime resistance, PenA is also linked with resistance to 
amoxicillin and clavulanic acid (co-amoxiclav). The PenA β-lactamase is effective at 
hydrolyzing the β-lactam ring of amoxicillin, and mutations to the PenA β-lactamase, including 
S72F, were shown to cause significant decreases in co-amoxiclav susceptibilities (97, 106). Co-
amoxiclav is a secondary choice for the eradication phase of melioidosis treatment and is 
recommended for use in pregnant women (26). This combination therapy is synergistic as the 
amoxicillin β-lactam is protected by the β-lactamase inhibitor clavulanic acid. However, 
resistance to co-amoxiclav was reported at 1.5% of clinical B. pseudomallei isolates in 1998 
(107).  
In such cases where ceftazidime cannot be used, the alternatives for the intensive phase 
of treatment are the carbapenems meropenem and imipenem (26). Meropenem is very effective 
for the treatment of melioidosis, though is much more expensive than ceftazidime and has lower 
stability at ambient temperature (26). Imipenem is also highly effective against B. pseudomallei 
but is currently not recommended due to higher frequency of severe side effects (26). To my 
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knowledge there have been no reports of resistance to these carbapenems in B. pseudomallei. But 
interestingly, our lab is currently investigating a potential carbapenemase present in 
Burkholderia ubonensis (L. Randall and H. P. Schweizer, unpublished work).  
The eradication phase of melioidosis treatment typically consists of at least 12-20 weeks 
of co-trimoxazole (26). Co-trimoxazole, a combination of trimethoprim and sulfamethoxazole, 
provides a sequential blockade of the folate synthesis pathway. Combination therapies are often 
used because of their synergist effect and the reduced risk of developing resistance. Despite this, 
there have been reported co-trimoxazole resistance frequencies of 2.5% in Australia (108) and 
13-16% in Thailand (109, 110). These resistance frequencies may be over-estimated due to the 
inherent technical difficulties associated with sulfonamide susceptibility testing. There has been 
very little work done to determine the causative mechanisms of this resistance. In other 
organisms, drug target mutations to the DHFR and DHPS are known to confer resistance to 
trimethoprim and sulfamethoxazole, respectively (42 1276, 111), however no such mutations 
have been documented in B. pseudomallei. A study characterizing the BpeEF-OprC efflux pump 
from B. pseudomallei showed that expression of this efflux pump in Pseudomonas aeruginosa 
resulted in efflux of trimethoprim and chloramphenicol (89), and is also known to efflux 
tetracyclines, including doxycycline (T. Mima and H.P. Schweizer, unpublished results). 
Doxycycline was previously used in combination with other drugs for the treatment of 
melioidosis, but is no longer recommended (26). Chloramphenicol is occasionally used in the 
case of neurologic melioidosis infection as it can cross the blood-brain barrier, but was shown to 
be ineffective for oral treatment of melioidosis (112). This BpeEF-OprC efflux pump is 
controlled by the BpeT lysR-type transcriptional regulator. Point mutations to BpeT have been 
shown to cause increased expression of the efflux pump (T. Mima and H.P. Schweizer, 
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unpublished results), as did the interruption of bpeT by a recombination event in a clinical B. 
pseudomallei isolate with decreased chloramphenicol and trimethoprim susceptibilities (104).  
 
2.4 Dissertation Aims and Preview of Chapters 
This introduction has provided an overview of our basic understanding of the 
Burkholderia pseudomallei bacterium and problems encountered clinically in the treatment of 
melioidosis. B. pseudomallei is resistant to many antimicrobials, however no work has been done 
to date has to elucidate the mechanisms of trimethoprim, sulfamethoxazole and co-trimoxazole 
resistance. Improved understanding of the underlying mechanisms leading to co-trimoxazole 
resistance would allow for appropriate antimicrobial usage to prevent the emergence of 
resistance and allow surveillance and monitoring of the resistance determinants. This information 
would also be of value to those working to improve the current treatment strategies and develop 
enhanced and novel therapeutics for the treatment of melioidosis. In this context, the dissertation 
describes experiments and results of 4 major research projects to investigate B. pseudomallei 
resistance mechanisms. The work that will be described focuses on the investigation and 
characterization of folate pathway inhibitor resistance in B. pseudomallei clinical and 
environmental isolates, as well as laboratory-induced mutants, as it particularly relates to the 
molecular mechanisms of trimethoprim and sulfamethoxazole resistance.  
 
The overarching questions to be addressed by this work are:  
 What resistance mechanisms are responsible for trimethoprim and sulfamethoxazole 
resistance in clinical isolates?   
 Are environmental isolates also resistant to trimethoprim and sulfamethoxazole, and 
if so are the same resistance mechanisms responsible? 
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 Are the mechanisms of trimethoprim and sulfamethoxazole resistance the same in 
laboratory induced mutants compared to clinical and environmental isolates? 
 Is co-trimoxazole resistance simply the result of a combination of trimethoprim and 
sulfamethoxazole resistance mechanisms? 
 What mechanism(s) are responsible for co-trimoxazole clinical and environmental 
isolates, and are these different than those in laboratory induced mutants? 
 
These questions lead to the hypothesis that the definition and characterization of 
trimethoprim and sulfamethoxazole resistance mechanisms will allow for the rapid identification 
of these resistant determinants in clinical isolates and maliciously engineered strains, which will 
enable timely administration of appropriate treatments and prophylaxis.  
To test this hypothesis, the following specific aims were pursued: 
I. Identify and characterize trimethoprim resistance mechanisms in clinical and 
environmental Burkholderia pseudomallei isolates in Chapter 3: “The BpeEF-OprC 
Efflux Pump is Responsible for Widespread Trimethoprim Resistance in Clinical and 
Environmental Burkholderia pseudomallei Isolates”. 
II. Generate and characterize trimethoprim and sulfamethoxazole resistant laboratory 
induced mutants of Bp82 in Chapter 4: “Mechanisms Responsible for Acquired 
Trimethoprim and Sulfamethoxazole Resistance in Burkholderia pseudomallei”. 
III. Generate and characterize co-trimoxazole resistant laboratory induced mutants of Bp82 in 




IV. Identify and characterize co-trimoxazole resistance mechanisms in clinical and 
environmental Burkholderia pseudomallei isolates in Chapter 6: “The BpeEF-OprC 
Efflux Pump is a Major Contributor to Co-Trimoxazole Resistance in Burkholderia 
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CHAPTER 3: The BpeEF-OprC Efflux Pump is Responsible for 
Widespread Trimethoprim Resistance in Clinical and 




The work presented in this chapter and published paper describes the frequency of 
trimethoprim resistance in a collection of clinical and environmental B. pseudomallei isolates 
from endemic regions. We identified BpeEF-OprC efflux pump expression as the essential 
determinant for trimethoprim resistance in the clinical and environmental isolates tested.  
 
3.1 Summary 
Trimethoprim-sulfamethoxazole (co-trimoxazole) is the primary drug used for oral 
eradication therapy of Burkholderia pseudomallei infections (melioidosis). Here, we demonstrate 
that trimethoprim resistance is widespread in clinical and environmental isolates from northeast 
Thailand and northern Australia. This resistance was shown to be due to BpeEF-OprC efflux 
pump expression. No dihydrofolate reductase target mutations were involved although frequent 
insertion of ISBma2 was noted within the putative folA transcriptional terminator. All isolates 
tested remained susceptible to trimethoprim-sulfamethoxazole, suggesting that resistance to 
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3.2    Introduction 
Burkholderia pseudomallei is a saprophytic Gram-negative bacterium mostly found in 
soil and water in many subtropical and tropical regions of the world including northern Australia 
and southeast Asia (1, 2). B. pseudomallei is the etiologic agent of the multifacted disease 
melioidosis (2-6). Treatment of melioidosis is complicated by the intrinsic resistance of B. 
pseudomallei to many classes of antimicrobials (7, 8). The current recommended therapy 
includes an initial intensive phase followed by a lengthy eradication phase to prevent relapse (6, 
9, 10). Most patients require at least 10-14 days of parenteral ceftazidime or a carbapenem 
followed by 12-20 weeks of oral trimethoprim-sulfamethoxazole with or without doxycycline. 
Trimethoprim and sulfamethoxazole inhibit the folic acid biosynthetic pathway by targeting 
dihydrofolate reductase (FolA) and dihydropteorate synthase (FolP), respectively (11). The 
synergistic trimethoprim-sulfamethoxazole combination, co-trimoxazole, has a potent 
antimicrobial effect. B. pseudomallei co-trimoxazole resistance has been previously documented 
in endemic regions (12-16) and rates range from 2.5% in Australia (13) to 13-16% in Thailand 
(12, 14). Previous studies have identified and characterized trimethoprim resistance mechanisms 
including resistant diyhdrofolate reductases in other organisms, such as Escherichia coli (11, 17), 
but in B. pseudomallei trimethoprim resistance has only been studied indirectly in surrogate (18) 
or closely related bacteria (19) showing that efflux could play an important role in resistance. 
The objective of this study was to identify and characterize the mechanism responsible for 
trimethoprim resistance in clinical and environmental B. pseudomallei isolates from northeast 





3.3   Materials and Methods 
3.3.1 Bacterial strains. 
B. pseudomallei 1026b was used as a prototype strain for all experiments in this study 
(20-22). Additionally, a collection of 30 clinical and 30 environmental isolates from Thailand 
(isolated in 2001 and 1990-2001 respectively) and 4 clinical and 1 environmental isolate from 
Australia (isolated between 1994-1997) were examined, see Table 3.1. All procedures involving 
B. pseudomallei were performed in Select Agent approved Biosafety Level 3 (BSL3) facilities in 
the Rocky Mountain Regional Biosafety Laboratory at Colorado State University using approved 
Select Agent compliant procedures and protocols. Escherichia coli strain DH5α (23) was 
primarily used for cloning experiments, in addition to HPS1, while RHO3 (24) was used as a 
conjugation donor strain to mobilize plasmids into B. pseudomallei (Table 3.2). The E. coli and 
B. pseudomallei strains were grown in Lennox Luria-Bertani (LB) broth or agar media (MO BIO 
Laboratories, Carlsbad, CA). Media was supplemented with 400 μg/mL of diaminopimelic acid 
(DAP) (SIGMA, St. Louis, MO) for growth of RHO3. For selection of desired plasmids in E. 
coli strains 100 μg/mL of ampicillin (SIGMA, St. Louis, MO) and 35 μg/mL of kanamycin (Km; 
SIGMA) were added to the media as necessary, while selection for kanamycin resistant markers 
in B. pseudomallei was performed at on media containing Km at 1 mg/ml. All strains were 




Table 3.1  Clinical and environmental B. pseudomallei isolates. 
Thai Clinical  
B. pseudomallei Isolates 
Thai Environmental 
B. pseudomallei Isolates 
Australian 
B. pseudomallei Isolates 
Strain Specimen Isolation Strain Specimen Isolation Strain Specimen Isolation 
1026b1 blood  1993 E0008 environmental 1990 MSHR 3052 brain 1994 
2613a blood 2001 E0016 environmental 1990 MSHR 491 environmental 1997 
2614a pus 2001 E0021 environmental 1990 MSHR 435 skin 1996 
2617a pus 2001 E0024 environmental 1990 MSHR 465a blood 1997 
2618a pus 2001 E0031 environmental 1990 MSHR 6682 blood 1995 
2625a blood 2001 E0034 environmental 1990    
2637a pus 2001 E0037 environmental 1990  
2640a pus 2001 E0181 environmental 1990  
2650a blood 2001 E0183 environmental 1990  
2660a blood 2001 E0235 environmental 1990  
2661a blood 2001 E0237 environmental 1990  
2665a blood 2001 E0241 environmental 1990  
2667a blood 2001 E0279 environmental 1990  
2668a blood 2001 E0342 environmental 1990  
2670a tracheal suction 2001 E0345 environmental 1990  
2671a blood 2001 E0350 environmental 1990  
2673a blood 2001 E0356 environmental 1990  
2674a blood 2001 E0366 environmental 1990  
2677a sputum 2001 E0371 environmental 1990  
2682a blood 2001 E0372 environmental 1990  
2685a pus 2001 E0377 environmental 1990  
2689b blood 2001 E0378 environmental 1990  
2692a blood 2001 E0380 environmental 1990  
2694a sputum 2001 E0383 environmental 1990  
2698a blood 2001 E0384 environmental 1990  
2704a blood 2001 E0386 environmental 1990  
2708a pus 2001 E0393 environmental 1990  
2717a pus 2001 E0394 environmental 1990  
2719a tracheal suction 2001 E0396 environmental 1990  
2764b blood 2001 E0411 environmental 1990  
2769a pus 2001     
1
 1026b source (20). 
2




Table 3.22 Escherichia coli strains and plasmids used in this study. 
Strain Description Reference 
DH5α 
E. coli general cloning strain 
F
–









E. coli general cloning strain 
F
-
(lac-proAB) endA1 gyrA96 hsdR17 supE44 relA1 recA1 thi zzx::mini-Tn5Lac4 
(26) 
RHO3 
E. coli conjugation donor strain 
F
-





















;  Allelic exchange vector (24) 
pTNS3  Amp
r
;  Tn7 transposase expression vector (24) 
pRK2013 Km
r





pPS2497  pEXKan4∆bpeEF-oprC Km
r
; Allelic exchange vector for knockout of bpeEF-oprC 
C. Lόpez, 
unpublished 
pPS2591  pEXKm5∆bpeEF-oprC Km
r
; 1696 bp EcoRI band from pPS2497 (∆[bpeEF-oprC]) ligated into pEXKm5  This study 
pPS1679 pUC20-bpeEF-oprC Amp
r





















; transposable element for complementation  (29) 
pPS2778 pCR2.1-PbpeT-bpeT Amp
r




;  1,234 bp KpnI+NsiI blunt-ended fragment from pPS2778 (PbpeT-bpeT), ligated 





, ampicillin resistant; Km
r
, kanamycin resistant. 
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3.3.2 Antimicrobial susceptibility testing. 
Trimethoprim, sulfamethoxazole and co-trimoxazole susceptibilities were assessed by 
determining minimal inhibitory concentrations (MIC) using the Etest
®
 method following 
manufacturer’s instructions (AB Biomérieux, Marcy l’Etoile, France). Briefly, strains were 
grown to mid-log phase (OD600nm = 0.6-0.8) and diluted to a 0.5 McFarland standard in 0.85% 
sterile saline. The resulting bacterial cell suspension was then used to swab Mueller Hinton II 
agar plates (Becton Dickinson and Company, Sparks, MD) to which the Etest strips were 
applied. MIC results were determined following 16-20 h incubation at 37°C. Results were read at 
80% inhibition, again following the manufacturer’s guidelines. Since there are no established 
breakpoints for non-Enterobacteriaceae, the following Enterobacteriaceae MIC cut-offs were 
used to define susceptibility and resistance for trimethoprim alone (≤ 8 μg/mL susceptible and > 
8 μg/mL resistance) from Table 2A of the CLSI guidelines (30). The non-Enterobacteriaceae 
sulfonamide cutoffs were used for sulfamethoxazole alone (≤ 256 μg/mL susceptible and > 256 
μg/mL resistant) from CLSI Table 2B-5, while the standard MIC cut-offs for B. pseudomallei 
were used for co-trimoxazole (≤ 2/38 μg/mL susceptible and > 2/38 μg/mL resistant) from CLSI 
Table 2K (30).  
MICs for other antimicrobials were determined by standard microdilution in Mueller 
Hinton II broth (Becton Dickinson), following CLSI guidelines (30). The antimicrobials used 
and their respective suppliers are listed: acriflavine (Acr, SIGMA), carbenicillin (Car, Gemini 
Bio-Products, West Sacramento, CA), chloramphenicol (Chl, SIGMA), erythromycin (Ery, 
SIGMA), gentamicin (Gen, SIGMA), norfloxacin (Nor, SIGMA), and tetracycline (Tet, 
SIGMA). Assays were incubated at 37°C in ambient air for 16-20 h before MIC determination. 
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Microdilution MICs was read at 100% inhibition of growth, as judged by eye. All MICs were 
tested in a minimum of biological triplicate. Results are reported as the mode of the replicates.  
 
3.3.3 DNA sequencing and analysis. 
The folA coding sequence was PCR amplified in four independent PCR reactions from 
genomic DNA isolated with the PureGene Core kit A (QIAGEN, Valencia, CA) using primers 
P1966 and P1967 (Integrated DNA Technologies, Coralville, IA), see Table 3.3, and Platinum 
Taq DNA Polymerase High Fidelity (Life Technologies Corporation, Grand Island, NY). The 
PCR products were pooled for each strain and purified from agarose gels using the GenElute gel 
extraction kit (Sigma-Aldrich, St. Louis, MO). The PCR products were sequenced using P1966 
and P1967 at the Colorado State University Proteomics and Metabolomics facility. Alignments 
of folA sequences from experimental samples and comparison with the 1026b folA sequence 
were performed using ClustalW2 (31). In strains that had an ISBma2 insertion downstream of 
folA, primer set P2182 and P2183 (Table 3.3) were used to amplify and sequence the upstream 
region of folA. 
Similarly, llpE), bpeE (P2169-2172), bpeF (P2094-2101, P2109-P2110) and oprC 
(P2173-P2167) (Table 3.3) were PCR amplified and sequenced as described above. A specific 
primer set (P2222-P2223) was designed for strain E0235, as this strain had several single 
nucleotide polymorphisms in the region where the primers annealed.  
The bpeT gene in the clinical and environmental isolates was sequenced either as described 
above using primers P1790 & P1791 (Table 3.3) or PCR products from this primer set were TA 
cloned into pGEM T-easy or PCR2.1 (Table 3.2). The plasmids were then sequenced using the 
M13F-20 and M13R primers.  
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Table 3.33 Oligonucleotide primers used in this study. 
Primer Descriptive Name Primer Sequence Source 
Dihydrofolate reductase (folA) experiments 
P1966 folA-F 5’-CTTCCGGCCTCTTTTCTTTC-3’ This study 
P1967 folA-R 5’-GTGCTGATCGAGCAGATGAC-3’ This study 
P2182 Upstream-folA-F 5’-CTGTATCGGCTGATGGTGTC-3’ This study 
P2183 Upstream-folA-R 5’-AGGCCTTCCTCGTACAGTTG-3’ This study 
P2578 ISBma2-orientation-F 5’- CCAACGATTTCACGTACGC-3’ This study 
P2569 ISBma2-orientation-R 5’-CCGTACAGCACGACCAATC-3’ This study 
P2579 ISBma2-orientation-R2 5’-GACGTTGACCTGGACCTCAC-3’ This study 
Construction of  bpeEF-oprC and bpeT deletion strains and genetic complements 
P1989 ∆bpeEF-oprC-F 5’-GGAAGTACGCGGACTTCGC-3’ (24) 
P1990 ∆bpeEF-oprC-R 5’-GCATCAACCTCGGCTACACG-3’ (24) 
P1791 bpeT-R 5’-CGACGCATCGCGATGGAAAC-3’ 
T. Mima, 
unpublished 
P1790 bpeT-F 5’-ATGGACCGGCTGCAAGCCAT-3’ 
T. Mima, 
unpublished 
P2224 PbpeT-bpeT-F 5’-TTACGCCACCCACTCGTTC-3’ This study 
P2225 PbpeT-bpeT-R 5’-CAGACATCGGGATAAATGCC-3’ This study 
P 479 Tn7L 5’-ATTAGCTTACGACGCTACACCC-3’ (29) 
P1509 BpglmS-1 5’-GAGGAGTGGGCGTCGATCAAC-3’ (29) 
P1510 BpglmS-2 5’-ACACGACGCAAGAGCGGAATC-3’ (29) 
P1511 BpglmS-3 5’-CGGACAGGTTCGCGCCATGC-3’ (29) 
DNA sequencing of llpE-bpeEF-oprC, bpeT and the bpeT to llpE intergenic region 
 M13F-20 5’- GTAAAACGACGGCCAGT-3’ (32) 
 M13R 5’- AACAGCTATGACCATG-3’ (32) 
P2142 bpeT-bpeE-F 5’- TCTGAATGATCGTCGTCACC-3’ This study 
P2143 bpeT-bpeE-R 5’- AATCGGTGATCGTCTTCGAC-3’ This study 
P2169 bpeE-F1 5’-TTCTTCCAGTTCCGCTTCAG-3’ This study 
P2170 bpeE-R1 5’-TGCAGGTAAGTCTGCTCGTC-3’ This study 
P2222 bpeE-F1 (E0235) 5’-CTATCGGGACGTGTCGCATG-3’ This study 
P2223 bpeE-R1 (E0235) 5’-CGACACGACGTTGCCGAG-3’ This study 
P2171 bpeE-F2 5’-CATCAACCTCGGCTACACG-3’ This study 
P2172 bpeE-R2 5’-TCGATCGATGAAGAATTTCG-3’ This study 
P2109 bpeF-F1 5’-GCATCTCGTGCCGATGAC-3’ This study 
P2110 bpeF-R1 5’-CGAACTCGTCCTCGTTCTG-3’ This study 
P2094 bpeF-F2 5’-ACATGACGTATCTGCGCAAC-3’ This study 
P2095 bpeF-R2 5’-CATCGCGAACTGCTTGTAGA-3’ This study 
P2096 bpeF-F3 5’-AACGTCGAGCGCAACATC-3’ This study 
P2097 bpeF-R3 5’-CGTTGATCTGGTAGCTCGTG-3’ This study 





Primer Descriptive Name Description Source 
P2099 bpeF-R4 5’-ACCACACCCATGATGAACG-3’ This study 
P2100 bpeF-F5 5’-AGGGCGACAACAACATCTTC-3’ This study 
P2101 bpeF-R5 5’-GGCCTTCAGGTTCTGGTTC-3’ This study 
P2173 oprC-F1 5’-GGTGTTCTTCGGGATGCTC-3’ This study 
P2174 oprC-R1 5’-GCCGGTACAGATCCTGGTC-3’ This study 
P2175 oprC-F2 5’-GTCGTACGAAGCGGACCTG-3’ This study 
P2176 oprC-R2 5’-CACCTGCTGCCGGTAGTTC-3’ This study 
P2177 oprC-F3 5’-AACCTGTTCCTGTGGTCGAG-3’ This study 
P2178 oprC-R3 5’-CCGCCTCTCTCAGGTTCTC-3’ This study 
Reverse transcription quantitative PCR experiments 
P1516 Bp23S-F 5’-GTAGACCCGAAACCAGGTGA-3’ (33) 
P1517 Bp23S-R 5’- CACCCCTATCCACAGCTCAT-3’ (33) 
P1524 bpeF-F1-RT 5’-TCCGAGTATCCGGAAGTCGT-3’ (33) 
P1525 bpeF-R1-RT 5’-GTCCTCGACACCGTTGATCT-3’ (33) 
P1814 bpeT-RT-for 5'-GAGCTTTCAGGTCAACAACC-3’ 
T. Mima, 
unpublished 




3.3.4 Multiplex ISBma2 PCR. 
Primers P2578, P2569 and P2579 (Integrated DNA Technologies) (Table 3.3) were 
designed and used in multiplex PCR to determine the orientation of ISBma2 in the clinical and 
environmental strains. P2578, P2569 and P2579 were all added at final concentrations of 0.6 
pmol/μl and standard Taq polymerase (New England Biolabs, Waltham, MA) was used. PCR 
conditions were an initial denaturation at 95°C for 2 minutes, 30 cycles of 95°C for 30 s, 55°C 
for 30 s, and 72°C for 1.5 min, followed by a final extension at 72°C for 10 min.  
 
3.3.5 Markerless deletion of bpeEF-opC and bpeT. 
A 4,314 bp region of the bpeEF-oprC operon was deleted in several of the clinical and 
environmental isolates by allelic exchange using a knockout construct integrated into the 
pEXKm5 vector system, pPS2497 (Table 3.2) (24). A 573 bp region of the bpeT gene was 
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deleted in the strains of interest, again using the pEXKm5 vector system, pPS2647. The 
pEXKm5 knockout constructs were introduced into B. pseudomallei by electroportation as 
previously described (34) or by conjugation using either a tri-parental mating helper plasmid 
(pRK2013) or the RHO3 strain (Table 3.2) as previously described (24). Transformants and 
exconjugates were selected on LB medium supplemented with 1 mg/ml Km. These merodiploids 
were then resolved by sucrose counter-selection as previously described (24) and screened by 
PCR using primers P1989 & P1990 for bpeEF-oprC and P1790 & P1791 for bpeT deletions. 
 
3.3.6 Complementation of bpeEF-oprC and bpeT deletions.  
Genetic complementation was accomplished utilizing the mini-Tn7 system, which allows 
for stable and site-specific single-copy insertions into the B. pseudomallei genome at three 
possible glmS-associated Tn7 insertion sites (34). Tri-parental conjugation with RHO3 was 
necessary to introduce the pTNS3 transposition helper plasmid and one of the following 
plasmids into the B. pseudomallei knockout strains: pPS2481, pPS2670, pPS2280 or pPS2787 
(Table 3.2). Single glmS2 insertions were confirmed by PCR with the glmS primer sets (P479 & 
P1509, P479 & P1510 and P479 & P1511) as previously described (Table 3.3) (34). 
The inducible E. coli lac operon Ptac promoter was used to express the bpeEF-oprC operon, 
which originated from strain 1026b (18). BpeEF-OprC expression in the complemented strains 
was induced by addition of isopropyl--D-thiogalactopyranoside (IPTG; Gold Biotechnology, 
St. Louis, MO) at a final concentration of 1 mM. Complementation of bpeT gene deletions were 
performed using the endogenous bpeT promoter amplified from the 1026b strain using primers 






3.3.7 Reverse transcription quantitative PCR (RT-qPCR). 
Expression levels of bpeF and bpeT mRNA were analyzed in bacteria grown to mid-log 
phase (OD600nm = 0.6-0.8) in Lennox Luria Broth (MO BIO Laboratories, Carlsbad, CA) at 
which point bpeEF-oprC expression remained either uninduced or was induced for 1 hour by 
addition of trimethoprim to a final concentration of 32 μg/mL. Trimethoprim stock solution was 
made in dimethylacetamide at a concentration of 100 mg/mL. RNA extraction, cDNA synthesis 
and RT-qPCR were done as previously described (33, 35) except that the RNeasy Protect 
Bacteria Mini Kit (QIAGEN, Valencia, CA) was used for RNA extraction. 23S rRNA was used 
as the housekeeping control. The primer sets used were P1516 & P1517 for 23S rRNA, P1524 & 
P1525 for bpeF (33), and P1814 & P1815 for bpeT (Table 3.3). RT-qPCR samples were tested 
in a minimum of technical and biological triplicate. Technical replicates were averaged for each 
biological replicate.  
 
3.3.8 Statistical analysis. 
The relative fold expression of each gene in the clinical and environmental isolates, 
compared to 1026b, was determined by the Bio-Rad iCycler iQ™ Optical System Software 
version 2.0 software using specific reference and target gene primer set amplification 
efficiencies. Subsequent comparisons of the relative expression data were analyzed by two-way 
analysis of variance (ANOVA) with Tukey’s multiple comparisons test (comparisons across 
strains) or Sidak’s multiple comparisons test (comparisons across conditions) using GraphPad 
Prism version 6.0c for Mac OSX (GraphPad Software, La Jolla, California). P-values < 0.05 





3.4 Results  
3.4.1  Initial characterization of isolates. 
To evaluate the innate frequency of trimethoprim, sulfamethoxazole, and co-trimoxazole 
resistance in B. pseudomallei clinical and environmental isolates, MICs were determined for a 
collection of 66 isolates from Northeast Thailand and Northern Australia.  
Using the susceptibility criteria explained in Section 3.3.2, MIC testing of strains from Thailand 
showed that 47% of clinical (14/30) and 30% of environmental strains (9/30) were trimethoprim 
resistant with MICs ranging from 12 μg/mL to the detection limit of ≥ 32 μg/mL (Figure 3.1). 
None of these isolates were resistant to sulfamethoxazole or co-trimoxazole. The frequency of 
trimethoprim resistance in Australian isolates was 60% (3/5) and these 5 isolates were all 
susceptible to sulfamethoxazole and co-trimoxazole. These data show that although trimethoprim 
resistance was highly prevalent in our collection of B. pseudomallei isolates, none of the strains 
tested showed clinically significant co-trimoxazole resistance.  
 
3.4.2  Further characterization of the isolates of interest. 
A sub-population of isolates, shown as black bars in Figure 3.1, was selected for further 
studies. These strains include the 1026b reference strain, a trimethoprim sensitive environmental 
isolate (E0237), a clinical isolate with a trimethoprim MIC of 16 µg/mL (2769a) and 10 other 
trimethoprim resistant isolates with MICs above the limit of detection that were chosen at 
random (Table 3.4). In addition to the trimethoprim, sulfamethoxazole and co-trimoxazole MICs 
reported for these isolates, the MICs of seven more antimicrobials, representing various drug 





Figure 3.16 Distribution of folate pathway inhibitor MICs in B. pseudomallei clinical and 
environmental isolates. Minimal inhibitory concentrations (MICs) for the co-trimoxazole (SXT) 
drug combination (panel A), sulfamethoxazole (Smx) (panel B) and trimethoprim (Tmp) (panel 
C) were determined in a collection of 35 clinical and 31 environmental isolates from Thailand 
and Australia. All 66 isolates tested were susceptible to co-trimoxaozle (panel A) and 
sulfamethoxazole (panel B). However, isolates in panel C with values above the dotted line are 
classified as trimethoprim resistant, while others below the cutoff are trimethoprim susceptible. 
Several isolates from this collection were selected for further testing (black bars, ■), the names 
of these 13 strains of interest are presented above panel A.  
 
MIC for norfloxacin and tetracycline compared to 1026b, but for others there was no change 
(Table 3.4). Unfortunately, these data did not have a lot of deviation from 1026b, and due to the 
complex genetic variability of each isolate compared to another; we could not draw any 




Table 3.44  Antimicrobial susceptibilities of selected B. pseudomallei isolates.  
1 
The detection limit for the Etest® method for trimethoprim is ≥ 32 µg/mL.  
Minimal inhibitory concentrations (MIC) for trimethoprim, sulfamethoxazole and co-
trimoxazole of 12 clinical and environmental isolates of interest are shown in comparison to the 
1026b reference strain (left panel). The majority of these strains had trimethoprim MICs above 
the detection limit. While all had increase sulfamethoxazole and co-trimoxazole MICs 
compared to 1026b, none of these strains were resistant to those antimicrobials.Additionally we 
tested the MICs of known BpeEF-OprC efflux pump substrates (middle panel) and non-
substrates (right panel). Abbreviations: Car, carbenicillin; Ery, erythromycin; Gen, 
gentamycin; Acr, acraflavine; Chl, chloramphenicol; ND, no data; Nor, norfloxacin; Tet, 
tetracycline; Tmp, trimethoprim; SXT, trimethoprim:sulfamethoxazole (1:19).  
  
3.4.3 DNA sequencing of the trimethoprim drug target, folA. 
Mutations affecting the trimethoprim target dihydrofolate reductase (FolA) can cause 
resistance to this antimicrobial. We compared the folA sequences of 12 B. pseudomallei strains to 
the trimethoprim susceptible 1026b reference strain (Table 3.4). Two mutations, V77A and 
A144T, were found in 5 of the trimethoprim resistant isolates compared to reference strain 
1026b. However, these conservative mutations were not linked to trimethoprim resistance in 
these isolates.  
 Minimal Inhibitory Concentration (g/mL) 
Strain Tmp
1 
Smx SXT Acr Chl Nor Tet Car Ery Gen 
1026b 0.75 4 0.094 32 8 4 0.5 256 128 256 
   Thai Clinical Isolates  
2650a ≥ 32 8 1 32 32 32 4 512 256 64 
2665a ≥ 32 16 1 32 8 16 2 512 256 128 
2677a ≥ 32 24 1.5 32 8 32 2 512 128 128 
2719a ≥ 32 12 1 32 8 16 2 512 256 128 
2769a 16 12 0.75 32 8 8 2 512 256 64 
   Thai Environmental Isolates  
E0016 ≥ 32 12 0.75 32 16 32 2 512 256 256 
E0235 ≥ 32 24 1.5 32 16 32 4 512 256 256 
E0237 4 8 0.5 32 16 8 2 512 128 64 
E0342 ≥ 32 24 0.75 32 8 32 2 512 256 512 
   Clinical and Environmental Isolates from Australia 
MSHR305 ≥ 32 32 0.5 ND ND ND ND ND ND ND 
MSHR465a ≥ 32 16 0.38 ND ND ND ND ND ND ND 
MSHR668 ≥ 32 32 1 ND ND ND ND ND ND ND 
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3.4.4 Identification and investigation of an ISBma2 insertion element. 
While attempting to PCR amplify the folA region we noticed that some of the strains 
(2665a, 2769a, E0016 and E0342) yielded the same 694 bp DNA fragment as 1026b (Figure 
3.2A). The remaining isolates (2650a, 2677a, 2719a and E0235), however, showed a 
substantially larger (≈ 2.3 kb) fragment when using the same primers. DNA sequencing of this 
fragment with P1967 revealed the presence of an ISBma2 insertion sequence (36). Further 
analyses were conducted using representative strains E0016 (694 bp fragment) and 2650a (≈ 2.3-
kb fragment). Employing genomic DNAs as templates and PCR amplification with the subset of 
primers shown in Figure 3.2A for E0016 and Figure 3.2B for 2650a followed by sequencing 
confirmed for E0016 the identical sequence and gene order found in 1026b. In strain 2650a the 
1,596 bp ISBma2 was inserted in the 130 bp folA-pmbA intergenic region in a palindromic 
sequence located between nucleotides 47 and 75 downstream of folA that most likely serves as 
this gene’s transcriptional terminator. The insertion site and orientation of ISBma2 was identical 
to that found in the genome of strain K96243 (37). In both 1026b and K96243 the folA and 
neighboring genes are located on chromosome 1, but in different locations and in reverse order 
(Figure 3.2).  
The two PCR amplification patterns observed in the isolates analyzed in this study 
indicate two distinct populations of strains, one similar to 1026b and another similar to K96243. 
The frequency of the ISBma2 insertion at this site was determined in the 65 clinical and 





























Figure 3.27 Genomic location and organization of the folA region of B. pseudomallei  in the 
two sequenced prototypes 1026b (A) and K96243 (B). Chromosome 1 sequence coordinates 
and gene nomenclatures are taken from the GenBank entries for strains 1026b (accession 
NC_017831.1) and K96243 (accession NC_006350.1). Gene annotations indicate: _I0835 (short 
for BP1026B_I0835) and BPSL2475, σ54-dependent transcriptional regulator; folA, 
dihydrofolate reductase; pmbA, protein belonging to the peptidase U62 family; tnpA, transposase. 
The same sequences and gene organizations were confirmed for Thai isolates E0016 (1026b-
like) and 2650a (K96243-like). Horizontal black lines indicate PCR fragments obtained with the 
indicated primers. Primers pairs used were P1966 & P1967 that amplify the folA gene with and 
without ISBma2, and P2578 & P2579 that amplify a fragment containing the folA-ISBma2 
junction sequences. In isolates where ISBma2 is in the opposite orientation primer set P2578 & 
P2579 is replaced by P2578 & P2569 and this combination yields a 647 bp fragment containing 
the folA-ISBma2 junction sequences (not shown). All primer sequences are given in the text. The 
folA upstream region and 5’ coding sequences can be amplified using primer pair P2182 & 
P2183. In panel A the sequence with underlined inverted repeats indicates the putative folA 
transcriptional terminator. In panel B, sequences that compose the 5’ and 3’ ISBma2 inverted 
repeats (IR, underlined) and the 23 bp duplicated genomic DNA segments (bold letters) are 
indicated. The sequences of ISBma2 elements and their organization as well as that of the 




analysis showed that 38% of clinical and 45% of environmental isolates contain the ISBma2 
insertion at this locus. Additionally, DNA sequencing of this region in strain MSHR305 and 
comparison to the whole genome shotgun sequence (38) revealed that the ISBma2 element was 
in the opposite orientation, relative to K96243, and thus can insert at this site in either 
orientation. In the strains that contained ISBma2, a multiplex PCR was used to determine the 
orientation of the insertion element. There was a near equal distribution of ISBma2 orientation, 
with 52% having the same orientation as K96243, resulting in a 440 bp product, and 48% having 
the opposite orientation, a 647 bp product. There was a slight bias in the orientation when 
comparing environmental isolates verses clinical isolates, where 64% of environmental and 38% 
of clinical isolates were in the same orientation as in strain K96243. However, a significantly 
larger sample size would be needed to determine the true orientation bias. The location of 
ISBma2 most likely does not affect folA expression but has implications regarding the design of 
PCR primers for folA amplification for diagnostic purposes. 
 
3.4.5 BpeEF-OprC and BpeT are necessary for trimethoprim resistance. 
The BpeEF-OprC efflux pump is encoded by the bpeEF-oprC genes that are the distal 
genes of the llpE-bpeEF-oprC operon located on B. pseudomallei chromosome 2 (33, 37). 
Expression of this operon is governed by the LysR-type regulator BpeT that is encoded by a gene 
located immediately upstream of the llpE-bpeEF-oprC operon (T. Mima, H.P. Schweizer, 
unpublished observations). BpeEF-OprC has been shown to efflux trimethoprim when expressed 
in Pseudomonas aeruginosa (18), in B. thailandensis isolates that are resistant to 
chloramphenicol (19) and in B. pseudomallei isolates that express BpeEF-OprC as a result of a 
BpeT truncation (20, 21).  
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To investigate a potential contribution of this efflux pump to trimethoprim resistance in 
clinical and environmental B. pseudomallei isolates, a 4,314 bp segment of the llpE-bpeEF-oprC 
operon was deleted from 11 trimethoprim resistant isolates and trimethoprim susceptible 
reference strains 1026b and E0237. Deletion of bpeEF-oprC from the trimethoprim resistant 
strains resulted in susceptible mutant derivatives with at least 10 fold decreases in MIC. A lower 
trimethoprim MIC was observed in E0237 but the susceptibility of 1026b remained unchanged 
(Table 3.5). No significant trimethoprim susceptibility changes were observed in uninduced 
complemented strains, but induction of BpeEF-OprC expression resulted in significant MIC  
 
Table 3.55 Reduced trimethoprim MICs are observed in the absence of BpeEF-OprC. 
 1   
The detection limit for the Etest® method for trimethoprim is ≥ 32 µg/mL.  
 2 







 element integrated at the chromosomal glmS2 locus, except for the MSHR668 







contained on this mini-Tn7 element is derived from the prototype strain, 1026b. 
 Trimethoprim
1















+1 mM IPTG 
1026b 0.75 0.5 0.5 6 
Clinical Isolates from Thailand 
2650a ≥ 32 1.5 1.5 ≥ 32 
2665a ≥ 32 1.5 1.5 16 
2677a ≥ 32 2 2 ≥ 32 
2719a ≥ 32 1 1 16 
2769a 16 1.5 2 ≥ 32 
Environmental Isolates from Thailand 
E0016 ≥ 32 1 1.5 16 
E0235 ≥ 32 1.5 3 ≥ 32 
E0237 4 1 2 16 
E0342 ≥ 32 1 1.5 16 
Clinical and Environmental Isolates from Australia 
MSHR305 ≥ 32 2 2 16 
MSHR668 ≥ 32 2 2 32 
MSHR465a ≥ 32 3 2 ≥ 32 
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increases such that all of the isolates, except for 1026b, became trimethoprim resistant (Table 
3.5). Similar results were observed with strains containing deleted and complemented bpeT, 
respectively (Table 3.6). We should note that while complementation with the endogenous PbpeT 
promoter did increase the trimethoprim MIC in most of the strains, this increase was lower than 
that observed in the bpeEF-oprC complementation experiment. Overall, these findings suggest 
that expression of the BpeEF-OprC pump is required for trimethoprim resistance in these 
isolates.  
 
Table 3.66 Reduced trimethoprim MICs are observed in the absence of the bpeEF-oprC 
transcriptional regulator, BpeT. 
1   
The detection limit for the Etest® method for trimethoprim is ≥ 32 µg/mL.  
2 
The respective strains containing the ∆(bpeT) mutation have an empty mini-Tn7 element 
integrated at the chromosomal glmS2 locus.  
3
 The respective strains containing the ∆(bpeT) mutation have a mini-Tn7T-PbpeT-bpeT element 
integrated at the chromosomal glmS2 locus. PbpeT-bpeT contained on this mini-Tn7 element is 

















1026b 0.75 0.25 0.38 0.5 
Clinical Isolates from Thailand 
2650a ≥ 32 0.38 0.38 0.5 
2665a ≥ 32 1.5 2 6 
2677a ≥ 32 2 1 6 
2719a ≥ 32 1.5 2 2 
2769a 16 1.5 2 4 
Environmental Isolates from Thailand 
E0016 ≥ 32 1.5 1.5 6 
E0235 ≥ 32 1.5 1.5 8 
E0237 4 1.5 3 2 
E0342 ≥ 32 1.5 2 4 
Clinical and Environmental Isolates from Australia 
MSHR305 32 1.5 2 4 
MSHR668 16 1.5 2 24 
MSHR465a 32 1.5 2 12 
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3.4.6 DNA sequencing of the BpeEF-OprC regulatory and structural components. 
To assess whether mutations in structural pump components were contributing to 
trimethoprim resistance we sequenced the bpeT-llpE-bpeE and oprC regions in 9 Thai isolates 
and the bpeF gene in 3 of those isolates using a primer walking strategy. These analyses showed 
that the DNA sequence of the entire region was highly conserved with few synonymous and 
conservative mutations. For example, when compared to the 1026b sequence the following 
mutations were found in ≤ 22% of the sequenced trimethoprim resistant isolates: BpeE (A401T) 
and OprC (V78A, A207Q, and T508A). There were only a few conservative mutations in the 
bpeT gene and no mutations in the bpeT-llpE intergenic region containing the putative promoter 
regions for both bpeT and the llpE-bpeEF-oprC operon. Given the conservative nature of the 
observed mutations and the results of the complementation study, which showed that the 1026b 
operon sequence was sufficient for the trimethoprim resistant phenotype, it is unlikely that 
changes in structural BpeEF-OprC components are root causes for resistance in any of the tested 
isolates.  
 
3.4.7 Relative expression of bpeEF-oprC and bpeT. 
RT-qPCR was used to determine the relative expression of bpeT and bpeF mRNAs, and 
thus gauge expression levels of the BpeT regulator and BpeEF-OprC. Interestingly, in uninduced 
cells bpeF mRNA levels were very similar between the 9 Thai isolates tested and 1026b (Figure 
3.2). However, when induced with 32 μg/mL trimethoprim, isolates with trimethoprim MICs ≥ 
32 μg/mL had significantly increased bpeF mRNA levels, with fold increases ranging from 3.2 





Figure 3.38 Relative expression of bpeF in B. pseudomallei clinical and environmental isolates.  Relative bpeF mRNA levels 
were determined in 10 B. pseudomallei isolates (blue and stippled blue bars) and their respective ΔbpeT derivatives (red and stippled 
red bars). Strains were grown in LB medium (solid bars) or LB medium with 32 mg/ml added 1 h prior to RNA harvest (+Tmp; 
stippled bars). All fold expression values are relative to the value obtained in uninduced 1026b. Error bars indicate the standard 
deviation between biological replicates, which were each performed in technical triplicate. Statistical differences were analyzed by 






Figure 3.49  Relative expression of bpeT mRNA in B. pseudomallei clinical and environmental isolates.  Relative bpeT mRNA 
levels were determined in 10 B. pseudomallei isolates and the respective ΔbpeT derivatives (brown bars) grown in LB medium (solid 
green bars) or LB medium with 32 µg/ml trimethoprim (Tmp) added for 1 h prior to RNA harvest (stippled green bars). All fold 
expression values are relative to the values obtained for uninduced strain 1026b. Error bars indicate the standard deviation between 
biological replicates, which were each performed in technical triplicate. There was no significant difference in bpeT mRNA 




and 16 μg/mL, and 1026b exhibited no change in bpeF expression levels when induced with 32 
μg/mL of trimethoprim (Figure 3.2). As this high concentration of trimethoprim may adversely 
affect strains with MICs lower than 32 g/mL, the experiment was repeated performing 
induction with trimethoprim at ½ the respective MICs for 1026b, 2769a and E0237 for 1 h. 
However, even when using ½ MIC levels of trimethoprim for induction no increases in bpeF 
expression levels were observed (data not shown). These data suggest that high-level 
trimethoprim resistance results from over-expression of the BpeEF-OprC efflux pump.  
Additionally we determined the relative expression of bpeF in strains derived from these 
isolates lacking the BpeT regulator. Interestingly, in all of the isolates there was a decrease in 
bpeF expression, though the only observed significant decrease was seen with strain 2650a 
(Figure 3.2). When these deletion mutants were induced with trimethoprim there was no 
significant increase in bpeF expression, as was observed in the wild-type strains (Figure 3.2). In 
the strains that overexpress bpeF after trimethoprim induction, the bpeF expression level 
returned to uninduced levels, with the exception of 2650a in which it was much lower than the 
initial expression level (Figure 3.2). Repetition of these experiments for bpeT showed no 
changes in expression both with and without trimethoprim induction (Figure 3.3).  
 
3.5   Conclusions 
This is the first study aimed at elucidation of the molecular mechanisms governing 
trimethoprim resistance in clinical and environmental B. pseudomallei isolates. The results show 
that resistance to trimethoprim alone is frequent in B. pseudomallei strains. However, resistance 
to sulfamethoxazole and co-trimoxazole was not detected in any of these clinical and 
environmental isolates tested. In all of the Australian and Thai isolates assessed, trimethoprim 
resistance was attributed to expression of BpeEF-OprC but not changes in the dihydrofolate 
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reductase target, indicating that efflux is the predominant trimethoprim resistance mechanism in 
B. pseudomallei. Increased transcription of the bpeEF-oprC structural genes in the presence of 
trimethoprim lead to high level resistance, with MICs above the detection limit of 32 g/mL. 
Since DNA sequencing revealed only conservative mutations in bpeT and qRT-PCR analysis 
indicated no changes in expression levels of this regulator, we conclude that BpeEF-OprC 
expression in the trimethoprim resistant clinical and environmental isolates tested is governed by 
a to date unidentified regulatory mechanism(s). 
In the course of these studies we discovered that the genomic location and organization of 
genes in the immediate folA region follow a distinct pattern that, in reference to three sequenced 
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CHAPTER 4:  Mechanisms Responsible for Acquired 
Trimethoprim and Resistance in Burkholderia pseudomallei  
 
This chapter describes the characterization of laboratory selected trimethoprim resistant 
strains derived from the Select Agent excluded Bp82 strain. Mutations to both the trimethoprim 
target, FolA, and the LysR-type regulator responsible for control of the BpeEF-OprC efflux 
pump, BpeT, were found to contribute to resistance. Additionally, antimicrobial susceptibility 
testing of a panel of 1026b-derived mutants expressing various combinations of efflux pumps 
shows that sulfamethoxazole may be a weak substrate of the BpeAB-OprB and BpeEF-OprC 
efflux pumps.  
 
4.1 Summary 
Burkholderia pseudomallei is a Gram-negative bacterium of interest as it is the causative 
agent of the disease melioidosis. Treatment of melioidosis is difficult and costly due to the 
organism’s intrinsic resistance to many commonly used antimicrobials. Currently a combination 
of trimethoprim and sulfamethoxazole (co-trimoxazole) is used for the eradication phase of 
treatment and is an option for post-exposure prophylaxis; however resistant isolates have been 
reported. Mutations to the dihydrofolate reductase (DHFR), trimethoprim drug target, are well-
documented mechanisms for resistance to trimethoprim. To our knowledge mutations to the 
DHFR have not been described previously in B. pseudomallei. To determine if such mutations 
can confer resistance to trimethoprim in B. pseudomallei, we used an attenuated, Select Agent 
excluded strain, Bp82, to isolate trimethoprim resistant mutants. These mutants were 
characterized by DNA sequencing of the DHFR encoding gene, folA. Additionally, we 
investigated the potential role of the BpeEF-OprC efflux pump in these induced mutants. 
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Trimethoprim resistance was found to be due to mutations in the folA gene, increased expression 
of the BpeEF-OprC efflux pump, or a combination of both. Similar experiments were performed 
to determine mechanisms of sulfamethoxazole resistance; however the ability of B. pseudomallei 
to grow at high concentration of sulfamethoxazole caused only small changes in the 
sulfamethoxazole susceptibilities. Antimicrobial susceptibility testing of several efflux mutant 
strains suggest that sulfamethoxazole may be effluxed at low levels by both the BpeAB-OprB 
and BpeEF-OprC pump. However, overexpression of these efflux pumps caused only slight 
changes to the sulfamethoxazole susceptibilites and did not confer clinically significant 
resistance to sulfamethoxazole.  
 
4.2   Introduction 
Burkholderia pseudomallei is a saprophyte endemic to tropical and sub-tropical regions 
of the world (1, 2). It is a genetically complex organism and the etiologic agent of the disease 
melioidosis. Melioidosis is a disease of varying severity that typically affects those with pre-
existing health conditions such as diabetes mellitus and impaired renal function (3, 4), but is also 
a rare pathogen of healthy individuals and many diverse fauna (5). Treatment of this disease has 
been improved over time with the introduction of novel antimicrobials such as ceftazidime (6) 
and increasing comprehension of the adaptive and intrinsic resistance of B. pseudomallei to 
many clinically available antimicrobials (7). B. pseudomallei is widely known to be resistant to a 





cephalosporins and some penicillins (8, 9). Currently the recommended treatment of melioidosis 
consists of two phases. The initial intensive phase of treatment typically involves at least 10 to 
14 days of ceftazidime or alternatively a carbapenem (7, 10, 11), while the subsequent 
eradication phase is typically 12 to 20 weeks of co-trimoxazole (trimethoprim-sulfamethoxazole 
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combination) or amoxicillin-clavulanic acid (7, 10, 11). Co-trimoxazole is also the recommended 
therapeutic for post-exposure prophylaxis in the event of accidental exposure to B. pseudomallei 
(7, 10). 
Trimethoprim is a diaminopyrimide that specifically inhibits bacterial dihydrofolate 
reductases (DHFR), while sulfamethoxazole, a sulfonamide, targets dihydropteroate synthetase 
(DHPS) (12). The combination of trimethoprim and sulfamethoxazole is synergistic (13) and 
efficacious for the treatment of many bacterial infections, including melioidosis. However, 
resistance to co-trimoxazole has been reported in endemic regions, such as Thailand (12, 14-17). 
Recently we described a high frequency of trimethoprim resistance approaching 40% in a 
collection of clinical and environmental strains from Thailand and Australia (18). This 
trimethoprim resistance was attributed to the expression of the BpeEF-OprC efflux pump and no 
DHFR target mutations were identified. The B. pseudomallei BpeEF-OprC efflux pump was 
shown to efflux both trimethoprim and chloramphenicol when expressed in Pseudomonas 
aeruginosa (19) but is also known to efflux tetracyclines and fluoroquinolones (T. Mima and 
H.P. Schweizer, unpublished results).  
Mutations to the trimethoprim drug target, DHFR, have been described as trimethoprim 
resistance mechanisms in many other genera of bacteria (20-22). Primarily this has been studied 
in Enterobacteriacea, since trimethoprim is still occasionally used alone for treatment of 
infections with these bacteria (21). DHFR mutations in B. pseudomallei have not, to our 
knowledge, been found to confer resistance to trimethoprim. Additionally, there has been no 
description of B. pseudomallei isolates resistant to sulfamethoxazole alone or mechanisms that 
may contribute to such resistance. Mutations to the sulfamethoxazole drug target DHPS have 
been shown to confer resistance in other bacteria (23). The purpose of this study was to further 
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investigate potential resistance mechanisms in B. pseudomallei for trimethoprim and 
sulfamethoxazole.  
 
4.3   Materials and Methods 
4.3.1 Bacterial strains. 
Escherichia coli strain DH5α was used for cloning manipulations, while the RHO3 strain 
was used as a conjugation donor strain to mobilize plasmids into Bp82 (Table 4.1). The E. coli 
strains were grown in Lennox Luria-Bertani (LB) broth or agar media (MO BIO Laboratories, 
Carlsbad, CA). Media were supplemented with diaminopimelic acid (DAP; SIGMA, St. Louis, 
MO) at 400 μg/mL for culture of RHO3. For selection of desired plasmids in E. coli, 100 μg/mL 
of ampicillin (Amp; SIGMA, St. Louis, MO) or 35 μg/mL of kanamycin (Km; SIGMA) were 
added to the media as necessary. B. pseudomallei strain 1026b and several derived efflux pump 
mutants were also used in the study (Table 4.2). All work done with B. pseudomallei isolates 
was performed in Select Agent approved Biosafety Level 3 (BSL-3) facilities at the Rocky 
Mountain Regional Biosafety Laboratory at Colorado State University using Select Agent 
compliant procedures and protocols. The B. pseudomallei 1026b∆purM strain, Bp82, was also 
used in this study (Table 4.2).Bp82 and its derivative strains were grown in LB broth or agar 
media supplemented with adenine (Ade; SIGMA) at 80 μg/mL. Work with Bp82 was performed 
at Biosafety Level 2 (BSL-2) as approved by the Colorado State University Institutional 
Biosafety Committee.  
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Table 4.17 Escherichia coli strains and plasmids used in this study. 
Strain Description Reference 
DH5α 
E. coli cloning strain 
(F
–









E. coli conjugation donor strain 
(F
-
















; Allelic exchange vector (25) 
pPS2951  pGEM-T Easy folA(F158V) Amp
r
; 694 bp folA PCR product from Bp82.102 ligated into pGEM-T Easy This study 
pPS2552  pGEM-T Easy folA(I99L) Amp
r
; 694 bp folA PCR product from Bp82.104 ligated into pGEM-T Easy This study 
pPS2959 pEXKm5 folA(F158V) Km
r
;  712 bp EcoRI fragment from pPS2951, folA (F158V), ligated into pEXKm5 This study 
pPS2960 pEXKm5 folA(I99L) Km
r
;  712 bp EcoRI fragment from pPS2952, folA (I99L), ligated into pEXKm5 This study 
pPS3137 pEXKm5 ∆bpeT Km
r
; 1,010 bp ∆bpeT SOEing PCR product ligated into pEXKm5 This study 
pPS3167  pGEM-T Easy bpeT(L265R) Amp
r
; 2,026 bp bpeT PCR product from Bp82.103 ligated into pGEM-T Easy This study 
pPS3168  pGEM-T Easy bpeT(C310R) Amp
r
; 2,026 bp bpeT PCR product from Bp82.102 ligated into pGEM-T Easy This study 
pPS3177 pEXKm5 bpeT(C310R) 
Km
r
;  2,477 bp PvuII fragment from pPS3168, bpeT (C310R), ligated into 
pEXKm5 
This study 
pPS3178 pEXKm5 bpeT(L265R) 
Km
r






, ampicillin resistant; Km
r
, kanamycin resistant. 
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Selection for the Km resistance marker in B. pseudomallei was performed on media 
containing 1 mg/ml of Km. Colorimetric screening for the presence of the gusA was done on 
media containing 50 µg/mL of 5-bromo-4-chloro-3-indolyl--D-glucuronide (X-Gluc; Gold 
Biotechnology, St. Louis, MO). All strains were incubated at 37°C with aeration, unless 
otherwise stated. 
 




Bp82 B. pseudomallei prototype strain  (26) 
Bp82.102 Bp82 Tmp
r
 isolate  This study 
Bp82.103 Bp82 Tmp
r
 isolate This study 
Bp82.104 Bp82 Tmp
r
 isolate This study 
Bp82.183 Bp82 folA (F158V) This study 
Bp82.184 Bp82 folA (I99L) This study 
Bp82.253 Bp82 ∆bpeT This study 
Bp82.268 Bp82 bpeT (C310R) This study 
Bp82.269 Bp82 bpeT (L265R) This study 
B. pseudomallei efflux mutants 
1026b B. pseudomallei prototype strain (27) 
Bp340 1026b ∆(amrAB-oprA) (28) 
Bp227 1026b ∆(bpeAB-oprB) (28) 
Bp207 1026b ∆(amrAB-oprA, bpeAB-oprB) (28) 
Bp58 1026b ∆(amrAB-oprC, bpeR) (28) 
Bp282 Bp207 bpeT(S280P) T. Mima, unpublished 




, trimethoprim resistant. 
 
4.3.2 Passive selection of resistant mutants. 
Bp82 (trimethoprim MIC = 0.5 g/mL) was plated onto LB media containing 16 μg/mL 
of trimethoprim and incubated at 37°C for several days. Similarly, Bp82 was passively selected 
on solid media containing various concentrations of sulfamethoxazole, ranging from 16 µg/mL 
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to 2,048 µg/mL. Isolates that grew were subsequently purified on the appropriate selective media 
and stored at -80˚C for further studies.  
 
4.3.3 Antimicrobial susceptibility testing. 
Trimethoprim, sulfamethoxazole and co-trimoxazole minimal inhibitory concentrations 
(MICs) were determined using the Etest
®
 method following manufacturer’s guidelines (AB 
Biomérieux, Marcy l’Etoile, France). Briefly, strains were grown to mid-log phase (OD600nm = 
0.6-0.8) and diluted to a 0.5 McFarland standard in sterile saline. The resulting bacterial cell 
suspension was swabbed for confluency on Mueller Hinton II agar plates (MHA; Becton 
Dickinson and Company, Sparks, MD), supplemented with 40 μg/mL of Ade for Bp82 testing, to 
which the Etest strips were applied. MIC results were determined following 20 h incubation at 
37°C. As described in the manufacturer’s guidelines, the MIC results were read at 80% 
inhibition of growth, as judged by eye. MIC breakpoints were used as described by Podnecky et 
al. (18).  
The MICs of other antibiotics were determined by microdilution method, following CLSI 
guidelines (29) with cation-adjusted Mueller Hinton broth (MHB, Becton Dickinson and 
Company) supplemented with 40 μg/mL of Ade for Bp82 derivatives. MIC results were 
determined following 20 h incubation at 37°C and were interpreted at 100% inhibition of growth, 
as judged by eye. Antibiotics for this microdilution MIC testing and the respective suppliers are 
listed: acriflavine (Acr; SIGMA), carbenicillin (Car; Gemini Bio-Products, West Sacramento, 
CA), chloramphenicol (Chl; SIGMA), erythromycin (Ery; SIGMA), gentamicin (Gen; SIGMA), 





4.3.4 Reverse-transcriptase quantitative PCR (RT-qPCR) 
Relative expression of bpeF and bpeT mRNA was determined in cultures grown to mid-
log phase (O.D.600nm = 0.6-0.8) using gene specific primer sets (Table 4.3), as previously 
described (Chapter 3) (18). The 23S rRNA was used as the reference gene for normalization. 
The relative fold expression compared to the wild-type Bp82 was determined by the Bio-Rad 
iCycler iQ™ Optical System software version 2.0 with defined amplification efficiencies for 
each primer set. Comparisons of the expression data were performed by two-way analysis of 
variance (ANOVA) followed by Tukey’s multiple comparisons tests using GraphPad Prism 
version 6.0c for Mac OS X (GraphPad Software, La Jolla, CA). P-values < 0.05 were considered 
significant.  
 
4.3.5 DNA Sequencing and analysis. 
Each of the genes of interest, folA and bpeT, were PCR amplified from genomic DNA 
using specific primer sets (Table 4.3), as previously described (18). Amplified DNA products 
were purified using the GenElute gel extraction kit (SIGMA), and sequenced at the Colorado 
State University Proteomics and Metabolomics facility. Alignments of the DNA sequences from 
experimental samples and subsequent comparison with the Bp82 sequences were performed 
using ClustalW2 (30) or Sequencher version 5.1 (31). 
 
4.3.6 Deletion of bpeT in Bp82. 
To build a deletion construct for the bpeT gene, the PCR products of primers P2636 & 
P2643 and P2638 & P2637 (Table 4.3) were assembled by splicing by overlap extension 
(SOEing) PCR, and the resulting 1,010 bp product was ligated into the pGEM-T easy vector 
(Table 4.1). The resulting plasmid was digested with NotI-HF and the 1,052 bp ∆bpeT construct 
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was ligated into the pEXKm5 allelic exchange vector to generate plasmid pPS3137. This plasmid 
was transformed into RHO3, which was used to mobilize the plasmid into Bp82, as previously 
described (25). Merodiploids were selected on media containing 1 mg/ml of Km, 50 µg/mL of 
X-Gluc and 80 µg/mL of Ade. Finally, sucrose counter-selection was used to resolve 
merodiploids as previously described (25). Putative mutants were screened by PCR to confirm 
deletion of the bpeT gene.  
 
Table 4.39 Oligonucleotides used in this study. 
Primer Descriptive Name
1
 Primer Sequence Source 
M13F-20 5’- GTAAAACGACGGCCAGT -3’ (32) 
M13R  5’- AACAGCTATGACCATG -3’ (32) 
P1966 folA-F 5’- CTTCCGGCCTCTTTTCTTTC -3’ (18) 
P1967 folA-R 5’- GTGCTGATCGAGCAGATGAC -3’ (18) 
P1791 bpeT-R 5’- CGACGCATCGCGATGGAAAC -3’ Chapter 2 
P1790 bpeT-F 5’- ATGGACCGGCTGCAAGCCAT -3’ Chapter 2 
Construction of bpeT deletion strain 
P2636 ∆bpeT-F 5’- AGCGAATAATCGACCGACAC -3’ This study 









Reverse transcription quantitative PCR experiments 
P1516 Bp23S-F 5’- GTAGACCCGAAACCAGGTGA -3’ (33) 
P1517 Bp23-R 5’- CACCCCTATCCACAGCTCAT -3’ (33) 
P1524 bpeF-F1-RT 5’- TCCGAGTATCCGGAAGTCGT -3’ (33) 
P1525 bpeF-R1-RT 5’- GTCCTCGACACCGTTGATCT -3’ (33) 
P1814 bpeT-RT-F 5'- GAGCTTTCAGGTCAACAACC -3’ 
T. Mima, 
unpublished 




 Abbreviations: SOE, splicing by overlap extension. 
 
4.3.7 Allelic replacement of folA and bpeT mutations in Bp82. 
The pEXKm5 allele replacement system was used to introduce mutations of interest into 
the Bp82 strain background. Primers P1966 & P1967 (Table 4.3) were used to amplify the folA 
gene and flanking regions from both Bp82.102 (F158V) and Bp82.104 (I99L) using the Platinum 
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Taq DNA Polymerase High Fidelity (Life Technologies Corporation, Grand Island, NY). The 
694 bp PCR products were initially cloned into pGEM-T easy and confirmed by DNA 
sequencing using the M13F-20 and M13R primers. DNA fragments containing the correct folA 
mutations were excised by EcoRI digest and ligated into the pEXKm5 plasmid, resulting in 
plasmids pPS2959 and pPS2960 (Table 4.1). These plasmids were transformed into RHO3 and 
conjugated into Bp82, as previously described (34).  
Similarly, primers P2636 & P2637 were used to amplify the bpeT gene and flanking 
regions from both Bp82.102 (C310R) and Bp82.103 (L265R) using the Phusion High-Fidelity 
PCR Master mix (New England BioLabs, Ipswich, MA). The 2,026 bp PCR products were 
purified using the GenElute DNA Extraction kit (SIGMA), and single 3’ adenine base overhangs 
were added to the blunt product using a standard Taq DNA polymerase (New England Biolabs). 
The constructs were then ligated into pGEM-T easy and confirmed by DNA sequencing as 
described above. The plasmids containing the correct mutant bpeT constructs were digested with 
PvuII and the resulting DNA fragments were ligated into SmaI linearized pEXKm5, resulting in 
plasmids pPS3177 and pPS3178 (Table 4.1). These plasmids were transformed into RHO3 and 
conjugated into Bp82.253, as previously described (34).  
Merodiploids for each mutation were selected on LB media containing 80 µg/mL of 
adenine, 1 mg/mL of Km and 50 µg/mL of X-Gluc. Sucrose counter-selection was used as 
previously described (25) to resolve the merodiploids. Resolved colonies were screened by PCR 









4.4  Results 
4.4.1 Characterization of trimethoprim resistant strains. 
Following selection of Bp82 on solid media containing trimethoprim, we obtained a 
collection of isolates with decreased trimethoprim susceptibilities. Of these, 3 isolates were 
selected at random for further testing and characterization, Bp82.102, Bp82.103 and Bp82.104 
(Table 4.2). The MICs of these isolates were above the detection limit of the assay for 
trimethoprim (≥ 32 µg/mL). Isolates Bp82.102 and Bp82.103 had increases in the co-trimoxazole 
MICs as well, but were not resistant to the combination (Table 4.4). In addition to the folate 
pathway inhibitors, we also determined the MICs of these strains for antimicrobials from several 
other classes. The Bp82.102 and Bp82.103 strains had increased MICs for several antimicrobials 
that are known substrates of the BpeEF-OprC efflux pump: acriflavine, chloramphenicol, 
norfloxacin and tetracycline (T. Mima and H.P. Schweizer, unpublished findings), whereas 
Bp82.104 did not and was more susceptible to norfloxacin than the Bp82 parent strain. While 
there were slight differences in MIC, there were no major changes in susceptibility of the strains 
to carbenicillin, erythromycin or gentamicin (Table 4.4).  
To confirm that the BpeEF-OprC efflux pump was contributing to the increased MICs 
observed in strain Bp82.102 and Bp82.103, RT-qPCR was used to determine the relative 
expression of bpeF and bpeT mRNA in the trimethoprim resistant strains compared to the Bp82 
parental strain. There was a significant increase in bpeF and bpeT mRNA expression in strains 
Bp82.102 and Bp82.103, but no change in Bp82.104 (Figure 4.1). Both Bp82.102 and Bp82.103 
had similar expression profiles with an over 35 fold increase in bpeF mRNA and over 2 fold 
increase in bpeT mRNA compared to Bp82. These results are consistent with the MIC results 
(Table 4.4).  
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Table 4.410 Minimal inhibitory concentrations of trimethoprim resistant Bp82 isolates. 
1
Abbreviations:  Car, carbenicillin; Ery, erythromycin; Gen, gentamycin;  
Acr, acriflavine; Chl, chloramphenicol; Nor, norfloxacin; Tet, tetracycline;  
Tmp, trimethoprim; SXT, co-trimoxazole (x trimethoprim + 19x sulfamethoxazole).  
2 
The detection limit for the Etest® method for trimethoprim is 32 µg/mL.  
 
4.4.2   BpeT mutations cause BpeEF-OprC overexpression and resistance.  
The bpeT gene encodes a LysR-regulator that controls expression of BpeEF-OprC. 
Previous work in our lab has demonstrated that mutations to this regulator can cause significant 
overexpression of the efflux pump (T. Mima and H.P. Schweizer, unpublished findings). To 
determine if mutations to bpeT were the cause of the observed overexpression of bpeEF-oprC 
and bpeT, the bpeT gene was sequenced in the 3 trimethoprim resistant isolates. In comparison to 
the Bp82 wild-type sequence, we identified 2 single nucleotide polymorphisms (SNPs) in bpeT 
resulting in amino acid substitutions: a cysteine to arginine change at position 310 in strain 
Bp82.102 and a leucine to arginine at position 265 in Bp82.103. Both of these mutations are in 
the co-inducer binding domain of BpeT. There were no bpeT mutations found in the Bp82.104 
trimethoprim resistant strain. 
 Minimal Inhibitory Concentrations
1
 (g/mL) 
Strain Car Ery Gen Acr Chl Nor Tet Tmp
2
 SXT 
Bp82 256 256 256 32 16 16 4 0.75 0.094 
   Trimethoprim-selected Bp82 derivatives 
Bp82.102 512 256 256 64 128 32 8 ≥ 32 1.5 
Bp82.103 512 512 256 64 128 16 8 ≥ 32 1.0 




Figure 4.110 bpeF and bpeT mRNA expression is significantly elevated in some 
trimethoprim resistant Bp82 mutants. The relative bpeF (blue) and bpeT (green) expression 
was determined in 3 Bp82-derived isolates. All fold expression values are relative to the Bp82 
parent strain. Error bars indicate the standard deviation between three biological replicates, 
which were each performed in technical triplicate. Statistical significance is indicated above 
(****, p ≤ 0.0001; **, p ≤ 0.01).  
 
To confirm that these mutations were causing the observed overexpression of bpeF and 
bpeT mRNA, they were individually introduced into the Bp82 wild-type background using allele 
replacement techniques. The resulting strains Bp82.268 (BpeT C310R) and Bp82.269 (BpeT 
L265R) were tested by RT-qPCR to compare the relative expression of bpeF and bpeT mRNA. 
These experiments demonstrated that introduction of the L265R and C310R mutations into Bp82 
resulted in a similar mRNA expression profile as that found in the original trimethoprim resistant 
strains (Figure 4.2). The expression levels of bpeF mRNA were all near or above 30-fold higher 
than Bp82, while bpeT expression was lower and ranged from below 1-fold to above 2-fold 
compared to Bp82.  
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The MICs for trimethoprim, sulfamethoxazole and co-trimoxazole were determined in 
the Bp82.268 and Bp82.269 strains. Both bpeT SNPs caused a greater than 4-fold increase in 
trimethoprim MICs (Table 4.5). Additionally there was an increase to the co-trimoxazole MICs 
and a small increase in the sulfamethoxazole MICs. These data suggest that both BpeT amino 
acid changes, C310R and L265R, cause overexpression of the BpeEF-OprC efflux pump, which 
in turn results in reduced susceptibility to trimethoprim.  
 
 
Figure 4.211  BpeT mutations cause significant increases in bpeF mRNA levels. The relative 
bpeF (blue) and bpeT (green) expression was determined in trimethoprim resistant Bp82-
derived isolates (Bp82.102 and Bp82.103), and the Bp82 mutants containing either the BpeT 
C310R or L265R mutation (Bp82.268 or Bp82.269, respectively). All fold expression values are 
relative to the Bp82 parent strain. Error bars indicate the standard deviation between three 
biological replicates, which were each performed in technical triplicate. Statistical significance is 










Tmp Smx SXT 
Bp82 ― 0.75 4    0.094 
Bp82.268 C310R 4 8  0.38 
Bp82.269 L265R 4 8  0.38 
                  Abbreviations: MIC, minimal inhibitory concentration; Smx, sulfamethoxazole; 
                   SXT, co-trimoxazole (x Tmp + 19x Sulfamethoxazole); Tmp, trimethoprim. 
 
4.4.3 Mutations to the dihydrofolate reductase result in trimethoprim resistance. 
DNA sequencing of the folA gene identified 2 SNPs encoding for amino acid 
substitutions in the dihydrofolate reductase. Strain Bp82.102 had a valine in place of 
phenylalanine at position 158, while strain Bp82.104 had a mutation resulting in a leucine 
instead of isoleucine at position 99. Interestingly, strain Bp82.102 had both a BpeT and FolA 
mutation. To determine if these mutations to folA confer trimethoprim resistance, allelic 
replacement was used to introduce each of these SNPs into the wild-type Bp82 background. The 
trimethoprim and co-trimoxazole MICs were then determined for each of these strains (Table 
4.6). 
 







Bp82 ― 0.75 0.094 
Bp82.184 I99L ≥ 32 0.5 
Bp82.183 F158V 24 0.5 
                  Abbreviations: MIC, minimal inhibitory concentration;  
                   SXT, co-trimoxazole (x Tmp + 19x Sulfamethoxazole); Tmp, trimethoprim. 
1 
The detection limit for the Etest® method for trimethoprim is 32 µg/mL. 
 
Both folA mutations caused increased trimethoprim MICs, such that the mutant strains 
were resistant (MIC > 8 µg/mL) to the antimicrobial. The I99L conferred a trimethoprim MIC 
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above the limit of detection. Additionally, as a result of these mutations we observed increases in 
the co-trimoxaozle MIC, though the strains were not resistant (MIC > 2 µg/mL) to this 
combination.  
Interestingly, in subsequent experiments Bp82 deletion mutants lacking either the 
BpeEF-OprC efflux pump or its cognate regulator, BpeT, were also selected on trimethoprim. 
Several of the resulting trimethoprim resistant isolates were tested, and in all of these isolates (n 
= 12) the FolA I99L mutation was present (data not shown).  
 
4.4.4 Bp82 can tolerate high concentrations of sulfamethoxazole. 
Following a similar experimental design, several unproductive attempts were made to 
isolate Bp82 derived mutants resistant to sulfamethoxazole using very high concentrations of 
sulfamethoxazole, up to 2 mg/mL. While we were able to obtain isolates that grew with high 
concentrations of sulfamethoxazole, the sulfamethoxazole MICs of most of the strains were over 
10-fold lower than the concentrations used for selection (data not shown). The phenotype of 
these isolates suggested that B. pseudomallei may be able to tolerate sulfamethoxazole even at 
very high concentrations, though further investigation would be necessary to fully understand 
these findings.  
 
4.5  Discussion 
Burkholderia pseudomallei is a Gram-negative pathogen and the etiologic agent of 
melioidosis. While this disease is primarily confined to regions in which it is endemic, it is a 
significant risk to travelers and B. pseudomallei has the potential to be used as a biothreat agent. 
Current recommendations advise a lengthy eradication phase, following initial treatment, with a 
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combination of trimethoprim and sulfamethoxazole (7). This combination is also recommended 
for post-exposure prophylaxis in the event of accidental exposure.  
In this current study we identified mutations to the trimethoprim drug target, 
dihydrofolate reductase (FolA), which conferred resistance to trimethoprim alone. Drug target 
alterations have been documented as effective resistance mechanisms to trimethoprim in several 
other instances (21, 22), however to our knowledge this is the first report of such a mutation in B. 
pseudomallei. The I99L FolA mutation has been previously described in Burkholderia 
cenocepacia (35). Additionally the equivalent mutation (I94L) was also described in mutator E. 
coli isolates selected on trimethoprim (36). Mutator strains are bacterial strains deficient in DNA 
repair mechanisms, often methyl-directed mismatch repair (MMR) (37) and thus have a higher 
than usual rate of genetic mutation. The I94L mutation was found in 8 independently selected 
trimethoprim resistant mutants that were derived from 4 strains with various deleted MMR genes 
(36). There is very little in the literature about the F158V FolA mutation, although the equivalent 
residue in E. coli (F153) has been shown to be associated with a β-bulge region. Mutation to this 
residue may result in a conformational change to the dihydrofolate reductase inhibiting the 
ability of trimethoprim to bind to the enzyme (38, 39).  
In addition to these mutations, we also observed SNPs in the bpeT gene. BpeT is a LysR-
type transcriptional regulator of BpeEF-OprC efflux pump expression which has been shown to 
efflux trimethoprim (18, 19) (Mima, T. and Schweizer H.P, unpublished observations). The 
BpeT mutations were located in the C-terminal co-inducer binding domain. BpeT mutations 
were found in isolates that were trimethoprim resistant and also had decreased susceptibility to 
several known substrates of the BpeEF-OprC efflux pump. These mutations were linked to over-
expression of the BpeEF-OprC efflux pump. While we cannot confirm that the described 
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mutations to folA and bpeT were the only mutations acquired in these strains during the selection 
on trimethoprim, the introduction of each of these mutations individually into the wild-type Bp82 
background allowed us to demonstrate that each mutation contributes to decreased trimethoprim 
susceptibility. Decreases in co-trimoxazole susceptibility were observed in these strains, but all 
remained susceptible to the antimicrobial combination.  
Finally, several attempts were made to investigate potential mechanisms of 
sulfamethoxazole resistance in B. pseudomallei. However, in contrast to the selection on 
trimethoprim, the ability to grow at high concentrations of the antimicrobial was not coupled 
with large changes in the sulfamethoxazole MIC. As there were slight differences in the 
sulfamethoxazole MICs observed in the trimethoprim resistant isolates, we determined the 
sulfamethoxazole MICs for a collection of efflux pump mutants derived from 1026b with 
varying expression levels of 3 efflux pumps: AmrAB-OprA, BpeAB-OprB and BpeEF-OprC. 
The MIC data did not provide any definitive answers, but suggested sulfamethoxazole may be 
effluxed at a low rate by the BpeEF-OprC and BpeAB-OprB pumps, as there were 2-fold 
changes observed between strains overexpressing and not expressing these pumps (data not 
shown). However, it is also possible that these changes are simply due to variable fitness of each 
strain caused by the expression or lack of various efflux pumps. Further studies are necessary to 
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CHAPTER 5:  Investigation of Adaptive Co-Trimoxazole  
Resistance Mechanisms in Burkholderia pseudomallei 
 
This chapter describes the identification of two novel resistance determinants responsible 
for decreased susceptibility to trimethoprim, sulfamethoxazole and the drug combination co-
trimoxazole. Here we identify and propose the name BpeS for a novel regulator of BpeEF-OprC 
efflux pump expression, a key contributor to decreases in both trimethoprim and 
sulfamethoxazole susceptibilities. We also identified mutations to a gene encoding a putative 
pteridine reductase, ptr1. Mutations to ptr1 were found in all of the co-trimoxazole resistant 
isolates, suggesting a role for this gene in folate synthesis and folate pathway inhibitor resistance 
in Burkholderia pseudomallei. These findings are applied in Chapter 6 to investigate a 
collection of clinical and environmental strains with decreased co-trimoxazole susceptibilities.  
 
5.1 Summary 
Burkholderia pseudomallei, the causative agent of the disease melioidosis, poses a 
serious threat as it is resistant to many antimicrobials. Due to the propensity for melioidosis 
infections to be difficult to treat, a combination therapy of trimethoprim and sulfamethoxazole, 
co-trimoxazole, is commonly used for the eradication phase and prophylaxis treatment of 
melioidosis. Co-trimoxazole resistant strains of B. pseudomallei have been reported in endemic 
regions, but to our knowledge there has been no description of the underlying resistance 
mechanisms. In this study we selected spontaneous co-trimoxazole resistant derivatives of the 
Select Agent excluded B. pseudomallei strain Bp82. The resulting isolates had decreased 
susceptibilities to co-trimoxazole and both trimethoprim and sulfamethoxazole individually. 
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Using reverse transcriptase quantitative PCR, we discovered that these isolates had significantly 
increased expression of the BpeEF-OprC efflux pump. Targeted deletion of this efflux pump 
confirmed that it was essential for the observed phenotype. DNA sequencing of the trimethoprim 
and sulfamethoxazole drug targets and known regulatory components of the BpeEF-OprC efflux 
pump offered no explanation for the observed resistant phenotype. However, using whole-
genome sequencing, mutations to genes encoding a novel BpeEF-OprC efflux pump regulator, 
bpeS, and a pteridine reductase, ptr1, were observed. Repair of these point mutations restored co-
trimoxazole sensitivity to the mutant strains. This is the first study to implicate sulfamethoxazole 
as a substrate of the BpeEF-OprC efflux pump in B. pseudomallei. Efflux was required but not 
sufficient to confer resistance to co-trimoxazole. Additionally, in the course of this study, we 
determined that both bpeS and ptr1 are non-essential genes for growth in vitro.  
 
5.2  Introduction 
Burkholderia pseudomallei is a soil-borne bacterium endemic to tropical and sub-tropical 
regions of the world (1, 2). It is a Gram-negative opportunistic pathogen and the etiologic agent 
of the disease melioidosis (2-4). Melioidosis has a highly variable clinical presentation, ranging 
from minor wound infection to severe, often life-threatening, septicemia and pneumonia (4). B. 
pseudomallei infections are challenging to treat, primarily due to the organism’s intrinsic 
resistance to many classes of antimicrobials (5, 6). Previous studies have suggested that relapse 
is very common among survivors of this disease (7, 8), which resulted in several changes in the 
clinical treatment of melioidosis. In order to improve the efficacy of treatment and reduce the 
risk of relapse, the current recommendations include a lengthy eradication phase following initial 
treatment (9-11). The eradication phase typically consists of 12 to 20 weeks of oral co-
trimoxazole with or without doxycycline, or alternatively co-amoxiclav can be used (11). Co-
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trimoxazole is a potent combination of the folate pathway inhibitors trimethoprim and 
sulfamethoxazole and is also recommended for post-exposure prophylaxis (10, 11). However, 
there have been reports of clinical isolates of B. pseudomallei that are resistant to co-trimoxazole 
(12-16). The overall frequency of co-trimoxazole resistance ranges from 2.5% to 16%. 
Variations in the reported frequencies may, in part, be a function of the method used for 
antimicrobial susceptibility testing (13, 14). While previous studies have investigated the 
molecular mechanisms of trimethoprim resistance in B. pseudomallei (Chapter 3 and Chapter 
4) (17), to our knowledge, there have been no studies aimed at investigating co-trimoxazole 
resistance in B. pseudomallei. Based on previous studies, we know that the BpeEF-OprC efflux 
pump is capable of conferring resistance to trimethoprim (17), as are mutations to the 
trimethoprim drug target, dihydrofolate reductase, FolA (Chapter 4). However, very little is 
known about sulfamethoxazole resistance in B. pseudomallei. In other species of bacteria, such 
as Haemophilus influenza (18), Streptococcus pneumonia (19), Escherichia coli, Streptococcus 
pyogenes and Neisseria meningitides (20), mutations to the sulfamethoxazole target, 
dihydropteroate synthetase (FolP), have been shown to confer resistance to sulfonamides (18, 20-
22). One can then postulate that mutations to both FolA and FolP or a combination of efflux and 
mutations to FolP could cause co-trimoxazole resistance in B. pseudomallei. The focus of this 
work was to investigate potential co-trimoxazole resistance mechanisms in B. pseudomallei. 
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5.3 Materials and Methods 
5.3.1 Bacterial Strains. 
The attenuated, Select Agent excluded, Bp82 strain of Burkholderia pseudomallei was 
used for all experiments in this study (Table 5.1). The work done with Bp82 was performed in 
Biosafety Level 2 (BSL-2) facilities, as approved by the Colorado State University Institutional 
Biosafety Committee. Bp82 and its derived strains were grown in Lennox Luria Bertani media 
(LB; Mo Bio Laboratories, Carlsbad, CA) supplemented with 80 µg/mL of adenine (Ade; 
SIGMA, St. Louis, MO). Escherichia coli strains DH5α and RHO3 were used for plasmid DNA 
manipulation and mobilization, respectively (Table 5.2). E. coli strains were grown in LB, which 
was supplemented with diaminopimelic acid (DAP, SIGMA) at 400 μg/mL when cultivating 
RHO3. The addition of 50 µg/mL of 5-bromo-4-chloro-3-indolyl--D-glucuronide (X-Gluc; 
Gold Biotechnology, St. Louis, MO) allowed colorimetric screening for the presence of the gusA 
gene in both pEXKm5-containing strains and merodiploids. To induce transcription of genes 
controlled by the Ptac promoter, 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG; Gold 
Biotechnology) was added to the media. For selection of desired plasmids in E. coli strains, 100 
μg/mL of ampicillin (Amp; SIGMA), 15 μg/mL of gentamicin (Gm; SIGMA), 35 μg/mL of 
kanamycin (Km; SIGMA), or 15 μg/mL of Zeocin (Zeo; Life Technologies, Carlsbad, CA) were 
added to the media as necessary. However, in Bp82 selection of resistance markers was 
performed at much higher concentrations: 2 mg/mL of Gm, 1 mg/mL of Km and 2 mg/mL of 






Table 5.113 Bacterial strains used in this study. 
Strain Description Reference 
DH5α 










E. coli conjugation donor strain  (F- thi-1 thr-1 leuB6 lacY1 tonA21 




Bp82 B. pseudomallei ΔpurM derivative  (23) 
Bp82.191-209 Bp82 SXT
r
 isolates This study 
Repair of ptr1 (V15G) and bpeS (K267T) SNPs in SXT
r 
isolates 
Bp82.202 Bp82 ptr1 (V15G), bpeS (K267T) This study 
Bp82.246 Bp82.202 ptr1 (V15G), bpeS (WT) This study 
Bp82.247 Bp82.202 ptr1 (WT), bpeS (K267T) This study 
Bp82.248 Bp82.202 ptr1 (WT), bpeS (WT) This study 
Bp82.204 Bp82 ptr1 (V15G), bpeS (K267T) This study 
Bp82.249 Bp82.204 ptr1 (V15G), bpeS (WT) This study 
Bp82.250 Bp82.204 ptr1 (WT), bpeS (K267T) This study 
Bp82.251 Bp82.204 ptr1 (WT), bpeS (WT) This study 
Knockout of ptr1 and bpeS in Bp82 
Bp82.256 Bp82∆ptr1::FRT-Km
r
-FRT This study 
Bp82.262 Bp82∆ptr1::FRT This study 
Bp82.263 Bp82∆bpeS::FRT-Km
r
-FRT This study 
Bp82.264 Bp82∆bpeS::FRT This study 
1
Abbreviations: FRT, Flp recombinase target; Km, kanamycin; 
r
, resistant; SNP, single 
nucleotide polymorphism; SXT, co-trimoxazole (trimethoprim:sulfamethoxazole, 1:19); WT, 
wild-type Bp82 sequence. 
 
5.3.2 Passive step-wise selection of co-trimoxazole resistant mutants. 
Co-trimoxazole is a combination of trimethoprim (Tmp) and sulfamethoxazole (Smx) at a 
1:19 ratio. For all co-trimoxazole (SXT) concentrations the formula is: x µg/mL SXT = x µg/mL 
Tmp + 19x µg/mL Smx. Spontaneous mutants of the attenuated Bp82 strain were selected by 
serial passage in increasing concentrations of SXT. Briefly, Bp82 was grown overnight in LB 
broth, then sub-cultured 1:100 into LB broth containing 0.064 µg/mL SXT. Successive 
subcultures were performed into fresh broth with 4-fold increases of co-trimoxazole ending at 8 
µg/mL SXT. The bacterial culture was plated on LB agar containing 8 µg/mL SXT. 
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Table 5.214  Plasmids used in this study. 
Plasmid Descriptive Name Relevant Properties
1
 Source 
pGEM-T Easy  Amp
r





; Allelic exchange vector (25) 
pEXGm5B  Gm
r





, inducible expression of Flp recombinase (27) 
pPS2593 pBADSce-T Zeo
r












Deletion constructs  
pPS2591  pEXKm5∆(bpeEF-oprC) Km
r
; Allelic exchange vector for deletion of bpeEF-oprC (17) 
pPS2481 pUC18T-mini-Tn7T-Ptac Km
r
; mini-Tn7T-Ptac empty control vector (28) 
pPS2670 pPS2481-bpeEF-oprC Km
r
; mini-Tn7T-Ptac-bpeEF-oprC complementation vector (17) 
pPS2647 pEXKm5∆bpeT Km
r
; Allelic exchange vector for deletion of bpeT (17) 
pPS2280 pUC18T-mini-Tn7T Km
r
; mini-Tn7T empty control vector (29) 
pPS2787 pPS2280-PbpeT-bpeT Km
r
; mini-Tn7T-PbpeT-bpeT complementation vector (17) 
pPS3130 pGEM-T Easy ∆ptr1 Amp
r
; 1,236 bp ∆ptr1 SOEing PCR product ligated into pGEM-T Easy This study 





; 1,514 bp FRT-Km
r



















; 2,641 bp ∆bpeS::FRT-Km
r








; 2,670 bp NotI fragment from pPS3127, ∆bpeS::FRT-Km
r
-FRT, 
ligated into pEXGm5B 
This study 
Repair of ptr1 (V15G) and bpeS (K267T) SNPs in Bp82.202 and Bp82.204  
pPS3099 pGEM-T Easy ptr1 (WT) Amp
r
; 1,560 bp ptr1 PCR product from Bp82 ligated into pGEM-T Easy This study 
pPS3093 pEXKm5 ptr1 (WT) Km
r
; 1,595 bp NotI fragment from pPS3099, ptr1 (WT), ligated into pEXKm5 This study 
pPS3097 pGEM-T Easy bpeS (WT) Amp
r
; 1,456 bp bpeS PCR product from Bp82 ligated into pGEM-T Easy This study 
pPS3090 pEXKm5 bpeS (WT) Km
r
; 1,490 bp NotI fragment from pPS3097, bpeS (WT), ligated into pEXKm5 This study 
1
Abbreviations: Amp, ampicillin; Km, kanamycin; Gm, gentamicin; Zeo, Zeocin; T
s
, temperature sensitive; 
r
, resistant; WT, wild-
type Bp82 sequence. 
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Isolated colonies were patched onto LB agar containing 16 µg/mL SXT and subsequently stored 
at -80˚C for further studies.  
 
5.3.3 Antimicrobial susceptibility testing. 
Minimal inhibitory concentrations (MIC) were determined for trimethoprim, 
sulfamethoxazole and co-trimoxazole by the Etest
®
 method, following manufactures guidelines 
(AB Biomérieux, Marcy l’Etoile, France) on Mueller Hinton II agar (Becton Dickinson, Franklin 
Lakes, NJ) supplemented with 40 µg/mL of Ade. Previously described MIC breakpoints were 
used to define susceptibility and resistance to trimethoprim, sulfamethoxazole and co-
trimoxazole (17, 30). MICs for other antimicrobials were determined by standard microdilution 
in Mueller Hinton II broth (Becton Dickinson) supplemented with 40 µg/mL Ade, following 
CLSI guidelines (30). Antibiotics for microdilution MIC testing and the respective suppliers are 
listed: acriflavine (Acr, SIGMA), carbenicillin (Car, Gemini Bio-Products, West Sacramento, 
CA), chloramphenicol (Chl, SIGMA), erythromycin (Ery, SIGMA), gentamicin (Gm, SIGMA), 
norfloxacin (Nor, SIGMA), and tetracycline (Tet, SIGMA). Microtiter plates were incubated at 
37°C in ambient air for 16-20 h before MIC determination. Etests were read at 80% inhibition, 
while microdilution was read at 100% inhibition of growth, as judged by eye. MICs were tested 
in a minimum of 3 replicates and final results were reported as the mode of the replicates.  
 
5.3.4 Reverse-transcriptase quantitative PCR (RT-qPCR). 
Expression levels of bpeF and bpeT mRNA in cultures grown to mid-log phase were 
analyzed as previously described (Chapter 3) (17). The following oligonucleotide sets were 
used for amplification of PCR fragments containing the genes of interest: P1516 & P1517 for 
23S ribosomal RNA (rRNA), P1524 & P1525 for bpeF, and P1814 & P1815 for bpeT (Table 
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5.3). The fold expression of each gene relative to the wild-type Bp82 reference was determined 
by the Bio-Rad iCycler iQ™ Optical System software version 2.0 with defined amplification 
efficiencies for each primer set. Comparisons of the relative mRNA expression data were 
analyzed by two-way analysis of variance (ANOVA) followed by Tukey’s multiple comparisons 
tests using GraphPad Prism version 6.0c for Mac OS X (GraphPad Software, La Jolla, CA). P-
value < 0.05 were considered significant.  
 
5.3.5 DNA sequencing and analysis. 
DNA sequencing of specific genes was performed as previously described  (Chapter 3) 
(17). Briefly, the gene encoding antimicrobial targets, folA (dihydrofolate reductase – 
trimethoprim target) and folP (dihydropteroate synthetase – sulfamethoxazole target), and 
regulatory components of BpeEF-OprC expression, bpeT (regulator) and bpeT-llpE (putative 
promoter region), were PCR amplified in four independent PCR reactions from genomic DNA 
isolated using the PureGene Core kit A (QIAGEN, Valencia, CA) using specific primer sets 
(Table 5.3). PCR reactions were pooled and sequenced at the Colorado State University 
Proteomic and Metabolomics core facility using gene-specific primers. Alignment of the 
sequencing reads and subsequent comparisons were performed using Sequencher version 5.1 











M13F-20  5’- GTAAAACGACGGCCAGT-3’ (32) 
M13R  5’- AACAGCTATGACCATG-3’ (32) 
P1966 folA-F 5’- CTTCCGGCCTCTTTTCTTTC-3’ (17) 
P1967 folA-R 5’- GTGCTGATCGAGCAGATGAC-3’ (17) 
P2323 folP-F 5’- CCAGATCAACGACATCATGG-3’ This study 
P2324 folP-R 5’- CGAGCATATAGCCCGATACC-3’ This study 
P1791 bpeT-R 5’- CGACGCATCGCGATGGAAAC-3’ (17) 
P1790 bpeT-F 5’- ATGGACCGGCTGCAAGCCAT-3’ (17) 
P2570 bpeS-F1 5’- GGATGACTTCGGCGCTATC-3’ This study 
P2571 bpeS-R1 5’- CCGTTCAACCTGACCTCAAC-3’ This study 
P2572 bpeS-F2 5’- GTCTTCCGCCAGCGCTAC-3’ This study 
P2573 bpeS-R2 5’- AAGCCGATTCATCTGGACAC-3’ This study 
P2592 ptr1-F1 5’- CTCGCTCACGCTGATTGC-3’ This study 
P2575 ptr1-R1 5’- CGTCGATGCGGTCTATACG-3’ This study 
P2576 ptr1-F2 5’- ATCGAAGCTCGGCAGGTG-3’ This study 
P2577 ptr1-R2 5’- CGCGCCTACGAGGAGTTC-3’ This study 
Construction of bpeEF-oprC and bpeT deletion strains, complementation vectors and determination 
of chromosomal mini-Tn7 insertion sites 
P1989 ∆bpeEF-oprC-F 5’- GGAAGTACGCGGACTTCGC-3’ (25) 
P1990 ∆bpeEF-oprC-R 5’- GCATCAACCTCGGCTACACG-3’ (25) 
P479 Tn7L 5’- ATTAGCTTACGACGCTACACCC-3’ (29) 
P1509 BpglmS-1 5’- GAGGAGTGGGCGTCGATCAAC-3’ (29) 
P1510 BpglmS-2 5’- ACACGACGCAAGAGCGGAATC-3’ (29) 
P1511 BpglmS-3 5’- CGGACAGGTTCGCGCCATGC-3’ (29) 
Reverse transcription quantitative PCR experiments 
P1516 Bp23S-F 5’- GTAGACCCGAAACCAGGTGA-3’ (33) 
P1517 Bp23-R 5’- CACCCCTATCCACAGCTCAT-3’ (33) 
P1524 bpeF-F1-RT 5’- TCCGAGTATCCGGAAGTCGT-3’ (33) 
P1525 bpeF-R1-RT 5’- GTCCTCGACACCGTTGATCT-3’ (33) 
P1814 bpeT-RT-F 5'- GAGCTTTCAGGTCAACAACC-3’ 
T. Mima, 
unpublished 




P2618 ∆bpeS-F1 5'- CCTGAAGCAGCAACAGCAC-3’ This study 


















Primer Descriptive Name1 Primer Sequence
2
 Source 




P2623 ∆bpeS-R2  5'-CTTTCGCGTGAACGATCC-3’ This study 
ptr1deletion 
P2640 ∆ptr1-F1 5'-CGAGCCGCGACGAAG-3’ This study 








P2641 ∆ptr1-R2 5'-CATCGACCACGGCACG-3’ This study 
1
 Abbreviations: SOE, splicing by overlap extension; Km
r
, kanamycin resistance. 
2
 Bold letters indicate an introduced HindIII restriction enzyme recognition site. 
 
5.3.6 Whole genome sequencing and analysis. 
Previously extracted genomic DNA samples (see above) for Bp82, Bp82.202 and 
Bp82.204 were prepared for paired-end sequencing on the Illumina GAIIx Genome Analyzer 
(Illumina, Inc, San Diego, CA) using the Kapa Biosystems library preparation kit (Woburn, MA, 
catalog #KK8201) protocol with an 8 bp index modification. Briefly, 2 µg double-stranded DNA 
from each sample was sheared to an average size of 350 bp and then input into the Kapa Illumina 
paired end library preparation protocol. Modified oligonucleotides (Integrated DNA 
Technologies, Coralville, IA) that provide 8 bp indexing capability (34), were substituted at the 
appropriate step. Prior to sequencing the libraries were quantified with qPCR on the ABI 
7900HT (Life Technologies Corporation, Carlsbad, CA) using the Kapa Library Quantification 
Kit (Catalog #KK4835). The libraries were sequenced to a read length of 100 bp on the Illumina 
GAIIx Genome Analyzer, yielding 13.2 M, 18.4 M and 20.8 M reads, respectively. The 
DNASTAR SeqMan NGen application (Madison, WI) was used to analyze the Illumina 
sequence data, using default settings. For SNP analysis, the sequence read data was aligned to 
the B. pseudomallei 1026b reference genome (NC_017831.1, NC_017832.1.) SNPs positions 
identified were required to have > 10X coverage depth and > 90% variant base calls.  
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5.3.7  Construction of gene deletion mutants in Bp82. 
The bpeEF-oprC structural efflux pump genes and the bpeT gene were deleted in Bp82 
derived strains using the pEXKm5 allelic exchange vector as previously described (17, 25) using 
plasmids pPS2591 and pPS2647, respectively (Table 5.2). Resulting deletion strains were 
complemented with specific gene(s) originating from 1026b or with an empty-mini-Tn7 element 
as a control, using pPS2481, pPS2670, pPS2280 and pPS2787 (Table 5.2) as previously 
described (17). 
 To build the knockout construct for the ptr1 gene, the PCR products of primers P2639 & 
P2640 and P2641 & P2642 (Table 5.3) were assembled by splicing by overlap extension 
(SOEing) PCR and cloned into the pGEM-T easy vector (Table 5.2). This plasmid was digested 
with HindIII (New England Biolabs, Ipswich, MA), which cut at a site introduced in the SOEing 
primers between the flanking DNA fragments. A Flp-recombinase target (FRT)-flanked 
kanamycin resistance marker (Km
r
, nptII) was excised from pFKm2 as a HindIII fragment and 
was ligated between the cloned chromosomal DNA fragments using T4 DNA ligase (Invitrogen, 
Carlsbad, CA). The ∆ptr1 construct was cloned into the pEXGm5B allelic exchange vector, 
moved into and then conjugated from RHO3 to Bp82. Finally, sucrose counter-selection was 




For deletion of the bpeS gene, primer pairs P2618 & P2619 and P2622 & P2623 (Table 
5.3) were used to amplify DNA fragments immediately upstream and downstream of the gene 
from Bp82 genomic DNA. These products were assembled with the FRT-flanked Km
r
 maker 
(nptII) internally using SOEing PCR and primers P2619-P2622 (Table 5.3). This SOEing 
product was initially cloned into the pGEM-T easy vector background, and then sub-cloned into 
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the pEXGm5B allelic exchange plasmid (Table 5.2). This plasmid was then conjugated from 
RHO3 into Bp82 using previously described methods (25). Selection for the merodiploid was 
done on LB media containing 80 µg/mL of Ade and 1 mg/mL of Km. Several unsuccessful 
attempts were made to resolve the merodiploids using sucrose counter-selection (25) while 
maintaining selection of the Km
r
 marker. The I-SceI endonuclease expressing plasmid pPS2593 
(Table 5.2) was conjugated into the merodiploid and both I-SceI and sucrose mediated counter-
selection methods were used simultaneously (25). The exconjugates were plated on media 
containing 80 of µg/mL Ade, 1 mg/mL of Km, 15% of Sucrose, 2 mg/mL of Zeo and 0.5% of L-
arabinose to finally obtain the Bp82ΔbpeS::Km
r
 strain, Bp82.263 (Table 5.1). The temperature 
sensitive I-SceI-encoding pPS2593 was then cured by incubation at 42°C (25).  
The FRT-flanked Km
r
 markers were removed from each of the knockout strains by Flp 
recombinase-mediated excision using the pFLPe2 plasmid, as previously described (27). pFLPe2 
was subsequently cured by growth at 42˚C. 
 
5.3.8 Allelic replacement of bpeS and ptr1 mutations. 
The pEXKm5 allele replacement vector was used to repair observed single nucleotide 
polymorphisms (SNPs) in selected resistant isolates. Primers P2640 & P2641 (Table 5.3) were 
used to amplify the ptr1 gene and flanking regions from the Bp82 (WT) strain using the Platinum 
Taq DNA Polymerase High Fidelity (Life Technologies Corporation, Grand Island, NY). The 
PCR product was initially cloned into pGEM-T easy and confirmed by DNA sequencing as 
described above. The exchange construct was then moved into the pEXKm5 plasmid and 
conjugated from RHO3 into the desired strain (pPS3093 into Bp82.204) (Table 5.2) as 
previously described (27). Merodiploids were selected with 1 mg/mL of Km, and sucrose was 
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used for counter-selection (25). Resolved colonies were screened by DNA sequencing to confirm 
the presence of the wild-type allele.  
Similarly, primers P2618 & P2623 were used to amplify the bpeS gene for allele 
replacement from the Bp82 (WT) strain. This construct was cloned into pGEM-T easy, 
confirmed by DNA sequencing and moved to the pEXKm5 plasmid. Conjugation of pPS3090 
from RHO3 into Bp82.204 resulted in merodiploids that were then resolved by sucrose counter-
selection and confirmed by DNA sequencing. This method allowed us to repair the bpeS K627T 
mutation in Bp82.204.  
 
5.4 Results  
5.4.1  Co-trimoxazole resistance is dependent on BpeEF-OprC mediated efflux. 
Following serial passage of Bp82 in increasing concentrations of both trimethoprim and 
sulfamethoxazole, we obtained a collection of isolates with decreased co-trimoxazole 
susceptibilities, Bp82.191-Bp82.209 (Table 5.1). From this population, several isolates were 
chosen for further testing. These 6 isolates had trimethoprim and sulfamethoxazole MICs above 
the limit of detection (32 µg/mL and 1024 µg/mL, respectively) (Table 5.4). This combination 
of reduced susceptibility to both trimethoprim and sulfamethoxazole resulted in increased co-
trimoxazole MICs, which ranged from 2 µg/mL to 6 µg/mL in contrast to the wild-type Bp82 
MIC of 0.047 µg/mL (Table 5.4).  
In addition to the MICs for the folate pathway inhibitors, we also tested the sensitivities 
of these strains to other classes of antimicrobials. We observed no major changes in the 
susceptibilities to carbenicillin, erythromycin or gentamicin. However, the MICs for acriflavine, 
chloramphenicol, norfloxacin and tetracycline were much higher than those of the parent strain 
(Table 5.4). The latter antimicrobials are known substrates of the BpeEF-OprC efflux pump (T. 
125 
 
Mima and H.P. Schweizer, unpublished findings), suggesting that the mutant strains are 
overexpressing this efflux pump.  
 
Table 5.416  Antimicrobial susceptibilities of co-trimoxazole resistant Bp82 isolates.  





 SXT Acr Chl
2
 Nor Tet Car Ery Gen 
Bp82 0.75 4 0.047 32 4 4 1 256 128 128 
   Co-trimoxazole selected isolates  
Bp82.191 ≥ 32 ≥ 1024 4 128 ≥ 128 32 2 128 128 64 
Bp82.193 ≥ 32 ≥ 1024 3 128 ≥ 128 32 4 256 128 128 
Bp82.199 ≥ 32 ≥ 1024 2 128 ≥ 128 32 16 256 256 64 
Bp82.202 ≥ 32 ≥ 1024 6 128 ≥ 128 32 4 128 128 128 
Bp82.204 ≥ 32 ≥ 1024 4 128 ≥ 128 32 4 128 128 128 
Bp82.207 ≥ 32 ≥ 1024 2 128 ≥ 128 32 4 128 128 64 
Abbreviations:  Car, carbenicillin; Ery, erythromycin; Gen, gentamicin;  
Acr, acriflavine; Chl, chloramphenicol; Nor, norfloxacin; Tet, tetracycline;  
Tmp, trimethoprim; SXT, co-trimoxazole. 
1 
Etest® detection limits: ≥ 1024 µg/mL for Smx and ≥ 32 µg/mL for Tmp.  
  2 Microdilution for chloramphenicol was not tested above 128 µg/mL. 
 
To confirm the contribution of the BpeEF-OprC efflux pump to the observed increase in 
co-trimoxazole MICs, allelic exchange methods were employed to delete the bpeEF-oprC 
structural genes from each of the 6 strains. The deleted bpeEF-oprC genes were complemented 
using site-specific, single copy insertion of a mini-Tn7 element carrying a wild-type bpeEF-oprC 
operon, as previously described (Chapter 3) (17). Similarly, bpeT deletion strains were 
constructed and complemented with a bpeT gene transcribed from the endogenous PbpeT 
promoter. The MICs of trimethoprim, sulfamethoxazole and co-trimoxazole were determined for 
each of these mutants. MICs were also determined in the presence of IPTG for expression of the 
bpeEF-oprC operon from the inducible Ptac promoter. In all 6 isolates, deletion of the BpeEF-
OprC efflux pump resulted in a significant drop in the co-trimoxazole MICs (Table 5.5). 
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Complementation resulted in increased MICs, though not to the levels observed with the original 
isolates (Table 5.5).  
 
Table 5.517 The BpeEF-OprC efflux pump is required for increased folate inhibitor MICs. 


























Bp82.191 ≥ 32 ≥ 1024 4 1.5 8 0.125 1.5 12 0.125 12 16 0.5 
Bp82.193 ≥ 32 ≥ 1024 3 1.5 6 0.094 1 6 0.094 6 8 0.5 
Bp82.199 ≥ 32 ≥ 1024 2 1.5 6 0.125 1.5 12 0.125 8 24 0.75 
Bp82.202 ≥ 32 ≥ 1024 6 1.5 6 0.125 1.5 16 0.125 12 24 0.5 
Bp82.204 ≥ 32 ≥ 1024 4 2 8 0.125 1.5 12 0.125 6 16 0.5 
Bp82.207 ≥ 32 ≥ 1024 2 1.5 12 0.125 1.5 16 0.125 8 24 0.5 
Abbreviations: IPTG, isopropyl-1-thio-β-D-galactopyranoside; Smx, sulfamethoxazole;  
SXT, co-trimoxazole (x Tmp + 19x Smx); Tmp, trimethoprim. 
1
 The detection limit for the Etest® assay is ≥ 32 g/mL for Tmp and ≥ 1024 g/mL for Smx. 
 
Similarly the absence of the bpeT gene resulted in lower trimethoprim, sulfamethoxazole 
and co-trimoxazole MICs, while complementation resulted in slight increases in most of the 
strains (Table 5.6). In contrast, the trimethoprim and sulfamethoxazole MICs of strains 
Bp82.199 and Bp82.204 appear unaffected by deletion of the bpeT gene. However, since these 
results are above the detection limit of the Etest® strips, it is impossible to determine if there was 
any change to these MICs. In Bp82.199 and Bp82.204 there was a slight drop in the co-
trimoxazole MICs from 2 g/mL to 1 g/mL and from 4 g/mL to 1 g/mL, respectively, 
indicating that the mutant strains are sensitive to the combination (Table 5.6). These results 
would suggest a difference in the mechanisms of resistance; while all of the isolates are 
dependent on presence of the BpeEF-OprC efflux pump a sub-population appears to be maintain 
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resistance to trimethoprim and sulfamethoxazole independent of the BpeT transcriptional 
regulator.  
 
Table 5.618 BpeT is required for increased folate inhibitor MICs in most of the tested strains. 




















Bp82.191 ≥ 32 ≥ 1024 4 4 16 0.38 4 16 0.38 ≥ 32 32 0.75 
Bp82.193 ≥ 32 ≥ 1024 3 2 12 0.25 2 8 0.19 8 24 0.38 
Bp82.199 ≥ 32 ≥ 1024 2 ≥ 32 ≥ 1024 1 ≥ 32 ≥ 1024 1 ≥ 32 ≥ 1024 1 
Bp82.202 ≥ 32 ≥ 1024 6 4 24 0.5 6 12 0.38 8 32 0.75 
Bp82.204 ≥ 32 ≥ 1024 4 ≥ 32 ≥ 1024 1 ≥ 32 ≥ 1024 1 ≥ 32 ≥ 1024 2 
Bp82.207 ≥ 32 ≥ 1024 2 3 16 0.38 4 16 0.25 ≥ 32 32 0.75 
Abbreviations: Smx, sulfamethoxazole; SXT, co-trimoxazole (x Tmp + 19x Smx);  
Tmp, trimethoprim. 
1
 The detection limit for the Etest® assay is ≥ 32 g/mL for Tmp and ≥ 1024 g/mL for Smx. 
 
5.4.2  bpeF mRNA is overexpressed in co-trimoxazole resistant isolates.  
RT-qPCR was used to determine the relative expression levels of bpeF and bpeT mRNA 
in the 6 co-trimoxazole resistant isolates compared to the parental strain, Bp82. Remarkably, 
each of the strains were expressing bpeF mRNA at over 100 times that of Bp82 (Figure 5.1). 
There was no significant difference in bpeF expression between the different co-trimoxazole 
resistant isolates. Based on previous work by T. Mima, we know that overexpression of BpeT 
will result in overexpression of BpeEF-OprC (T. Mima and H. P. Schweizer, unpublished 
results). Small increases in bpeT mRNA expression were observed in all 6 isolates relative to 
Bp82 (Figure 5.2), however these increases were not statistically significant.  
The bpeF mRNA expression levels were also determined in mutant derivatives of the 6 




Figure 5.112  bpeF mRNA levels are significantly elevated in co-trimoxazole resistant Bp82 
mutants. The relative bpeF expression was determined in 6 Bp82 derived-isolates (blue) and 
mutant derivatives lacking the BpeT regulator (red) under normal growth conditions. All fold 
expression values are relative to the Bp82 parent strain. Error bars indicate the standard deviation 
between three biological replicates, which were each performed in technical triplicate. The bpeF 
mRNA expression levels were very high in the strains compared to the parent Bp82 strain. 
However, there was a significant drop in bpeF expression in the absence of bpeT. Statistical 
significance is indicated above (****, p ≤ 0.0001; **, p ≤ 0.01).  
 
the absence of bpeT. However, relative to Bp82, these isolates still overexpress bpeF by at least 
30 fold. These results suggest that mutations in these resistant strains may have affected another 
regulator of bpeEF-oprC expression causing enhanced expression of the llpE-bpeEF-oprC 
operon even in the absence of the BpeT transcriptional regulator. Of note, reduced bpeF mRNA 
expression was observed in strains Bp82.199 and Bp82.204 in the absence of bpeT. This result is 
intriguing, as in all of the other strains decreased BpeEF-OprC efflux was linked with increased 
susceptibility to the folate pathway inhibitors (Table 5.6). While there were decreases in 
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Bp82.199 and Bp82.204 MICs, as discussed above, they were noticeably higher than those of the 
other strains tested. 
 
 
Figure 5.213  bpeT mRNA levels are marginally elevated in co-trimoxazole resistant Bp82 
mutants. The relative bpeT expression was determined in 6 Bp82 derived-isolates under normal 
growth conditions (green). All fold expression values are relative to the Bp82 parent strain. Error 
bars indicate the standard deviation between biological replicates, which were each performed in 
technical triplicate. There was no significant change in bpeT expression in these strains, and no 
bpeT mRNA was detected in the ΔbpeT strains (brown), as expected.  
 
5.4.3  DNA sequencing of suspected co-trimoxazole resistance determinants. 
PCR amplification and Sanger sequencing methods were used to investigate mutations, 
which could account for the overexpression of BpeEF-OprC in these isolates. We sequenced 
bpeT and the intergenic region containing predicted promoters for both bpeT and the llpE-
bpeEF-oprC operon in the 6 strains of interest. However, there were no mutations to the 
nucleotide sequence of these regions. Similar to previous work by Podnecky et al. (17) (Chapter 
3) these data suggest involvement of an additional unidentified regulator of BpeEF-OprC efflux 
pump expression. While expression of the BpeEF-OprC efflux pump appears to be the major 
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determinant   of   co-trimoxazole   resistance,  we  also  sequenced  the  genes  encoding  the 
trimethoprim and sulfamethoxazole drug targets, dihydrofolate reductase (folA) and 
dihydropetorate synthetase (folP). We found no mutations in folA or folP, confirming that drug 
target modification is not responsible for the co-trimoxazole resistance in the tested isolates. 
 
5.4.4  Whole genome sequencing reveals mutations in bpeS and ptr1.  
Comparison of whole genome sequences of the co-trimoxazole resistant mutants to the 
Bp82 parent revealed two single nucleotide polymorphisms (SNPs) found in both Bp82.202 and 
Bp82.204. The first SNP is a thymine to guanine transversion in the carboxy-terminal effector 
binding domain of a LysR family transcriptional regulator encoded by a gene designated 
BP1026B_I1290, which was renamed bpeS (Figure 5.3-A). This mutation results in a lysine to 
tyrosine amino acid substitution at position 267 of BpeS. BpeS was found to have high sequence 
homology to the known BpeEF-OprC LysR transcriptional regulator, BpeT. A key region in 
these regulators, the N-terminus of the protein containing the DNA binding domain, is 90% 
identical over the first 60 amino acids. This suggests that these two proteins likely bind to similar 
regulatory sequences.  
The second SNP is an adenine to cytosine transversion in a pteridine reductase 1 
encoding gene designated BP1026B_II0040, ptr1 (Figure 5.3-B). The mutation encodes a valine 
to glycine amino acid change at position 15 in the N-terminus NADPH binding domain of Ptr1. 
Pteridine reductases are most notable for conferring resistance to methotrexate in parasites (35). 
Pteridine reductases are also homologs of an enzyme, FolM, in bacteria that can function as a 
dihydrofolate reductase similar to folA (36). The folM gene is commonly found to cluster 
genetically with folE, a gene necessary for initiation of pterin synthesis (37, 38). This is true in B. 




Figure 5.314Genomic location and organization of the bpeS (A) and ptr1 (B) regions of B. 
pseudomallei 1026b.  Sequence coordinates are taken from the GenBank entries for the 1026b 
strain (accession numbers NC_017831.1 and NC_017832.1). Gene annotations are as follows: 
_I2791 (BP1026B_I2791), peptidase; bpeS (BP1026B_I1290), LysR-type transcriptional 
regulator; _I2789 (BP1026B_I2789), two-component regulator histidine sensor kinase; _II0039 
(BP1026B_II0039), serine O-acetyltransferase; ptr1 (BP1026B_II0040), pteridine reductase 1; 
folE (BP1026B_II0041), GTP cyclohyrolase; and _II0042 (BP1026B_II0042), LysR-type 
transcriptional regulator. The bpeS transcriptional regulator is distal from the llpE-bpeEF-oprC 
operon, which is located on Chromosome II. The ptr1 gene is located immediately downstream 
of the folE gene, which is essential for pterine synthesis (37).  
 
Both the BpeS K267T and Ptr1 V15G mutations were confirmed in Bp82.202 and 
Bp82.204 by targeted Sanger sequencing. Additionally, DNA sequencing of these genes showed 
that all of the co-trimoxazole resistant isolates in this study had the BpeS K267T mutation, and 
all had the Ptr1 V15G mutation with one exception. Strain Bp82.193 did not have the Ptr1 V15G 
mutation, but instead has a single base deletion at position 203 causing a frame shift mutation 
starting at amino acid 67. The resulting frame shift causes early termination of the protein 
following the 92
nd
 residue. Bp82.193 is phenotypically similar to the 5 other strains in all other 
aspects, suggesting that the V15G mutation in Ptr1 may also disrupt function. 
 
5.4.5  Mutations in bpeS and ptr1 cause co-trimoxazole resistance. 
To determine the effect of the identified mutations in bpeS and ptr1, the SNPs were repaired 
individually and in combination in strains Bp82.202 and Bp82.204. MIC testing of these strains 
indicated that loss of either SNP individually resulted in antimicrobial susceptibility; 
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demonstrated by the reduced MICs for trimethoprim, sulfamethoxazole and co-trimoxazole 
(Table 5.7).  
 
Table 5.719 Antimicrobial susceptibilities of genetically repaired co-trimoxazole isolates.  






Bp82 0.75 4 0.047 
   Co-trimoxazole resistant isolates  
Bp82.202 ≥ 32 ≥ 1024 6 
Bp82.204 ≥ 32 ≥ 1024 4 
   Co-trimoxazole resistant isolates with wild-type bpeS 
Bp82.246 0.5 4 0.064 
Bp82.249 0.5 4 0.064 
   Co-trimoxazole resistant isolates with wild-type ptr1 
Bp82.247 ≥ 32 32 0.75 
Bp82.250 ≥ 32 32 0.75 
   Co-trimoxazole resistant isolates with wild-type bpeS and ptr1 
Bp82.248 0.19 1.5 0.032 
Bp82.251 0.19 1.5 0.032 
Abbreviations: Smx, sulfamethoxazole; SXT, co-trimxoazole; Tmp, trimethoprim, 
1 
The detection limit for the Etest® method for trimethoprim is ≥ 32 µg/mL.  
  2 
The detection limit for the Etest® method for sulfamethoxazole is ≥ 1024  
    µg/mL.  
 
Repair of the bpeS gene caused a greater drop in MIC, where the susceptibility to each 
drug was reduced to that of the parental Bp82 strain. Repair of the ptr1 gene had a lesser effect, 
but still reduced the MICs of sulfamethoxazole from the detection limit of 1024 μg/mL to 32 
μg/mL and co-trimoxazole from 4-6 μg/mL to 0.75 g/mL. Surprisingly, the repair of both SNPs 
resulted in MICs below those of the original Bp82 parent strain. 
In addition to measuring the MICs of the repaired mutant strains, RT-qPCR was used to examine 




Figure 5.415The BpeS (K267T) mutation is responsible for increased bpeEF-oprC 
expression. The relative bpeF mRNA expression was determined in Bp82 derived-isolates 
grown in LB medium. All fold expression values are relative to the Bp82 parent strain. Error bars 
indicate the standard deviation between three biological replicates, which were each performed 
in technical triplicate. Isolates containing the BpeS K267T mutation had very high expression, 
whereas all other isolates had expression similar to the parental strain Bp82. 
 
In each of the mutant strains that contained the BpeS K267T mutation, there was close to 
100 fold increased expression of bpeF relative to Bp82. There was no change to the gene 
expression with the introduction of the Ptr1 V15G mutation, as was expected. This evidence 
clearly indicates that BpeS plays a major role in regulation of BpeEF-OprC expression.  
 
5.4.6  bpeS and ptr1 are non-essential in Bp82. 
In order to further investigate the bpeS and ptr1 genes in B. pseudomallei, allelic 
exchange methods were used to delete each of these genes individually in the Bp82 strain 
background. Successful deletion of these genes indicates the neither are essential for in-vitro 





plays in the folate synthesis pathway of B. pseudomallei. However, this result could suggest that, 
similar to previous findings, Ptr1 could provide redundancy to this essential pathway (36). 
 






Bp82 ― 0.5 4 0.094 
Bp82.262 ∆ptr1 1.5 12 0.125 
Bp82.264 ∆bpeS 0.5 4 0.094 
Abbreviations: MIC, minimal inhibitory concentration; Smx, sulfamethoxazole;  
         SXT, co-trimoxazole (x Tmp + 19x Smx); Tmp, trimethoprim. 
 
Deletion of the ptr1 gene in Bp82 (Bp82.262) resulted in 3-fold increases to the 
trimethoprim and sulfamethoxazole MICs and a small increase in the co-trimoxazole MIC 
(Table 5.8). These data suggest that mutations that inactivate Ptr1 function may contribute, to 
but are sufficient alone, to confer resistance. In contrast, there were no MIC changes in Bp82 
lacking bpeS (Table 5.8).  
 
5.5 Discussion 
Major folate pathway inhibitors are known to be efficacious against B. pseudomallei. A 
combination of trimethoprim and sulfamethoxazole, co-trimoxazole, is commonly part of the 
treatment for melioidosis. Unfortunately, co-trimoxazole resistant isolates have been identified in 
the clinical setting further complicating the treatment of this notoriously antimicrobial resistant 
organism. Resistance to co-trimoxazole is complex, as strains resistant to either trimethoprim or 
sulfamethoxazole alone remain susceptible to the combination. Typically resistance to 
trimethoprim and sulfamethoxazole is the result of mutant FolA and FolP proteins insensitive to 
the respective drug (18, 22). Additionally, overexpression of the folA target gene can lead to 
resistance (39). However, mutations in the drug targets were not observed in this study.  
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We instead identified several mutations that contribute to co-trimoxazole resistance in 
laboratory-selected mutants of Bp82. Efflux has been previously shown to mediate resistance to 
both trimethoprim and sulfamethoxazole (40). In B. pseudomallei clinical and environmental 
isolates overexpression of the BpeEF-OprC efflux pump has been previously shown to confer 
resistant to trimethoprim and to low-level increases in co-trimoxazole MICs (17). The BpeS 
mutation K267T identified in this study resulted in high-level expression of the BpeEF-OprC 
efflux pump, even in the absence of the BpeT regulator. Interestingly, when this mutation is 
repaired or the efflux pump deleted, the MICs of both trimethoprim and sulfamethoxazole drop. 
This is the first evidence that sulfamethoxazole may also be a BpeEF-OprC pump substrate. This 
is alarming, as efficient efflux of both drugs could confer co-trimoxazole resistance. However, it 
is important to note that, while increased expression of BpeEF-OprC led to increased co-
trimoxazole MICs, according to the CLSI cutoffs (30), the strains remained sensitive to this drug 
combination. These findings suggest that efflux by BpeEF-OprC alone may not be sufficient to 
confer clinically significant co-trimoxazole resistance in B. pseudomallei.  
Pteridine reductases are short-chain dehydrogenase/reductase (SDR) enzymes that have 
been previously shown to confer resistance to methotrexate, a dihydrofolate reductase inhibitor, 
in trypanosomatids (35, 36). The genetically similar folM gene from E. coli encodes an enzyme 
with dihydrofolate reductase activity in the absence of folA (36). We identified two mutations to 
prt1 in the B. pseudomallei co-trimoxazole resistant isolates in this study. A frame shift mutation 
causing early termination of the protein most likely results in a non-functional enzyme. A recent 
study showed increased trimethoprim MICs in E. coli strains lacking FolM (41). The authors 
argue that while this result was unexpected, absence of the FolM dihydrofolate reductase may 
prompt increased expression and activity of FolA resulting in decreased trimethoprim 
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susceptibilities (41). However, we observed slight increases to both the trimethoprim and 
sulfamethoxazole MICs. It is possible that the acquired mutations to ptr1 in the selected B. 
pseudomallei isolates may have a similar effect on both the folA and folP genes. Further studies 
to investigate the relative expression of each of these genes and the role of Ptr1 in folate 
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CHAPTER 6: The BpeEF-OprC Efflux Pump is a Major 
Contributor to Co-Trimoxazole Resistance in Burkholderia 
pseudomallei Clinical Isolates 
 
This chapter applies methods used in the preceding chapters to look for previously 
described resistance mechanisms for trimethoprim (Chapter 3 and Chapter 4) and 
sulfamethoxazole (Chapter 4 and Chapter 5) in a collection of clinical isolates from Thailand 
with a range of co-trimoxazole MICs. This work demonstrates that while complex, the clinical 
isolates can be grouped phenotypically based on antimicrobial resistance profiles and expression 
of the BpeEF-OprC efflux pump. 
 
6.1 Summary 
Burkholderia pseudomallei is a saprophyte capable of causing the disease melioidosis. B. 
pseudomallei is naturally resistant to many antimicrobials, which limits and complicates the 
treatment of melioidosis. Co-trimoxazole, a potent combination of trimethoprim and 
sulfamethoxazole is typically used for the eradication phase treatment of this infection. However, 
co-trimoxazole resistant isolates have been identified in endemic regions in the clinical setting. 
These resistant isolates are concerning as there are currently limited treatment options for this 
broadly antimicrobial resistant bacterium. The purpose of this study was to characterize a 
collection of clinical isolates from Thailand and determine the mechanisms responsible for co-
trimoxazole resistance. We found that the BpeEF-OprC efflux pump is essential for co-
trimoxazole resistance in the isolates used in this study. Deletion of the bpeEF-oprC operon 
resulted in a co-trimoxazole sensitive and trimethoprim resistant phenotype; however the bpeT 
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gene was only necessary for resistance in some of the strains. Reverse-transcriptase quantitative 
PCR experiments showed that bpeEF-oprC is greatly overexpressed in co-trimoxazole resistant 
strains, though in some isolates bpeT is not necessary for this overexpression. A single amino 
acid substitution in the BpeS LysR-type regulator may be the cause of BpeT independent 
constitutive overexpression of bpeEF-oprC; however DNA sequence comparisons did not 
suggest explanations for bpeEF-oprC overexpression in other strains.  
 
6.2 Introduction 
Burkholderia pseudomallei is a pathogen endemic to soils and ground water in tropical 
and sub-tropical regions of the world (1, 2). B. pseudomallei is known to cause an uncommon 
but often-serious disease, melioidosis (2-4). B. pseudomallei is notorious for its resistance to a 
wide-range of antimicrobials (5, 6), resulting in limited options for the treatment of melioidosis. 
Trimethoprim and sulfamethoxazole are folate pathway inhibitors that are synergistic and 
effective against B. pseudomallei. The co-trimoxazole combination is typically given for a 
minimum of 12-20 weeks following the initial phases of treatment (7, 8). Additionally co-
trimoxazole is recommended for post-exposure prophylaxis in the event of accidental laboratory 
exposure or intentional release of the agent (7). B. pseudomallei is currently listed as a Tier 1 
Select Agent by the United States government. The potential for its use as a bioweapon and 
further increases to the antimicrobial resistance of this organism is cause for concern. Naturally 
occurring resistance to co-trimoxazole is found at rates ranging from 2.5% to 16% in endemic 
regions (9, 10). With limited alternatives for efficacious therapeutics, improved understanding of 
the mechanisms of resistance is vital to allow for the development of novel therapeutics.  
Previously we have investigated trimethoprim resistance in clinical, environmental and 
laboratory-selected B. pseudomallei isolates (Chapter 3 and Chapter 4). These studies have 
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shown that a resistance nodulation and cell division (RND) efflux pump, BpeEF-OprC, can 
confer resistance to trimethoprim alone, as do mutations to the drug target dihydrofolate 
reductase, FolA. The BpeEF-OprC efflux pump also appears to efflux sulfamethoxazole and 
contributes to co-trimoxazole resistance (Chapter 5). Mutations to the sulfamethoxazole target, 
dihydropteroate synthetase (FolP), have been shown to confer resistance to sulfonamides in other 
bacteria (11-14), however no such mutations have been reported in B. pseudomallei. Finally, 
mutations observed in the ptr1 gene, encoding for a putative pteridine reductase, were found to 
contribute to sulfamethoxazole and co-trimoxazole resistance. Previous studies have suggested 
that a homologue of this gene, folM, found in Escherichia coli can act as a dihydrofolate 
reductase and contribute to methotrexate, or potentially trimethoprim, resistance (15). However it 
is unclear what role Ptr1 plays in folate synthesis in B. pseudomallei. The purpose of this study 
was to determine which, if any, of the above mechanisms contribute to co-trimoxazole resistance 
in clinical B. pseudomallei isolates.  
 
6.3 Material and Methods 
6.3.1  Bacterial strains. 
The Burkholderia pseudomallei strain 1026b (16) was used as a prototype strain for experiments 
with clinical B. pseudomallei isolates. A collection of 14 clinical isolates from Thailand (isolated 
between 1993-2009) was used in this study (Table 6.1). Additionally a collection of 9 clinical 
and environmental strains from Thailand and 3 clinical and environmental isolates from 
Australia used by Podnecky et al. (Chapter 4) (17) was further examined in the current study. 
All procedures involving B. pseudomallei clinical isolates were performed in Select Agent 
approved Biosafety Level 3 (BSL-3) facilities at the Rocky Mountain Regional Biosafety 
Laboratory at Colorado State University using Select Agent compliant procedures and protocols. 
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Additionally, the Select Agent excluded B. 
pseudomallei 1026b-derived strain; Bp82 (Table 6.2) 
was used for several experiments performed at 
Biosafety Level 2 (BSL-2), as approved by the 
Colorado State University Institutional Biosafety 
Committee. B. pseudomallei was grown in Lennox 
Luria-Bertani (LB; MO BIO Laboratories, Carlsbad, 
CA) broth or LB agar at 37°C unless otherwise noted. 
LB was supplemented with 80 μg/mL of adenine (Ade; 
SIGMA, St. Louis, MO) and with or without 80 μg/mL 
of thiamine (Thi; SIGMA) for cultivation of Bp82 and 
its derivatives. E. coli strains DH5α and XL1-Blue were 
used for genetic manipulation of plasmid DNA and the RHO3 strain was used as a conjugation 
donor strain for mobilization of plasmids (Table 6.2). E. coli strains were grown in LB media at 
37°C, which for cultivation of RHO3 was supplemented with 400 μg/mL of diaminopimelic acid 
(DAP; SIGMA). For selection of plasmids in E. coli strains, 100 μg/mL of ampicillin (Amp; 
SIGMA, St. Louis, MO), 15 μg/mL of gentamicin (Gm; SIGMA) or 35 μg/mL of kanamycin 
(Km; SIGMA) was added to the media as necessary, while selection for the Km resistance 
marker in B. pseudomallei was performed on media containing 1 mg/ml of Km. Colorimetric 
screening for the presence of the gusA gene in pEXKm5-containing strains and merodiploids was 
done on media containing 50 µg/mL of 5-bromo-4-chloro-3-indolyl--D-glucuronide (X-Gluc; 
Gold Biotechnology, St. Louis, MO). Induction of genes controlled by the Ptac promoter was  
 
Table 6.121 Clinical isolates used in 
this study. 
Thai Clinical  
B. pseudomallei Isolates 
Strain Specimen Isolation 
1026b blood  1993 
1130 pus 1993 
1374 pus 1995 
1468 sputum 1995 
1553 blood 1996 
1641 sputum 2000 
2131 pus 1998 
2259 pus 1999 
2411 pus 2001 
2431 blood 2000 
2444 urine 2000 
2517 blood 2000 
2703 throat swab 2001 
5041 sputum 2008 




Table 6.222 Bacterial strains and plasmids used in this study. 
Strain Description Reference 
DH5α 
E. coli general cloning strain    (F
–





phoA supE44 thi-1 gyrA96 relA1 λ
–
) 
   (18) 
RHO3 
E. coli conjugation donor strain  (F
-




   (19) 
XL1-Blue 







Santa Clara, CA 
Bp82 1026bΔpurM  (Select Agent excluded Burkholderia pseudomallei strain)    (20) 
Bp82.265 Bp82 folP (A120V)  This study 
Plasmid Descriptive Name Relevant Properties
1
 Source 
pGEM-T Easy  Amp
r





; Allelic exchange vector (19) 
pTNS3  Amp
r
; Tn7 transposase expression vector (19) 
pPS2591  pEXKm5∆(bpeEF-oprC) Km
r
; Allelic exchange vector for deletion of bpeEF-oprC (17) 
pPS2481 pUC18T-mini-Tn7T-Ptac Km
r
; mini-Tn7T-Ptac empty control vector (21) 
pPS2670 pPS2481-bpeEF-oprC Km
r
; mini-Tn7T-Ptac-bpeEF-oprC complementation vector (17) 
pPS2647 pEXKm5∆bpeT Km
r
; Allelic exchange vector for deletion of bpeT (17) 
pPS2280 pUC18T-mini-Tn7T Km
r
; mini-Tn7T empty control vector (22) 
pPS2787 pPS2280-PbpeT-bpeT Km
r
; mini-Tn7T-PbpeT-bpeT complementation vector (17) 
pPS3129 pGEM-T Easy-folP Amp
r
; 1,351 bp  folP PCR product ligated into pGEM-T Easy This study 
pPS3143 pGEM-T Easy-folP (A120V) 
Amp
r
; pPS3129 following QuikChange II mutagenesis with P2644 & P2645 
to c362t 
This study 
pPS3145 pEXKm5-folP (A120V) Km
r
; 1,384 bp NotI pPS3143 fragment (FolP A120V) ligated into pEXKm5 This study 
1
 Abbreviations: Amp, ampicillin; Gm, gentamicin; Km, kanamycin; 
r
, resistant; Tet, tetracycline. 
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accomplished by the addition of 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG; Gold 
Biotechnology) to the media, as needed. 
 
 6.3.2 Antimicrobial susceptibility testing. 
The minimal inhibitory concentrations (MIC) for trimethoprim, sulfamethoxazole and co-
trimoxazole were determined by Etest
®
 method (AB Biomérieux, Marcy l’Etoile, France) on 
Mueller Hinton II agar (Becton Dickinson, Franklin Lakes, NJ). The MIC breakpoints used 
previously to define trimethoprim, sulfamethoxazole and co-trimoxazole resistance in B. 
pseudomallei (17) were used in this study. Co-trimoxazole (SXT) is a combination of 
trimethoprim (Tmp) and sulfamethoxazole (Smx) at a 1:19 ratio. SXT concentrations are based 
on the formula:  x µg/mL SXT = x µg/mL Tmp + 19x µg/mL Smx. 
 
6.3.3 Reverse-transcriptase quantitative PCR (RT-qPCR). 
The mRNA expression levels of bpeF and bpeT were assessed in cultures grown to mid-
log phase with or without trimethoprim induction (1 h incubation with 32 μg/mL of 
trimethoprim; trimethoprim stock solution was made in dimethylacetamide at a concentration of 
100 mg/mL), as previously described (17). Relative expression was determined by the Bio-Rad 
iCycler iQ™ Optical System software version 2.0 with specific primer set efficiencies. Analysis 
of the data was performed in GraphPad Prism version 6.0c for Mac OS X (GraphPad Software, 
La Jolla, CA) using a two-way analysis of variance (ANOVA) on log transformed relative 
expression data followed by Tukey’s multiple comparisons test for comparison across strains or 




6.3.4 DNA sequencing and analysis. 
DNA sequencing of specific genes was performed as previously described (Chapter 3) 
(17). Briefly, the genes encoding antimicrobial targets, folA and folP, ptr1 (pteridine reductase), 
key BpeEF-OprC efflux related genes, as well as other pertinent DNA regions including the 
regulators bpeT and bpeS, the bpeT-llpE-bpeE intergenic region (containing putative promoters) 
and bpeF (cytoplasmic membrane transporter) were PCR amplified in 4 independent PCR 
reactions using the Platinum Taq DNA Polymerase High Fidelity (Life Technologies 
Corporation, Grand Island, NY) with specific primer sets (Table 6.3). PCR reactions were 
pooled and sequenced using gene-specific primers. Additionally, internal primers were used for 
ptr1 and bpeS sequencing. Alignment of the sequence reads and comparisons were performed 
using Sequencher version 5.1 (Gene Codes Corporation, Ann Arbor, MI) (25) and ClustalW2 
(26). 
 
6.3.5  Markerless deletion and complementation of bpeEF-oprC and bpeT. 
Deletion of large portions of the coding regions for the bpeEF-oprC and bpeT genes were 
performed individually on clinical strains of interest using the pEXKm5-based allelic exchange 
method, as previously described (17, 19). The deletion mutants were complemented with their 
respective mini-Tn7 constructs from pPS2670 and pPS2280 (Table 6.2). Deletion mutants 
containing the empty mini-Tn7 constructs were used as controls, as previously described (17).  
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Table 6.323 Oligonucleotides used in this study. 
Primer Descriptive Name Primer Sequence Source 
M13F-20  5’- GTAAAACGACGGCCAGT-3’ (23) 
M13R  5’- AACAGCTATGACCATG-3’ (23) 
T7  5’- TAATACGACTCACTATAGGG-3’  
P1966 folA-F 5’- CTTCCGGCCTCTTTTCTTTC-3’ Chapter 3 
P1967 folA-R 5’- GTGCTGATCGAGCAGATGAC-3’ Chapter 3 
P2182 Upstream-folA-F 5’- CTGTATCGGCTGATGGTGTC-3’ Chapter 3 
P2183 Upstream-folA-R 5’- AGGCCTTCCTCGTACAGTTG-3’ Chapter 3 
P2323 folP-F 5’- CCAGATCAACGACATCATGG-3’ Chapter 5 
P2324 folP-R 5’- CGAGCATATAGCCCGATACC-3’ Chapter 5 
P1791 bpeT-R 5’- CGACGCATCGCGATGGAAAC-3’ Chapter 3 
P1790 bpeT-F 5’- ATGGACCGGCTGCAAGCCAT-3’ Chapter 3 
P2142 bpeT-bpeE-F 5’- TCTGAATGATCGTCGTCACC-3’ Chapter 3 
P2143 bpeT-bpeE-R 5’- AATCGGTGATCGTCTTCGAC-3’ Chapter 3 
P2109 bpeF-F1 5’- GCATCTCGTGCCGATGAC-3’ Chapter 3 
P2110 bpeF-R1 5’- CGAACTCGTCCTCGTTCTG-3’ Chapter 3 
P2094 bpeF-F2 5’- ACATGACGTATCTGCGCAAC-3’ Chapter 3 
P2095 bpeF-R2 5’- CATCGCGAACTGCTTGTAGA-3’ Chapter 3 
P2096 bpeF-F3 5’- AACGTCGAGCGCAACATC-3’ Chapter 3 
P2097 bpeF-R3 5’- CGTTGATCTGGTAGCTCGTG-3’ Chapter 3 
P2098 bpeF-F4 5’- GCGGCTTCAAGATGCAG-3’ Chapter 3 
P2099 bpeF-R4 5’- ACCACACCCATGATGAACG-3’ Chapter 3 
P2100 bpeF-F5 5’- AGGGCGACAACAACATCTTC-3’ Chapter 3 
P2101 bpeF-R5 5’- GGCCTTCAGGTTCTGGTTC-3’ Chapter 3 
P2570 bpeS-F1 5’- GGATGACTTCGGCGCTATC-3’ Chapter 5 
P2571 bpeS-R1 5’- CCGTTCAACCTGACCTCAAC-3’ Chapter 5 
P2572 bpeS-F2 5’- GTCTTCCGCCAGCGCTAC-3’ Chapter 5 
P2573 bpeS-R2 5’- AAGCCGATTCATCTGGACAC-3’ Chapter 5 
P2592 ptr1-F1 5’- CTCGCTCACGCTGATTGC-3’ Chapter 5 
P2575 ptr1-R1 5’- CGTCGATGCGGTCTATACG-3’ Chapter 5 
P2576 ptr1-F2 5’- ATCGAAGCTCGGCAGGTG-3’ Chapter 5 
P2577 ptr1-R2 5’- CGCGCCTACGAGGAGTTC-3’ Chapter 5 
Reverse transcription quantitative PCR experiments 
P1516 Bp23S-F 5’- GTAGACCCGAAACCAGGTGA-3’ (24) 
P1517 Bp23S-R 5’- CACCCCTATCCACAGCTCAT-3’ (24) 
P1524 bpeF-F1-RT 5’- TCCGAGTATCCGGAAGTCGT-3’ (24) 
P1525 bpeF-R1-RT 5’- GTCCTCGACACCGTTGATCT-3’ (24) 
P1814 bpeT-RT-F 5'- GAGCTTTCAGGTCAACAACC-3’ Chapter 3 





Primer Descriptive Name Primer Sequence Source 
Construction of bpeEF-oprC and bpeT deletion strains, complementation vectors and 
determination of chromosomal mini-Tn7 insertion sites 
P1989 ∆(bpeEF-oprC)-F 5’- GGAAGTACGCGGACTTCGC-3’ (19) 
P1990 ∆(bpeEF-oprC)-R 5’- GCATCAACCTCGGCTACACG-3’ (19) 
P479 Tn7L 5’- ATTAGCTTACGACGCTACACCC-3’ (22) 
P1509 BpglmS-1 5’- GAGGAGTGGGCGTCGATCAAC-3’ (22) 
P1510 BpglmS-2 5’- ACACGACGCAAGAGCGGAATC-3’ (22) 
P1511 BpglmS-3 5’- CGGACAGGTTCGCGCCATGC-3’ (22) 
Mutagenic PCR oligonucleotides 
P2644 folP (A120V)-QC-F 5’-TCGCCGCGGGCGTCGATCTGATCAAC-3’ This study 
P2645 folP (A120V)-QC-R 5’-GTTGATCAGATCGACGCCCGCGGCGA-3’ This study 
 
Deletion mutants and mini-Tn7 containing strains were confirmed by PCR using specific 
primers (Table 6.3). The BpeEF-OprC complementation construct contains the 1026b bpeEF-
oprC operon controlled by the Ptac inducible promoter. Expression of bpeEF-oprC was induced 
by the addition of 1 mM IPTG to the media.  
 
6.3.6 Allelic replacement of the folP mutation in Bp82. 
The pEXKm5 allele replacement vector was used to introduce point mutations into the 
wild-type Bp82 strain. Primers P2640 & P2641 (Table 6.3) were used to amplify the folP gene 
from 1026b genomic DNA isolated using the PureGene Core Kit A (QIAGEN, Valencia, CA). 
This PCR product was ligated into the pGEM-T Easy vector (Promega, Madison, WI) resulting 
in pPS3129 (Table 6.2). The A120V mutation was introduced into the folP gene using primers 
P2644 & P2645 (Table 6.3) designed using the QuikChange Primer Design software (Agilent 
Technologies, Santa Clara, CA). The QuikChange® II Site-Directed Mutagenesis kit (Agilent 
Technologies) was used for mutagenesis and transformation into XL1-Blue competent E. coli. 
Introduction of the desired mutation was confirmed by DNA sequencing of plasmid pPS3143 
using primers M13R and T7 (Table 6.3). Merodiploids were selected on LB media containing 80 
µg/mL of Ade, 1 mg/mL of Km and 50 µg/mL of X-Gluc. The merodiploids were resolved by 
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sucrose counter-selection, as previously described (19). Resolved merodiploids were screened 
for the FolP A120V mutation by PCR amplification and DNA sequencing of folP using specific 
primers (Table 6.3).  
 
6.4 Results 
6.4.1 Identification of co-trimoxazole resistant clinical isolates. 
Trimethoprim, sulfamethoxazole and co-trimoxazole MICs were determined for each of 
the 14 clinical and environmental isolates obtained from the Mahidol University collection. 
Using the interpretation criteria from the Clinical Laboratory Standards Institute (CLSI), as 
described by Podnecky et al. (17), 11 of the 14 isolates were resistant (MIC > 8 μg/mL) to 
trimethoprim alone (Table 6.4). Only strains 2444, 1130 and 1641 were susceptible to 
trimethoprim. The majority of the strains were susceptible to sulfamethoxazole, while strains 
1374, 1468, 5041 and 5242 had MICs at or above the 1024 μg/mL limit of detection (Table 6.4).  
A total of 4 of the 14 tested isolates were co-trimoxazole resistant. Each of these strains (1374, 
1468, 5041 and 5242) had MICs above the limit of detection for both trimethoprim and 
sulfamethoxazole alone. Strains 1641 and 1130 had the lowest MICs for all of the antimicrobials 
tested. We observed that strain 1641 appeared to be infected with a lysogenic phage, as plates 
struck for confluency frequently showed zones of lysis, which made Etest MIC determination 
difficult and likely inaccurate.  
 
6.4.2 bpeEF-oprC is overexpressed in co-trimoxazole resistant strains. 
Relative bpeF mRNA levels were determined for each of the 14 clinical isolates 
compared to the 1026b strain using RT-qPCR (Figure 6.1). There was significant overexpression 
of bpeF mRNA 
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Table 6.424  Antimicrobial susceptibilities of B. pseudomallei clinical isolates. 









1374 ≥ 32 ≥ 10240 4.0000 
1468 ≥ 32 ≥ 10240 4.0000 
5041 ≥ 32 ≥ 10240 4.0000 
5242 ≥ 32 ≥ 10240 3.0000 
1553 ≥ 32 1920 2.0000 
2703 ≥ 32 1280 1.5000 
2411 ≥ 32 640 1.0000 
2259 ≥ 32 320 0.7500 
2517 ≥ 32 240 0.7500 
2431 ≥ 32 240 0.5000 
2131 012 320 0.3800 
2444 008 160 0.3800  
1130 004 40 0.0640 
1641 0000.5 30 0.0320 
Abbreviations: Smx, sulfamethoxazole; SXT, co-trimoxazole (x Tmp + 19x Smx);       
Tmp, trimethoprim. 
1
 Red lettering indicates antimicrobial resistance: Tmp > 8 μg/mL, Smx > 256 μg/mL,      
and SXT > 2 μg/mL. 
2
 The detection limits for Etest® are 32 µg/mL for Tmp and 1024 µg/mL for Smx. 
 
observed in strains 1374, 5041 and 5242 grown in LB medium (p ≤ 0.0001). Strain 1468 did not 
overexpress bpeF under these conditions, but produced nearly 6 times as much bpeF mRNA as 
1026b when induced with trimethoprim. These 4 strains had the highest bpeF expression and the 
highest MICs for sulfamethoxazole and co-trimoxazole (Table 6.4).  
None of the other 10 clinical isolates had significantly increased expression of bpeF 
under normal growth conditions, but interestingly strain 1130 had significantly decreased 
expression of bpeF compared to 1026b (p ≤ 0.0001). All of the strains showed some increase in 
bpeF expression when treated with trimethoprim, though this difference was statistically 
significant only in roughly half of the strains (Figure 6.1).  
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There was a large change is bpeF expression when strain 1641 was induced with 
trimethoprim, however the MICs of this strain to each of the 3 drugs tested were the lowest of all 
the isolates.  
 
6.4.3 bpeT is differentially expressed in strains 5242 and 1641. 
We also determined the relative bpeT mRNA expression level for each of the 14 clinical 
isolates compared to 1026b both with and without induction with trimethoprim (Figure 6.2). 
Interestingly, there was no significant overexpression of bpeT in the clinical strains under non-
inducing growth conditions, expect for strain 5242 (p < 0.05). The bpeT mRNA levels in strain 
5242 were influenced by induction with trimethoprim (Figure 6.2). Strain 1641 was the only 
other strain with a significant increase of bpeT expression in the presence of trimethoprim. The 
inducible expression of bpeT in strains 5242 and 1641 may account for the observed 
overexpression of bpeF under these conditions (Figure 6.1), as previous work has shown that 
increased bpeT mRNA results in increased bpeEF-oprC expression (T. Mima and H.P. 
Schweizer, unpublished results). However, there are significant differences between the bpeT 
(Figure 6.2) and bpeF (Figure 6.1) mRNA expression levels of these 2 strains relative to one 
another, which may explain the very large differences in their respective MICs (Table 6.4).  
Using previously published methods (17, 19), the bpeEF-oprC efflux pump structural 
genes were deleted in each of these isolates, and mutants were complemented with a mini-Tn7 
element carrying the 1026b-derived bpeEF-oprC operon under control the    inducible Ptac 
promoter. MICs were determined for trimethoprim, sulfamethoxazole and co-trimoxazole in each 




Figure 6.116Relative expression of bpeF mRNA in clinical isolates from Thailand. The relative bpeF mRNA levels were 
determined in 14 clinical isolates from Thailand. The relative expression was assessed both under non-inducing growth conditions 
(solid bars) and following induction with 32 µg/mL of trimethoprim for 1 h (+Tmp; stippled bars). Fold expression was determined 
relative to the uninduced 1026b control strain. Error bars show the standard deviation between biological replicates, each of which 
were tested in technical triplicate. Statistical analysis by two-way ANOVA and Tukey multiple comparisons test showed significantly 
increased bpeF expression in strains 1374, 5041 and 5242. Statistical differences dependent on induction with trimethoprim are 




Figure 6.217 Relative bpeT mRNA levels were determined in 14 clinical isolates from Thailand. The relative expression was 
assessed both under non-induced growth conditions (solid bars) and following induction with 32 µg/mL of  trimethoprim for 1 h prior 
to RNA harvest (+Tmp; stippled bars). Fold expression was determined relative to the uninduced 1026b control strain. Error bars 
show the standard deviation between biological replicates, each of which were tested in technical triplicate. Statistical analysis by two-
way ANOVA and Tukey multiple comparison test showed significantly increased bpeT expression in strain 5242. Statistical 
differences resulting from induction with trimethoprim are indicated above (***, p < 0.001; *, p < 0.05). 
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strain derivatives (Table 6.5). The co-trimoxazole MICs for the 4 resistant isolates were 0.25 
µg/mL or lower in the absence of bpeEF-oprC and increased when the complemented strains 
were induced with IPTG. These findings suggest that BpeEF-OprC is required for co-
trimoxazole resistance in these strains. 
 
Table 6.525 The BpeEF-OprC efflux pump is required for co-trimoxazole resistance. 


























1374 ≥ 32 ≥ 1024 4 1.5 8 0.125 1.5 12 0.125 ≥ 32 64 1 
1468 ≥ 32 ≥ 1024 4 ≥ 32 48 0.25 ≥ 32 64 0.5 ≥ 32 384 1.5 
5041 ≥ 32 ≥ 1024 4 16 16 0.19 ≥ 32 32 0.38 ≥ 32 192 1.5 
5242 ≥ 32 ≥ 1024 3 8 24 0.25 4 24 0.25 ≥ 32 384 1.5 
1553 ≥ 32 ≥ 1024 2 ≥ 32 48 0.25 16 48 0.38 ≥ 32 256 1.5 
2131 12 32 0.38 1 6 0.094 1.5 6 0.125 8 64 0.5 
2444 8 16 0.38 6 12 0.19 6 16 0.25 8 24 0.25 
Abbreviations: IPTG, isopropyl-1-thio-β-D-galactopyranoside; Smx, sulfamethoxazole; SXT, 
co-trimoxazole (x Tmp + 19x Smx); Tmp, trimethoprim. 
1
 The detection limits for Etest® are 32 µg/mL for Tmp and 1024 µg/mL for Smx. 
 
Similarly, the MICs for sulfamethoxazole dropped in all of the strains lacking the bpeEF-
oprC genes and increased in induced complemented strains. In testing the trimethoprim MICs we 
noted, that several of the strains remained near or at the limit of detection (32 µg/mL) in the 
absence of the BpeEF-OprC pump. It is not possible to determine if the trimethoprim MICs have 
decreased in these strains (1468, 5041 and 1553) using the Etest method. Determining the MIC 
by microdilution would allow for testing above 32 µg/mL, however this method has been shown 
to be highly variable and inaccurate in determining MICs for the bacteriostatic trimethoprim 
antimicrobial (N.L. Podnecky, T. Mima and H.P. Schweizer, unpublished findings). The 
trimethoprim MICs were shown to drop noticeably in strains 1374, 5242 and 2131 in the absence 
155 
 
of bpeEF-oprC. Interestingly, there were only very slight changes to any of the MICs for strain                                                                                                                                                                  
2444 in the absence of the bpeEF-oprC genes. 
 
6.4.4 BpeT is necessary for co-trimoxazole resistance in some strains. 
Similar studies were done to examine changes to the MICs in the absence of BpeT in 
these 7 clinical isolates (Table 6.6). We observed a substantial drop in MIC for both 
sulfamethoxazole and co-trimoxazole in all but 2 of the strains tested (Table 6.6).  
 
Table 6.626 BpeT is required for co-trimoxazole resistance in some clinical isolates. 




















1374 ≥ 32 ≥ 1024 4 ≥ 32 ≥ 1024 6 ≥ 32 ≥ 1024 6 ≥ 32 ≥ 1024 12 
1468 ≥ 32 ≥ 1024 4 ≥ 32 96 0.38 ≥ 32 96 0.38 ≥ 32 256 1.5 
5041 ≥ 32 ≥ 1024 4 ≥ 32 ≥ 1024 6 ≥ 32 ≥ 1024 8 ≥ 32 ≥ 1024 12 
5242 ≥ 32 ≥ 1024 3 6 16 0.19 8 24 0.25 ≥ 32 48 0.75 
1553 ≥ 32 ≥ 1024 2 3 8 0.125 6 16 0.19 ≥ 32 32 1 
2131 12 32 0.38 2 16 0.19 2 16 0.125 3 16 0.125 
2444 8 16 0.38 1.5 6 0.094 1 8 0.094 3 12 0.125 
Abbreviations: Smx, sulfamethoxazole; SXT, co-trimoxazole (x Tmp + 19x Smx); Tmp, 
trimethoprim. 
1
 The detection limits for Etest® are 32 µg/mL for Tmp and 1024 µg/mL for Smx. 
 
Complementation with the 1026b-derived PbpeT-bpeT resulted in increases to these MICs 
in most of the tested strains. Strains 1374 and 5041 remained resistant to both sulfamethoxazole 
and co-trimoxazole in the absence of BpeT. Additionally, in these 2 strains and strain 1468 there 
was no detected drop in trimethoprim MIC (Table 6.6). The remaining 4 strains (5242, 1553, 
2131 and 2444) had marked decreases to MICs for trimethoprim alone in the absence of bpeT 
(Table 6.6). Overall, these findings indicated that BpeT can contribute to increased 
trimethoprim, sulfamethoxazole and thus co-trimoxazole MICs in B. pseudomallei isolates. 
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However, BpeT is not essential for resistance to these folate-pathway inhibitors, as demonstrated 
in strains 1374 and 5041.  
 
6.4.5 bpeEF-oprC expression in 1374 and 5041 is BpeT-independent. 
In addition to determining the MICs of each of the clinical strains lacking BpeT, the 
expression of bpeF mRNA was compared among the clinical isolates. We found that in most of 
the strains there was a drop in bpeF expression (Figure 6.3). We however saw no change in 
bpeF expression in strains 1374 and 5041, which overexpress bpeF nearly 100 times that of 
strains 1026b, 2444 and the trimethoprim resistant 1553 and 2131 (Figure 6.3). The very high 
expression of bpeF in the absence of BpeT explains the unaffected trimethoprim, 
sulfamethoxazole and co-trimoxazole MICs and suggests that expression is BpeT-independent 
(Table 6.5).  
 
6.4.6  Clinical isolates fall into distinct phenotypic groups. 
The clinical isolates are clustered by phenotype into 5 groups based on their respective 
MIC and gene expression data (Figure 6.3). (1) The folate pathway inhibitor sensitive strains 
1026b and 2444 do not overexpress bpeF or bpeT when grown in the absence of an inducer. 
Strain 2444 does however significantly increase bpeF expression in the presence of 
trimethoprim. (2) Strains 2131 and 1553 are resistant to trimethoprim alone and do not have high 
expression of bpeF under normal growth conditions. However, there is a significant increase in 
bpeF expression in strain 2131 when induced with high concentrations of trimethoprim. (3) 
Strain 1468 is resistant to all of the folate pathway inhibitors, but does not overexpress bpeF 
under normal growth conditions. However, it does express bpeF at a higher level when induced 




Figure 6.318Comparison of MIC and bpeF expression data in 8 clinical isolates from Thailand. Comparison of resistance to the 
folate pathway inhibitors trimethoprim (Tmp), sulfamethoxazole (Smx) and co-trimoxazole (SXT) is shown in the table. The relative 
bpeF mRNA levels are shown both LB with (solid blue & 2
nd
 row) and without (∆bpeT; solid red & 4
th
 row) BpeT and in wild-type 
strains following induction with 32 µg/mL for 1 h (+Tmp; blue stippled & 3
rd
 row). Relative bpeT mRNA expression was also 
compared (5
th
 row, data from  Figure 6.2). Error bars indicate the standard deviation. Two-way ANOVA with Tukey’s and Sidak’s 
multiple comparisons tests were used (****, p ≤ 0.0001; ***, p ≤ 0.001; *, p < 0.05; n.s., not significant).  
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 (4) Strain 5242 is also resistant to all of the folate pathway inhibitors and greatly overexpresses 
bpeF mRNA under normal conditions. The addition of trimethoprim further increases the 
expression of bpeF mRNA in 5242, while the absence of bpeT reduces bpeF expression to the 
level seen in strain 1026b. (5) Finally, strains1374 and 5041 are grouped together as both are 
resistant to the folate pathway inhibitors and highly express bpeF mRNA under normal 
conditions, similar to strain 5242. However, these 2 strains are unique in that the high level bpeF 
expression does not increase in the presence of trimethoprim, nor does it decrease in the absence 
of bpeT. This suggests that there constitutive overexpression of the efflux pump encoding genes 
in these strains. In contrast, all of the other resistant strains appear have inducible phenotypes. 
Genetic mutations to bpeEF-oprC regulatory elements and other trimethoprim and 
sulfamethoxazole resistance determinants may explain the variety of observed phenotypes in this 
collection of clinical isolates. 
 
6.4.7 Genetic mutations contributing to increased bpeEF-oprC expression. 
DNA sequencing of clinical and environmental B. pseudomallei isolates was employed to 
identify mutations of interest. Several of the clinical isolates in this study, 1374, 5041 and 5242, 
significantly overexpress bpeF mRNA (Figure 6.1). DNA sequencing of the bpeT-llpE 
intergenic region containing the putative bpeT and llpE-bpeEF-oprC promoters did not identify 
any nucleotide changes specific to the overexpressing strains compared to 1026b and other 
isolates that do not overexpress bpeF mRNA (Table 6.7). However, we did observe an amino 
acid substitution in the putative lipase llpE (D293A) of strain 5041, which is the first gene in the 
llpE-bpeEF-oprC operon. Previous work has shown that the LlpE lipase is not essential for 
BpeEF-OprC-mediated efflux (T. Mima and H.P. Schweizer, unpublished results). We also 
observed a single nucleotide insertion 12 bases upstream of the bpeE start site in strains 1468 and 
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2650a. Both of these strains overexpress bpeF mRNA when induced with trimethoprim and are 
bpeT dependent (Figure 6.3, Chapter 3), however, based on the location of this mutation it is 
unlikely to have an effect on BpeEF-OprC expression or function.  
The bpeT gene was sequenced to see if mutations to the BpeT LysR-type regulator are 
responsible for increased efflux pump expression in these clinical isolates. However, only 
synonymous mutations were found in this gene, there were no amino acid substitutions in any of 
the tested strains (Table 6.7). Additionally, we sequenced the recently described BpeS LysR-
type regulator (Chapter 5) to determine if mutations to bpeS are responsible for bpeEF-oprC 
overexpression. We identified a number of mutations to this gene in both clinical and 
environmental isolates (Table 6.7). Several of the observed mutations were common among the 
clinical and environmental isolates, such as a nucleotide substitution 4 bp upstream of the bpeS 
start site, and the following amino acid substitutions: K88R, T178A, and L211S (Table 6.7). 
These mutations were common to isolates that overexpress bpeF and others that do not, 
suggesting that they are not involved in regulation of bpeEF-oprC expression. Several mutation 
were observed that were unique to single trimethoprim resistant strains (2677a, E0235, MSHR 
305 and MSHR 668). While these mutations may contribute to trimethoprim resistance, they are 
not sufficient to confer resistant to the co-trimoxazole combination. However, the BpeS proline 
to serine substation at amino acid 28 was found to be unique to strains 1374 and 5041, which are 
phenotypically similar (Figure 6.3). Further studies are necessary to confirm that this mutations 
to BpeS in responsible for the constitutive overexpression of bpeEF-oprC in these strains.  
Recent work suggests that sulfamethoxazole may be a substrate of the BpeEF-OprC 
efflux pump (Chapter 5) and the current MIC data supports this finding (Table 6.5 & Table 
6.6). Structural changes to the membrane associated transporter protein of an efflux pump can 
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alter substrate specificity. The bpeF gene, which encodes for the RND transporter of the BpeEF-
OprC efflux pump, was sequenced. However there were no non-synonymous mutations 
identified (Table 6.7). This may suggest that sulfamethoxazole is a standard substrate of the 
BpeEF-OprC efflux pump, and that substantial overexpression is necessary for the observed 
increases in sulfamethoxazole MIC.  
 
6.4.8 Drug target and biosynthetic pathway modifications. 
The BpeEF-OprC efflux pump plays a necessary role in resistance to co-trimoxazole, but 
it is unclear if there are other mutations contributing to the observed resistance. To investigate 
this further, the folA and folP genes were sequenced in each of the co-trimoxazole clinical 
isolates, as well as, additional clinical and environmental isolates (Table 6.7). Interestingly, we 
found 2 mutations to the folA gene (V61A & A145T) in strains 1374, 1553 and 2444, relative to 
1026b. The V61A mutation was also found in 5 other trimethoprim resistant clinical and 
environmental isolates (Table 6.7). However, these mutations do not likely contribute to 
resistance as strain 1553 is co-trimoxazole susceptible and strain 2444 is susceptible to both 
trimethoprim and co-trimoxazole.  
DNA sequencing of the folP gene in the clinical isolates revealed only one mutation, 
FolP A120V. This mutation was found in strain 1468, which is co-trimoxazole resistant (Table 
6.4), but expresses bpeF at a significantly lower level than the other co-trimoxazole resistant 
isolates in this study (Figure 6.3). To determine if this mutation alone contributes to increases in 
sulfamethoxazole MIC, this single nucleotide polymorphism (SNP) was introduced into the 
attenuated Bp82 strain using allelic exchange. MIC testing of Bp82.265 showed no major 




Table 6.727  Genetic variation in clinical and environmental B. pseudomallei isolates.  






FolA FolP Ptr1 BpeT 
IR (bpeT- 
llpE -bpeE)














t-4c, T178A - 










- - - - t-4c - 

















2665a 1 V61A ND - - - K88R, L211S ND 
2719a 1 V61A ND - - - t-4c, T178A - 
MSHR 465a 1 ND ND - - ND t-4c, T178A ND 




E0016 0.75 V61A ND - - - T178A, L211S ND 




E0237 0.5 - ND - - - - ND 











- - - - T178A - 
MSHR 668 0.38 ND ND R113C - ND 
c-68a, t-25c, t-4c, 
T178A 
ND 
Abbreviations: IR, intergenic region; ND, no data; SXT, co-trimoxazole; ::, insertion;  
Δ, deletion. 
1
 B. pseudomallei isolates are ordered by decreasing co-trimoxazole MIC. 
Red text indicates resistance to co-trimoxazole (SXT MIC > 2 μg/mL). Lower case font indicates 
nucleotide, upper case indicates amino acid. Bold type font indicates nucleotide insertion or 






parental strain (Table 6.9). These data suggest that FolP A120V does not contribute to co-
trimoxazole resistance.  
 






Bp82 WT 0.5 4 0.094 
Bp82.265 A120V 0.5 4 0.094 
Abbreviations: MIC, minimal inhibitory concentration; Smx, sulfamethoxazole;  
       SXT, co-trimoxazole (x Tmp + 19x Smx); Tmp, trimethoprim. 
 
In addition to drug target modification, previous studies have suggested that mutations to a 
gene encoded pteridine reductase (Ptr1) may contribute to increased trimethoprim MICs in E. 
coli (15, 27) or sulfamethoxazole and co-trimoxazole resistance in B. pseudomallei (Chapter 5). 
DNA sequencing of this gene in these clinical isolates revealed 2 mutations leading to amino 
acid substitutions in strain 1468 (G33D and R42H) and a 7 nucleotide deletion resulting in a 
frame shift mutation in strain 5041. The G33D and R42H mutations were also observed in the 
trimethoprim resistant 2677a strain. However, the frame shift mutation is unique to strain 5041 
and causes amino acid substitutions starting at amino acid 20 and early termination of the protein 
after 90 residues. Previous studies have suggested that absence of a functional Ptr1 homolog, 
FolM, may result in overexpression of the FolA trimethoprim drug target causing increases to the 
trimethoprim MIC (15). A similar frame shift mutation was described in a recent study 
investigating co-trimoxazole resistance in laboratory induced mutants (Chapter 5). MIC testing 
of a Bp82∆ptr1 strain had slight (3-fold) increases in both trimethoprim and sulfamethoxazole 
MICs (Chapter 5), suggesting that the pteridine reductase mutation in 5041 may contribute to 
increased co-trimoxazole MICs but alone would not likely confer resistance. Further study is 
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needed to elucidate the role of Ptr1 in folate synthesis in B. pseudomallei and understand the role 
it may play in decreased co-trimoxazole susceptibility. 
 
6.5 Conclusions 
Co-trimoxazole, a potent combination of trimethoprim and sulfamethoxazole, is often 
used for melioidosis treatment and prophylaxis. This is the first study to investigate the 
mechanisms responsible for co-trimoxazole resistance in clinical B. pseudomallei isolates. 
Clinical isolates are difficult populations to work with as the genetic diversity between the 
isolates is high and there are often multiple explanations for observed phenotypes and 
convoluted observations. Despite this complexity, we were able to group these isolates into 5 
unique populations based on antimicrobial resistance and BpeEF-OprC efflux pump expression 
phenotypes. However, characterization of a larger population of isolates is necessary to 
determine if there are other naturally occurring factors responsible for folate pathway inhibitor 
resistance in B. pseudomallei isolates.  
We observed that the BpeEF-OprC efflux pump was necessary for co-trimoxazole 
resistance. Overexpression of this pump was observed in all of the co-trimoxazole resistant 
isolates relative to those that were co-trimoxazole sensitive. This RND efflux pump has 
previously been reported to be responsible for trimethoprim resistance (Chapter 3) (17), co-
trimoxazole resistance in laboratory induced mutants (Chapter 5), and resistance to other 
clinically relevant antimicrobials, including chloramphenicol and doxycycline (T. Mima and H. 
P. Schweizer, unpublished results). Previous work with laboratory selected co-trimoxazole 
resistant B. pseudomallei isolates suggests that overexpression of the BpeEF-OprC efflux pump 
was necessary but not sufficient for co-trimoxazole resistance (Chapter 5). Due to the genetic 
diversity of the strains, it is unclear if BpeEF-OprC efflux is the only contributing factor for co-
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trimoxazole resistance in these clinical isolates. While mutations to the antimicrobial targets 
FolA and FolP do not appear to contribute to resistance, mutations to Ptr1 may contribute to the 
increased co-trimoxazole MIC but alone are not sufficient for co-trimoxazole resistance.  
BpeEF-OprC regulation is complex and mutations to the known LysR-type regulators 
BpeT and BpeS have been shown to cause increased expression of bpeEF-oprC. BpeEF-OprC 
expression is largely dependent on BpeT, however we identified 2 isolates that do not require 
BpeT for high level expression. Further research is needed to better understand the mechanism of 
action for these regulators and other components contributing to expression of BpeEF-OprC. 
Repression of BpeEF-OprC efflux pump expression or supplementation of treatment with a 
specific efflux pump inhibitor would likely reduce or prevent the development of co-trimoxazole 





1. Currie BJ, Dance DA, Cheng AC. 2008. The global distribution of Burkholderia 
pseudomallei and melioidosis: an update. Trans R Soc Trop Med Hyg 102 Suppl 1:S1-4. 
2. Wiersinga WJ, Currie BJ, Peacock SJ. 2012. Melioidosis. N Engl J Med 367:1035-
1044. 
3. Cheng AC, Currie BJ. 2005. Melioidosis: epidemiology, pathophysiology, and 
management. Clin Microbiol Rev 18:383-416. 
4. Currie BJ, Ward L, Cheng AC. 2010. The epidemiology and clinical spectrum of 
melioidosis: 540 cases from the 20 year Darwin prospective study. PLoS Negl Trop Dis 
4:e900. 
5. Jenney AW, Lum G, Fisher DA, Currie BJ. 2001. Antibiotic susceptibility of 
Burkholderia pseudomallei from tropical northern Australia and implications for therapy 
of melioidosis. Int J Antimicrob Agents 17:109-113. 
6. Sookpranee T, Sookpranee M, Mellencamp MA, Preheim LC. 1991. Pseudomonas 
pseudomallei, a common pathogen in Thailand that is resistant to the bactericidal effects 
of many antibiotics. Antimicrob Agents Chemother 35:484-489. 
7. Peacock SJ, Schweizer HP, Dance DA, Smith TL, Gee JE, Wuthiekanun V, 
DeShazer D, Steinmetz I, Tan P, Currie BJ. 2008. Management of accidental 
laboratory exposure to Burkholderia pseudomallei and B. mallei. Emerg Infect Dis 14:e2. 
8. Lipsitz R, Garges S, Aurigemma R, Baccam P, Blaney DD, Cheng AC, Currie BJ, 
Dance D, Gee JE, Larsen J, Limmathurosakul D, Morrow MG, Norton R, O'Mara 
E, Peacock SJ, Pesik N, Rogers LP, Schweizer HP, Steinmetz I, Tan G, Tan P, 
Wiersinga WJ, Wuthiekanun V, Smith TL. 2012. Workshop on treatment of and 
postexposure prophylaxis for Burkholderia pseudomallei and B. mallei infection, 2010. 
Emerg Infect Dis 18:e2. 
9. Piliouras P, Ulett GC, Ashhurst-Smith C, Hirst RG, Norton RE. 2002. A comparison 
of antibiotic susceptibility testing methods for cotrimoxazole with Burkholderia 
pseudomallei. Int J Antimicrob Agents 19:427-429. 
10. Wuthiekanun V, Cheng AC, Chierakul W, Amornchai P, Limmathurotsakul D, 
Chaowagul W, Simpson AJ, Short JM, Wongsuvan G, Maharjan B, White NJ, 
Peacock SJ. 2005. Trimethoprim/sulfamethoxazole resistance in clinical isolates of 
Burkholderia pseudomallei. J Antimicrob Chemother 55:1029-1031. 
11. Sköld O. 2001. Resistance to trimethoprim and sulfonamides. Vet Res 32:261-273. 




13. Swedberg G, Fermer C, Sköld O. 1993. Point mutations in the dihydropteroate synthase 
gene causing sulfonamide resistance. Advances in experimental medicine and biology 
338:555-558. 
14. Huovinen P. 2001. Resistance to trimethoprim-sulfamethoxazole. Clin Infect Dis 
32:1608-1614. 
15. Girgis HS, Hottes AK, Tavazoie S. 2009. Genetic architecture of intrinsic antibiotic 
susceptibility. PLoS One 4:e5629. 
16. DeShazer D, Brett PJ, Carlyon R, Woods DE. 1997. Mutagenesis of Burkholderia 
pseudomallei with Tn5-OT182: isolation of motility mutants and molecular 
characterization of the flagellin structural gene. J Bacteriol 179:2116-2125. 
17. Podnecky NL, Wuthiekanun V, Peacock SJ, Schweizer HP. 2013. The BpeEF-OprC 
efflux pump is responsible for widespread trimethoprim resistance in clinical and 
environmental Burkholderia pseudomallei isolates. Antimicrob Agents Chemother 
57(9):4381-4386. 
18. Liss LR. 1987. New M13 host: DH5αF' competent cells. Focus 9:13. 
19. López CM, Rholl DA, Trunck LA, Schweizer HP. 2009. Versatile dual-technology 
system for markerless allele replacement in Burkholderia pseudomallei. Appl Environ 
Microbiol 75:6496-6503. 
20. Propst KL, Mima T, Choi KH, Dow SW, Schweizer HP. 2010. A Burkholderia 
pseudomallei ΔpurM Mutant is Avirulent in Immune Competent and Immune Deficient 
Animals: Candidate Strain for Exclusion from Select Agent Lists. Infect Immun. 
21. Rholl DA, Papp-Wallace KM, Tomaras AP, Vasil ML, Bonomo RA, Schweizer HP. 
2011. Molecular Investigations of PenA-mediated beta-lactam Resistance in 
Burkholderia pseudomallei. Front Microbiol 2:139. 
22. Choi KH, DeShazer, D., Schweizer, H.P. 2006. mini-Tn7 insertion in bacteria with 
multiple glmS-linked attTn7 sites: example Burkholderia mallei ATCC 23344. Nat 
Protoc 1:162-169. 
23. Messing J. 1983. New M13 vectors for cloning. Methods in enzymology 101:20-78. 
24. Kumar A, Mayo M, Trunck LA, Cheng AC, Currie BJ, Schweizer HP. 2008. 
Expression of resistance-nodulation-cell-division efflux pumps in commonly used 
Burkholderia pseudomallei strains and clinical isolates from northern Australia. Trans R 
Soc Trop Med Hyg 102 Suppl 1:S145-151. 
25. Gene Codes Corporation. Sequencher
®
 version 5.1 sequence analysis software, Ann 
Arbor, MI. 
26. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, 
Valentin F, Wallace IM, Wilm A, Lopez R, Thompson JD, Gibson TJ, Higgins DG. 
2007. Clustal W and Clustal X version 2.0. Bioinformatics 23:2947-2948. 
27. Giladi M, Altman-Price N, Levin I, Levy L, Mevarech M. 2003. FolM, a new 




CHAPTER 7: Concluding Remarks 
 
Burkholderia pseudomallei is a pathogen capable of causing the severe disease 
melioidosis. This bacterium is of great concern in endemic regions; though its global distribution 
appears to be expanding, this is likely a result of improved surveillance and awareness (1), but 
may also be due to increased foreign travel and a changing climate (2-4). Additionally, B. 
pseudomallei is of concern as it is naturally resistant to many antimicrobials and is currently 
listed as a Tier 1 Select Agent. Elucidation of the mechanisms of antimicrobial resistance will 
provide useful information for the development of improved and novel therapeutics.  
While B. pseudomallei is intrinsically resistant to numerous antimicrobials, it is generally 
susceptible to co-trimoxazole, a combination of the folate pathway inhibitors trimethoprim and 
sulfamethoxazole. Co-trimoxazole is the primary recommended therapy for the eradication phase 
and prophylaxis treatment of melioidosis with few alternatives. Co-trimoxazole resistance is 
relatively rare, but of great concern. The main purpose of this work was to explore and 
characterize the molecular mechanisms responsible for antimicrobial resistance to the clinically 
relevant folate pathway inhibitors, trimethoprim and sulfamethoxazole, in B. pseudomallei. In 
the course of several research studies described in this dissertation, significant contributions were 
made to improve our understanding of the mechanisms contributing to trimethoprim and 
sulfamethoxazole resistance in clinical and environmental isolates, as well as other potential 
mechanisms that could arise due to acquired mutations. These mechanisms include: 
(i) Trimethoprim and sulfamethoxazole efflux by BpeEF-OprC. 
The B. pseudomallei BpeEF-OprC efflux pump was previously shown to efflux 
trimethoprim when expressed in Pseudomonas aeruginosa (5). This efflux pump was 
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found to be responsible for trimethoprim, sulfamethoxazole and/or co-trimoxazole 
resistant isolates throughout this study, as briefly described below: 
In Chapter 3, the BpeEF-OprC efflux pump was found to be essential for 
trimethoprim resistance in all of the clinical and environmental isolates tested. The 
trimethoprim resistant strains overexpress bpeEF-oprC in the presence of trimethoprim. 
This trimethoprim-induced overexpression requires expression of the BpeT LysR-type 
regulator. However, it remains unclear what regulatory component is responsible for the 
observed inducible expression, as there were no significant mutations observed in bpeT 
or the bpeT and llpE-bpeEF-oprC promoter regions. 
In Chapter 4, Bp82 was passively selected on media containing trimethoprim. 
Unique mutations to the BpeT regulator (L265R and C310R) were found in strains that 
were trimethoprim resistant and overexpressed bpeF mRNA more than 30 fold higher 
than the parent strain. Introduction of these mutations into the wild-type Bp82 strain 
confirmed that each of the bpeT mutations resulted in overexpression of the BpeEF-OprC 
efflux pump and conferred resistance to trimethoprim. There also was a decrease in the 
co-trimoxazole susceptibility and a slight decrease in sulfamethoxazole susceptibility. 
Antimicrobial susceptibility testing of efflux pump mutant derivatives of the 1026b strain 
suggest that sulfamethoxazole is an efflux substrate of both the BpeAB-OprB and 
BpeEF-OprC efflux pumps. Though overexpression of these pumps caused decreased 
susceptibility, the strains remained well below resistant levels.  
A similar technique was used in Chapter 5 to investigate the mechanisms of co-
trimoxazole resistance. The observed resistance in co-trimoxazole selected isolates of 
Bp82 was dependent on BpeEF-OprC, as deletion of the structural genes for this efflux 
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pump caused increased susceptibilities to trimethoprim, sulfamethoxazole and co-
trimoxazole. The strains expressed bpeF mRNA over 100 times more than the parent 
strain, and deletion of bpeT caused a significant reduction of bpeF mRNA expression. In 
the absence of BpeT there was a significant increase of the susceptibility in most of the 
strains; it is unclear why some of the strains remain resistant to trimethoprim and 
sulfamethoxazole individually. Overexpression of the BpeEF-OprC efflux pump was 
found to be a result of mutation to a previously undescribed LysR-type regulator, BpeS. 
Repair of the BpeS mutation resulted in bpeF mRNA expression levels comparable to the 
Bp82 parental strain.  
Finally in Chapter 6, the BpeEF-OprC efflux pump was shown to be essential for 
co-trimoxazole and sulfamethoxazole resistance in clinical isolates from Thailand. The 
clinical strains that are co-trimoxazole resistant overexpress bpeEF-oprC either under 
normal growth conditions or when induced with trimethoprim. Of the tested strains two 
had very high level expression that was BpeT-independent and both strains had a notable 
mutation to BpeS that warrants further investigation.  
 
(ii) Acquired mutations to the trimethoprim drug target, dihydrofolate reductase. 
In Chapter 4, adaptive resistance to trimethoprim alone was studied in Bp82. 
Trimethoprim resistant Bp82 isolates either had mutations to BpeT causing BpeEF-OprC 
overexpression (as described above), or one of two mutations to FolA (I99L and F158V). 
The I99L mutation has been previously described in a Burkholderia cenocepacia strain 
J2314 (6), and is equivalent to the I94L FolA mutation previously reported in 
trimethoprim resistant Escherichia coli (7). This FolA mutation was also found in 12 
more trimethoprim resistant Bp82 isolates lacking either the BpeT regulator or the 
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BpeEF-OprC efflux pump structural genes. The FolA F158V mutation, to my knowledge, 
has not been previously described, but in E. coli a mutation to the equivalent residue 
(F153S) may cause alteration of a nearby β-bulge catalytic domain (8). The introduction 
of each FolA mutation into the Bp82 background caused decreased susceptibility to both 
trimethoprim and co-trimoxazole. One of the selected Bp82 isolates had mutations to 
both FolA and BpeT, however despite over 30 fold increase in BpeEF-OprC expression, 
this strain remained co-trimoxazole sensitive. It would be expected that drug target 
modification of both the trimethoprim and sulfamethoxazole targets would result in a co-
trimoxazole resistant strain. However, no significant mutations to FolP were found to 
contribute to resistance in these studies.  
 
(iii)  Modification of the folate biosynthetic pathway. 
In Chapter 5, the Bp82 strain was passively selected in the presence of co-
trimoxazole. This resulted in two mutations to previously uncharacterized genes that were 
identified by whole genome sequencing; a mutation to BpeS (described above) and a 
V15G mutation to Ptr1. The ptr1 gene of B. pseudomallei is annotated as a pteridine 
reductase, a gene originally identified in trypanosomatids responsible for resistance to a 
DHFR inhibitor, methotrexate (9, 10). Repair of the ptr1 mutation caused a significant 
increases in sulfamethoxazole and co-trimoxazole susceptibilities. Interestingly, deletion 
of ptr1 from Bp82 caused decreased trimethoprim and sulfamethoxazole susceptibility, 
but did not result in resistance to either drug. These data suggest that mutations to ptr1 
may partially contribute to both trimethoprim and sulfamethoxazole resistance, though it 
is unclear what role Ptr1 plays in the folate synthesis pathway in B. pseudomallei.  
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In trypanosomes overexpression of Ptr1 confers resistance to methotrexate (11, 
12). Similarly, overexpression of FolM (a Ptr1 homolog) in E. coli caused decreased 
susceptibility of the strain to trimethoprim (9). FolM was shown to act as a dihydrofolate 
reductase (9) and Ptr1 can fulfill similar function (13, 14). Thus, it is perplexing that ptr1 
deletion in B. pseudomallei actually reduces drug susceptibility. This has been reported in 
E. coli where decreased susceptibility was reported in strains lacking FolM (15). The 
authors suggested a compensatory overexpression of FolA may contribute to the 
observed phenotype. In this context, it is possible that Ptr1 inactivation or deletion results 
in overexpression of both FolA and FolP, causing decreased susceptibilities to both 
trimethoprim and sulfamethoxazole. Alternatively, the absence of ptr1 may induce other 
modifications to either improve the efficiency of the folate synthesis pathway or bypass 
the inhibited enzymatic steps of this process.  
 
The research in this dissertation has contributed to our understanding of the mechanisms 
for folate pathway inhibitor resistance in B. pseudomallei. We were able to conclusively show 
that the BpeEF-OprC efflux pump is a key resistance determinant for folate pathway inhibitor 
resistance in B. pseudomallei. Combination therapy is generally thought to be superior to mono-
therapy for preventing the emergence of antimicrobial resistance, as it is assumed that mutations 
resulting in resistance to both drugs individually are required and would be infrequent.  
In most cases the BpeEF-OprC efflux pump was insufficient alone to confer co-
trimoxazole resistance; however, if this efflux pump can effectively expel both antimicrobials, 
resistance could emerge rapidly. Much work is needed to understand the regulation of BpeEF-
OprC expression. It appears that there are more regulatory components than have currently been 
identified, as differential expression could not be explained by mutations to currently known 
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regulators, including the newly described BpeS LysR-type regulator. It would also be prudent to 
determine whether sulfamethoxazole is a natural substrate of BpeEF-OprC or if it is effluxed 
only under certain conditions. As a way to prevent treatment failure, further characterization of 
the BpeEF-OprC efflux pump and investigation of potentially effective efflux pump inhibitors 
may prove useful, as deletion of bpeEF-oprC in all co-trimoxazole resistant strains tested 
resulted in co-trimoxazole susceptibility. The efflux pump inhibitor would have to be specific to 
limit toxicity to eukaryotic cells; for example a compound that specifically blocks the association 
of the BpeF transporter and the antimicrobial(s) (16).  
Future work is also necessary to investigate the folate synthesis pathway in B. 
pseudomallei. The role of Ptr1 remains unclear, but the elucidation of its function as a resistance 
determinant could provide useful information for improvement or development of novel folate 
pathway inhibitors. This could include investigation of the expression levels of folA, folP and 
ptr1 under various conditions to determine if folA and/or folP overexpression is in fact 
responsible for decreased susceptibility. Additionally biochemical analyses, similar to those 
previously described (17), could be used to study Ptr1.  
Antimicrobial resistance is no longer an emerging problem; it is a current problem. This 
is true especially in organisms that are already intrinsically resistant to many antimicrobials. 
Determination and monitoring of the mechanisms of resistance will assist clinicians in adapting 
antimicrobial therapies to improve outcome and reduce the emergence of resistance. Also these 
studies may provide useful information to those who are developing improved treatment options 
for multi-drug resistant organisms, including one particularly remarkable organism: 
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LIST OF ABBREVIATIONS 
 
a  adenine 
A  alanine 
ABC  ATP binding cassette superfamily 
Acr  acriflavine 
Ade  adenine 
AHL  N-acyl-homoserine lactone 
Amp  ampicillin 
ANOVA analysis of variance 
APHIS  U.S. Department of Agriculture – Animal and Plant Health Inspection Service 
ATP  adenosine triphosphate 
 
B.  Burkholderia 
BLAST Basic Local Alignment Search Tool 
bp  base pairs 
BSL  Biosafety Level 
 
°C  degrees Celsius 
c  cytosine 
C  cysteine 
Car  carbenicillin 
CDC U.S. Dept. of Health and Human Services – Centers for Disease Control and 
Prevention 
cDNA  complementary DNA 
CLSI   Clinical Laboratory Standards Institute 
CFU  colony forming units 
Chl  chloramphenicol 
CRE  carbapenem-resistance Enterobacteriacea 
Ct  threshold cycle 
 
D  aspartic acid 
DAP  diaminopimelic acid 
DHFR  dihydrofolate reductase 
DHPPP 6-hydroxymethl-7,8-dihydropterin pyrophosphate 
DHPS  dihydropteroate synthase 
DNA  deoxyribonucleic acid 
DMSO  dimethyl sulphoxide  
Dox  doxycycline 
 
E.  Escherichia 
e.g.  for example 
ELISA  enzyme-linked immunosorbent assay 
EPI  efflux pump inhibitor 
Ery  erythromycin 
et al.  and others 
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FRT  Flp Recombinase Target 
 
g  guanine 
G  glycine 
Gen  gentamicin 
GTP  guanosine triphosphate 
GCHY-I GTP cyclohydrolase I 
 
h  hour(s) 
H  histidine 
HIV  human immunodeficiency virus 
 
I  isoleucine 
IHA  indirect hemagglutination assay 
Imp  imipenem 
IPTG  isopropyl-1-thio-β-D-galactopyranoside 
 
K  lysine 
kb  kilobase(s) 
Km  kanamycin 
 
L  leucine 
LB   Lennox Luria-Bertani  
LD  lethal dose 
LD50  lethal dose 50%, dose necessary to kill 50% of an experimental population 
LPS  lipopolysaccharide 
LPSN  List of Prokaryotic Names with Standing Nomenclature 
 
MATE  multi-drug and toxic compound extrusion family 
MDR TB multi-drug resistant tuberculosis 
MFP  membrane fusion protein 
MFS  major facilitator superfamily 
mg  milligram 
μg  microgram 
MHA   Mueller Hinton II Agar  
MHB  Mueller Hinton Broth (cation-adjusted) 
MIC   minimal inhibitory concentration 
mL  milliliter 
μL  microliter 
mM  millimolar 
µm  micrometer  
mRNA  messenger ribonucleic acid 
MRSA  methicillin-resistant Saphylococcus aureus 
 
N  asparagine 
ND  not done / no data 
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Nor  norfloxacin 
 
OD  optical density 
OMP  outer membrane protein 
 
P  proline 
P.  Pseudomonas 
pABA  para-aminobenzoic acid 
pABGlu para-aminobenzoyl-glutamate 
PBP  pencillin-binding protein 
PCR  polymerase chain reaction 




R  arginine 
RNA  ribonucleic acid 
RND  resistance-nodulation and cellular-division family 
rRNA  ribosomal RNA 
RT-qPCR reverse transcriptase quantitative polymerase chain reaction 
 
s  seconds 
S  serine 
SCID  severe combined immunodeficiency 
SDR  short-chain dehydrogenase/reductase 
SMR  small multi-drug resistance family 
SOE  splicing by overlap extension 
Smx   sulfamethoxazole 
SNP  single nucleotide polymorphism 
SXT   co-trimoxazole (trimethoprim + sulfamethoxazole) 
 
t  thymine 
T  threonine 
Tet  tetracycline 
Tmp  trimethoprim 
tRNA  transfer RNA 
 
V  valine 
VBNC  viable but non-culturable 
VRSA  vancomycin-resistant Staphylococcus aureus 
 
WHO  World Health Organization 
 
XDR TB extensively drug resistant tuberculosis 
X-Gluc 5-bromo-4-chloro-3-indolyl-β-D-glucuronic acid 
 
Zeo   Zeocin 
